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ABSTRACT

PROTEIN-PROTEIN INTERACTIONS OF HUMAN MITOCHONDRIAL AMIDOXIMEREDUCING COMPONENT IN MAMMALIAN CELLS

By
John A. Thomas
December 2016

Dissertation supervised by Partha Basu
Newly discovered pterin-molybdoenzymes mammalian proteins, mARC1, and mARC2,
are though to activate pro-drug, metabolize mutated base pairs, and producing nitric
oxide from nitrite. However, the physiological function of the mARC proteins remain
unclear. It is hypothesized that identifying partner proteins through protein-protein
interactions can provide evidence to their physiological function. This study aimed to
further investigate the potential function of mARC proteins through the identification of
protein-protein interaction in human cell lysate, utilizing co-immunoprecipitation,
crosslinking reagent, and pull-down assays. Several proteins (e.g. mitogen-activated
protein kinase 5, phosphatidylinositol 4-phospahte 3-kinase C2 domain-containing
subunit beta, ADP/ATP translocase 1, and myotubularin) were identified as interacting
partners of mARC1, and mARC2. These interacting proteins are affiliated with various
KEGG signaling pathways. From the interacting proteins we infer, mARC1 and mARC2
may be involved in the regulation of nitric oxide signaling under hypoxic. Reverse coimmunoprecipitation experiments using select proteins from the pathways detected
mARC proteins. The investigation was then expanded to include pig liver mitochondrial
fraction and rat liver cell lysate, in which all experimental conditions identified mARC
proteins using reverse co-immunoprecipitation.
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Chapter 1: Introduction
1.1 Molybdenum-containing Enzymes and their Classes
Molybdenum is an essential trace element in all forms of life.[1] Molybdenumcontaining enzymes play important roles in a vast array of metabolic processes in all
forms of life. Enzymes requiring molybdenum cofactor for full functionality are capable
of redox reactions involving carbon, sulfur, and nitrogen metabolism.[2-4] These
enzymes require molybdenum to be ligated by a cofactor, resulting in two general
categories for molybdenum cofactors, iron-molybdenum cofactor (FeMoco) and pterinbased molybdenum cofactor (Moco).[5-9] Reactions involving Moco-containing enzymes
can be characterized into either the transformation of species utilizing hydroxylation or
oxygen atom transfer to/from a substrate involving two electrons.[2, 5, 10-12] Moco is
commonly comprised of a molybdenum atom directly coordinated by a dithiolene ligand
which is appended to a pyranopterin (Figure 1.1) or metal binding pterin.[13]

Figure 1.1: The general structure of pyranopterin
cofactor for molybdenum containing enzymes.
Molybdenum atom is covalently bound to the enedithiolate. R = H, monophosphate, guanidine
dinucleotide, or cytosine dinucleotide.
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The two molybdenum-containing enzyme categories, FeMoco, and Moco can be
further divided into different families based on active site structure. An example of a
FeMoco containing enzyme is nitrogenase, the enzyme is involved in dinitrogen
fixation.[14-17] Moco-containing enzymes, can further be divided into three families;
sulfite oxidases (SO), xanthine oxidases (XO), and dimethyl sulfoxide reductases
(DMSOR).[18] SO and XO family proteins contain a simple molybdopterin (MPT)-type
cofactor.[5] They differ in the third Mo-S ligand in which SO contains an enzyme-derived
cysteine and XO contains a sulphido ligand.[5] In DMSOR family of enzymes, two
pyranopterin cofactors coordinate the molybdenum center, each having an additional
guanosine monophosphate.[5] It has been proposed that there may be a fourth family in
this category, mitochondrial amidoxime reducing-component (mARC), which may
contain a structurally unique active site when compared to the other three families.[19]
However, it has been recently accepted that mARC is indeed a part of the sulfite oxidase
family.[8] Pterin-based molybdenum enzymes are generally mononuclear, where the
molybdenum atom is coordinated by the pterin. In addition, the molybdenum is also
coordinated by a sulfur, oxygen or selenium donor. The pterin-based molybdenum
cofactor families typically function via oxygen atom transfer reactions or hydroxylation,
and during catalysis the molybdenum center shifts between a fully oxidized and a
reduced state. Figure 1.2 shows a comprehensive tree of the categories and families of
molybdenum containing enzymes as well as the corresponding enzyme commission (EC)
2

number and the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways
involved.
Iron-molybdenum
Cofactors

Nitrogenase
EC:1.18.6.1
Nitrogen Metabolism

Molybdenum-containing
Enzyme

Sulfite Oxidase
mARC
EC:1.8.3.1
Sulfur Metabolism

Pterin-based
Molybdenum Cofactors

Xanthine Oxidase
EC:1.17.1.4,1.17.3.2
Purine Metabolism,
Caffeine Metabolism,
Drug Metabolism

Dimethyl sulfoxide
Reductase
EC:1.8.5.3
Sulfur Metabolism

Figure 1.2: Categories of molybdenum containing enzymes. The families, enzyme
function and corresponding metabolisms are listed.
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1.2 Mammalian Molybdenum-containing Enzymes
There are four mammalian molybdenum containing enzymes known. They
include SO, XO, aldehyde oxidase (AO), and mARC.[11, 18, 20] The structural differences
of the cofactor in these enzymes can be seen in Figure 1.3. The four proteins can be
categorized into two or potentially three families. SO belongs to the SO family which
contains a conserved cysteine ligated to the molybdenum center.[18] Xanthine
oxidoreductase and AO belong to the xanthine oxidase family which contains a sulfido
group bound the to the molybdenum center.[18] The active site in AO and XO can be
superimposed, demonstrating a high degree of similarity.[21] The Moco-containing

A

B

Figure 1.3: The structural differences in the
mammalian molybdenum enzymes cofactors. A.
Moco for sulfite oxidase family enzymes, B. Moco
for xanthine oxidase family enzymes.

4

enzyme, mARC, is suggested to belong to the SO family based on the conserved cysteine
residue or may potentially represent a new type of molybdenum-containing enzyme.[22]
SO and XO are among the more well-known mammalian molybdenum containing
enzymes with defined physiological roles in cysteine and purine metabolism.[2] The
physiological roles of AO and mARC enzymes remain unclear; both proteins have been
proposed to function in pro-drug activation.[23, 24] Aldehyde oxidases have a broad
substrate specificity corresponding to compounds containing carboxylic acids and
heterocycles, transforming substrates into hydroxylated derivatives.[23] The mARC
enzymes have been shown to reduce substrates containing amidoxime groups into their
active drug forms; these include antiprotozoal, anti-inflammatories, anti-cancer, and
antidepressants.[24]
The four mammalian molybdenum containing enzymes all have markedly
different catabolic properties. SO catalyzes the oxidation of sulfite to sulfate. XO catalyzes
the formation of hypoxanthine to xanthine and xanthine to uric acid.[18] AO catalyzes
the oxidation of aldehydes to carboxylic acids.[2] Recently, mARC proteins have been
found to metabolize compounds with N-hydroxylated side groups.[24, 25] These types
of compounds are regularly used as pro-drugs (Figure 1.4 shows three pro-drugs. A more
complete set of examples can be found in Figure 1.8). Interestingly, mARC proteins can

5

reduce nitrite to nitric oxide, which is a potent signaling molecule in mammalian
systems.[26]

Figure 1.4: Three example pro-drugs that mARC has been
shown to be able to catalyze the activation by reducing the
amidoxime functional groups.

1.3 Molybdenum-containing Enzymes and their Involvement in Mammalian Nitric
Oxide
There are two distinct nitric oxide synthesis pathways in mammalian systems. The
first pathway is the nitric oxide synthase (NOS)-dependent pathway in which arginine is
metabolized to form nitric oxide. The NOS pathway requires oxygen to catalyze the
reaction. Under oxygen-limiting conditions, however, the body can produce nitric oxide
using a second pathway involving the conversion of nitrite to nitric oxide. Nitrate is more
available than nitrite in mammalian systems and requires the aid of oral commensal
bacteria to generate nitrite from nitrate.[27] The subsequent reduction of nitrite to nitric
oxide occurs in the mitochondria of cells. Nitric oxide is an important signaling molecule
in multiple pathways. Figure 1.5 demonstrates two different pathways for nitric oxide

6

production. The first is the normal oxygen conditions under which NOS can catalyze the
formation of nitric oxide from arginine. The second pathway is under the hypoxic
conditions when mARC proteins can be used to reduce nitrite into nitric oxide and the
subsequent pathways associated with nitric oxide. Investigating the mammalian nitrite
reductase pathways is of great interest for human health and disease, as the effects of
nitrite are largely mediated by its reduction to nitric oxide.

Figure 1.5: (Left) NOS pathway for nitric oxide production in which L-arginine or N-omegahydroxy-L-arginine can be oxidized by nNOS, iNOS, or eNOS to form L-citrulline and nitric
oxide under normal oxygen conditions. (Right) Formation of nitric oxide by mARC proteins;
nitrite is reduced by mARC proteins but requires cytochrome b5 (Cb5) and cytochrome b5
reductase (Cb5R) as well as NADH. Nitric oxide has been found to be associated with different
pathways in mammalian systems.
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In mammals there are a several sources of nitric oxide namely, L-arginine, Snitrosothiols, nitrate and nitrite. The oxidation of L-arginine catalyzed by NOS is a wellcharacterized pathways for nitric oxide production.[28-31] There are three distinct
isozymes that have been identified in mammalian systems, neuronal NOS (nNOS or
NOS-1), inducible NOS (iNOS or NOS-2), and endothelial NOS (eNOS or NOS-3).[32-34]
It was found that if all three proteins were knocked out in mice, they displayed a shorter
life expectancy, with increased risk of cardiovascular disease including hypertension,
cardiac hypertrophy, diastolic heart failure, arteriosclerosis, and myocardial infarction;
demonstrating the importance of nitric oxide production in mammalian systems.[35] The
full functioning NOS proteins require five cofactors to effectively catalyze the formation
of nitric oxide from L-arginine; tetrahydrobiopterin, flavin adenine dinucleotide, flavin
mononucleotide, calmodulin, and iron protoporphyrin IX.[32, 36] The monomeric NOS
isozyme is incapable of producing nitric oxide, producing instead oxygen.[36] NOS
enzymes require substrates NADPH, L-arginine, and oxygen in order to produce NADP+,
L-citrulline, and nitric oxide.[32] It is imperative that the NOS proteins form dimers in
order to bind the tetrahydrobiopterin cofactor and the substrate L-arginine subsequently
forming nitric oxide.[37]
In addition to the oxidation of L-arginine to form nitric oxide, S-nitrosothiols are
utilized to regulate protein expression for nitric oxide production and can also provide a
source of nitric oxide.[38] S-nitrosothiols can be formed two ways; exogenously by a S8

nitrosothiol donor (i.e., S-nitrosoglutathione) or endogenously by NOS proteins.[39]
Furthermore, donor S-nitrosylated proteins can transfer the nitric oxide group to acceptor
S-nitrosylation protein complexes.[40] While nitric oxide has a very short half-life (2 ms)
in plasma, S-nitrosoproteins have half-lives of approximately one hour.[39] The release
of nitric oxide from S-nitrosothiols have been shown to be achieved several ways in vitro;
trace amounts of transition metal ions (Cu2+ or Fe2+), flash photolysis, as well as the
addition of dithiothreitol, or vitamin C.[41-43]
Nitrate can undergo a reductive process in which nitrite is formed by microbial
nitrate reductase, and subsequently nitrite can be reduced to nitric oxide by different
mammalian enzymes. Although many proteins and catalysts are known, this latter
pathway is not well understood in mammalian cells at a molecular level. Nitrate and
nitrite are now considered to be biological reservoir of nitric oxide, however, all the key
enzymes influencing the process have yet to be understood.[38, 44] There is no known
mammalian nitrate reductase, although several mammalian enzymes can reduce nitrate
to nitrite with millimolar (mM) binding, which is orders of magnitude lower than the
micromolar (μM) Km determined for bacterial and plant enzymes.[45] Thus, mammalian
nitrate reduction is catalytically less efficient. Our assertion is that the nitrate to nitrite
transformation is likely to be achieved by commensal bacterial nitrate reductase, a
process we have been investigating for years.[46, 47] Several in vitro studies have
indicated that nitrite to nitric oxide reduction is achieved by essentially three different
9

types of biomolecules: members of the globin family (e.g., hemoglobin, myoglobin and
neuroglobin), pterin-containing molybdenum enzymes (e.g., XO; AO; SO) and nitrite
anhydrase enzymes (e.g., carbonic reductase). Under specific conditions, these pterincontaining enzymes have been reported to be able to catalyze the reduction of nitrate and
nitrite to nitric oxide (Table 1.1).[26, 48-50] Hemoglobin and myoglobin are iron and
Table 1.1: The in vitro enzymatic properties of some known mammalian
proteins capable of reducing nitrite to nitric oxide.
𝑵𝑶−

𝑵𝑶−

−

Protein Name

Reducing Substrate, pH

𝒌𝒄𝒂𝒕𝟐
(s-1)

𝒌𝒎 𝟐
(mM)

𝒌𝑵𝑶𝟐
(M-1s-1)

Aldehyde oxidase [48]

Aldehyde, pH 7.4

0.47

4.1

115

Mitochondrial
amidoxime reducingcomponent [26]

NADH, pH 7.4

0.1

9.5

11

Sulfite oxidase [50]

Sulfite, pH 7.4
Phenosafranine, pH 7.4

0.002
1.9

1.6
80

1.3
26

Xanthine oxidase
[48,49]

Aldehyde, pH 7.4

0.41

2.2

186

oxygen-binding proteins are capable of catalyzing the formation of produce nitric oxide.
Hemoglobin, which is used in oxygen transport, has demonstrated potential to produce
nitric oxide from nitrite at a max rate under the conditions of 40-60% saturation at a pH
of 6.4.[51-53] The second protein, myoglobin, is capable of producing nitric oxide from
nitrite; deoxymyoglobin has been shown to reduce nitrite at a rate of 36 times faster than
deoxyhemoglobin.[54] Hemoglobin and myoglobin are oxygen-sensing proteins that aid
in the scavenging of nitric oxide, but under conditions of hypoxia the roles change to
nitric oxide producers; inducing vasodilation and increasing blood flow to tissue.[55-57]
Xanthine oxidoreductase is capable of producing nitric oxide from both nitrate and nitrite
in anoxic tissue.[58, 59] Under hypoxic conditions mitochondrial cytochrome c oxidase
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has been shown to produces nitric oxide depending on the pH of the system.[60] Xanthine
oxidoreductase and mitochondrial cytochrome c oxidase potentially demonstrate a role
in increasing blood flow to ischemic tissue.[60-62]
Organic nitro compounds have been shown to be reduced to nitric oxide by
aldehyde dehydrogenase 2 under normoxic conditions.[62, 63] Although aldehyde
dehydrogenase 2 has been shown to reduce nitroglycerin, the proteins physiological
function have eluded researchers.[62, 63] Interestingly, the activity and expression of
aldehyde dehydrogenase 2 in the vascular system when there is a tolerance to organic
nitrates.[64, 65] The final proteins that have demonstrated their capabilities to reduce
nitrate and nitrite to nitric oxide are cytochrome P450 reductase and cytochrome
P450.[66]
Nitric oxide is an important signaling molecule in the vascular endothelium,
nervous and immune systems, aiding in the regulation of behavior, gastrointestinal
motility, and defense mechanisms against infectious disease and tumors.[67-73] The
signaling molecule stimulates soluble guanylyl cyclase (sGC) and promotes the
formation of cyclic guanosine monophosphate (cGMP) through a signaling cascade
referred to as cGMP-PKG signaling pathway.[74-78] The signaling cascade is used in
smooth muscle cell relaxation by activating protein kinase G (PKG) and increases the
reuptake of calcium into the sarcoplasmic reticulum, reducing cytosolic calcium
concentrations, resulting in the activation of potassium channels.[79-83] Myosin light
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chain kinase is a calcium/calmodulin-dependent enzyme, the decrease concentration of
cytosolic calcium prevents the phosphorylation of myosin and subsequently causes the
relaxation of smooth muscle.[84-88] In addition to being a key signaling molecule in
muscle relaxation, in the presence of electron acceptors, nitric oxide can form Snitrosylated proteins by reacting with deprotonated cysteines.[89] S-nitrosylations aids
in the regulation and function of G protein-coupled receptors, as well as help to modulate
pathways within vascular cells.[40, 90] The activity of G protein-coupled receptors kinase
2 regulates the phosphorylation of β-adrenoceptors, this system can be regulated by nitric
oxide and S-nitrosylation. In some cases S-nitrosylation helps prevent the reduction of βadrenergic signaling in vivo by mediating the phosphorylation of β-adrenoceptors and
avoiding the receptors desensitization.[90, 91] Activation of β1 and β2-adrenoceptors in
heart tissue increases muscular contraction; while the opposite occurs in blood vessels,
activation of β-adrenoceptors results in vasodilation.[92-98] Thus, NO-cGMP signaling
cascade is therapeutically relevant for treating cardiovascular disorders with therapies
targeting sGC.[99]
1.4 Novel Mammalian Enzyme: mARC
The newly discovered pterin molybdenum-containing enzyme, mitochondrial
amidoxime-reducing component (mARC) has been shown in vitro to reduce nitrite to
nitric oxide more efficiently than any other human molybdenum containing enzymes.[26]
As previously stated, mARC proteins are proposed to belong to the SO family of
12

Figure 1.6: Sequence alignment of human mARC1 and mARC2 proteins. Similar domains in
mARC proteins are highlighted; mitochondrial signaling sequence (red), MOSC, N-terminal βbarrel sequence (blue), molybdenum cofactor sulfurase, C-terminal (green), and conserved
cysteines (purple) which may coordinate to Moco.

molybdenum containing enzymes.[2, 100] There are two isoforms of mARC proteins that
have been annotated in humans with an overall sequence identity/similarity of 66/80%,
mARC1 and mARC2 (UniProt ID: Q5VT66, Q969Z3) (Figure 1.6).[19] The number of
amino acids in both mARC proteins is very similar (mARC1: 337 amino acids, and
mARC2: 335 amino acids).[22] The proteins contain similar domains; amino-terminal
mitochondrial signal sequence, a predicted β-barrell domain, and a MOSC domain near
the carboxyl terminus.[101] Even though mARC is a mitochondrial protein it has been
found through cellular staining to be also located outside the mitochondria, as it is
anchored to the outer mitochondrial membrane and may detach.[102, 103] Both mARC
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proteins are capable of reducing N-oxygenated species, although the rate of the reaction
are not high. These proteins require cytochrome b5, and cytochrome b5 reductase ancillary
proteins to perform reduction.[24, 25, 104, 105] The physiological function of mARC
enzymes is uncertain at a cellular level, but an in vitro study demonstrated that they may
be utilized in the pro-drug metabolism by catalyzing the reduction of amidoxime
functional groups to amidines.[46, 106-109] There is also evidence that mARC proteins
can function in lipid synthesis, nitrite reduction to for nitric oxide and the detoxification
of N-hydroxylated nucleotides.[19, 26, 105, 110] The expression of mARC1 and mARC2
is found throughout the body with varying degrees of expression of each protein in
selected tissue (Figure 1.7). Using a method referred to as intensity based absolute
quantitation (iBAQ) in which the sum of all peptide peak intensities are divided by the
number of theoretically observed tryptic peptides the relative abundances of mARC1 and
mARC2 proteins were quantitated in different tissues.[111] Figure 1.7 shows that mARC2
is expressed to a higher degree in similar tissues as mARC1. This may indicate that the
physiological roles of mARC1 and mARC2 may be different. In the kidneys and liver,
both involved in detoxification of harmful metabolites, mARC2 showed a higher
expression than mARC1; indicating that one potential role of these proteins is the
catabolism of harmful substrates. In addition, mARC2 was found to be expressed in the
heart while mARC1 was not. To this end, the physiological function of mARC proteins
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in humans is unknown and this investigation seeks to provide clarity in the physiological
role of mARC.
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Figure 1.7: Protein expression of mARC1. Expression of mARC1 in females (left), males (center), and the iBAQ intensities for tissue (right).
(proteomicsdb.org/)[112]

17
Figure 1.8: Protein expression of mARC2 in humans. Expression of mARC2 in females (left), males (center), and the iBAQ intensities for
tissue (right). (proteomicsdb.org/)[112]

The presence of NADH, cytochrome b5, and cytochrome b5 reductase has been
shown to be important to the activity of mARC proteins.[19, 25, 105, 108, 113] In in vitro
studies, during the regeneration step, the catalytic center of the mARC enzyme receives
electrons from NADH via electron transfer partner proteins, cytochrome b5, and
cytochrome b5 reductase, without which mARC proteins’ function is impaired. Given the
slow rate of the reaction, it is not clear whether cytochrome b5, and cytochrome b5
reductase are the physiological electron transfer partners with mARC. There are two
isoforms of cytochrome b5 encoded by different genes, type A and type B.[114, 115] Type
A cytochrome b5 is localized as membrane-bound in microsomes as well as a soluble
form.[114, 116] The type B isoform is localized to the mitochondrial outer membrane.[117119] The catalytic properties of mARC have been achieved in vitro using both types of
cytochrome b5.[120] However, a knockout study demonstrated that type B-cytochrome b5
is required for the N-reductive pathways.[25, 105]
As previously stated mARC proteins may have an involvement in several different
pathways, but the exact physiological role of mARC proteins is not well understood.[22]
There is the potential that mARC proteins may be involved in nitric oxide production in
humans. Under aerobic conditions, mitochondrial fractions of different tissue containing
heterologously expressed mARC1 and mARC2 have been shown to produce nitric oxide
from Nω-hydroxy-L-arginine.[113] Under hypoxic conditions mARC proteins coupled
with the ancillary proteins cytochrome b5, and cytochrome b5 reductase have been
18

identified to reduce nitrite into nitric oxide.[26] As previously stated nitric oxide is a
potent signaling molecule and affects several different mammalian pathways, suggesting
that mARC proteins may be involved in signaling cascades.
Human mARC proteins may also participate in the metabolic detoxification of Nhydroxylated

nucleobases

and

nucleosides

such

as

N-hydroxycytosine,

N-

hydroxyadenine, cytidine, and adenine.[19, 110] The down-regulation of mARC2 in colon
tumors demonstrated a significant role of mARC-mediated detoxification of mutagenic
DNA bases.[121] This suggests that mARC proteins may be involved in the detoxification
and prevention of accumulation of mutagenic substances within the cells.
It has also been found that the expression of mARC2 and N-reductive activity were
increased in adipose tissue, suggesting that mARC2 may be regulated under lipogenic
conditions within differentiation of murine cells into mature adipocytes.[22, 105, 122, 123]
The down-regulation of mARC2 was found to impact lipid synthesis in cells
negatively.[105] It has also been observed that the expression of mARC proteins and Nreductive activity were affected by fasting and a high-fat-diet in mice, suggesting that
mARC proteins may be involved lipid metabolism within cells.[116]
Currently, mARC proteins are exploited for their potential in pro-drug
metabolism to reduce amidoxime to amidines.[22] Compounds containing amidine
functional groups are used in several types of treatment including; factor Xa inhibitors,
thrombin inhibitors, factor VIIa inhibitors, urokinase-type plasminogen activators, anti19

microbial agents (i.e. parasitic, bacterial, malaria), and antiplatelet GPIIb/IIIa-receptor
antagonist.[124-131] The issue with compounds containing amidines is their strong
basicity and under physiological conditions can readily be protonated, resulting in a low
bioavailability within the body.[132, 133] By converting the amidines to amidoxime
functional groups the compounds can no longer be protonated, and the basicity is also
greatly reduced, allowing for a bioreversible compound that utilizes enzymes like mARC
proteins to catalyze the reduction of the pro-drug into the active form.[22] The mARC
protein system has been tested and showed success in several model substrates, prodrugs including anti-cancer and antiprotozoal agents, transforming drug metabolites,
and the reduction of mutated nucleotides and harmful metabolites (Figure 1.8).[19, 26,
107-110, 113, 116, 126, 134, 135] Thus, the physiological function of mARC proteins
remains unknown in human systems, but studies have demonstrated that they may be
involved in nitric oxide production, detoxification of mutated base pairs, and lipid
metabolism. By understanding the metabolic properties of the mARC system,
physiological functions may be proposed.
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Figure 1.9: Substrates that have been evaluated using the mARC system.

1.5 Specific Aims of Study
The global objective of this study is to understand potential the physiological role
of mARC1 and mARC2 through identifying interacting proteins through protein-protein
interaction in vitro experiments. Protein-protein interactions can provide insight into the
physiological function of mARC proteins. One of the issues with performing proteinprotein interaction studies is the number of falsely identified proteins (false
positives).[136] The experimental conditions, cell types, and reagents used affect the
protein-protein interactions. To collect a more comprehensive the data set for this study,
three

different

methods

to

identify

protein-protein

interactions

were

used;

chemical/photoactivated crosslinking, co-immunoprecipitation, and pull-down assay.
Interactions were probed in human embryonic kidney (HEK-293) cell lysate using
purified mARC1 and mARC2 overexpressed in Escherichia coli. Proteins were selected for
reverse co-immunoprecipitation specifically looking for mARC1 and mARC2 for the
selected proteins. Reverse co-immunoprecipitation experiments were carried out in HEK293 cells lysate as well rat liver tissue lysate and pig mitochondrial lysate. By identifying
potential interacting partners of mARC proteins, a better understanding of the
physiological function can be probed.
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Chapter 2: Sample Preparation and Experimental Methods
All reagents, materials, and kits used in the subsequent experiments can be found
in Appendix I, Table A1.
2.1 Lysate Preparation and Recombinant mARC Protein
HEK-293 cells were grown, harvested, and lysed at the University of Pittsburgh,
Pittsburgh, PA, by Dr. Courtney Sparacino-Watkins. The cells used were modified to
overexpress mARC2 with a green fluorescent protein (GFP) tag, as reported in the
literature.[26] Rat liver tissue was supplied by Dr. Courtney Sparacino-Watkins
University of Pittsburgh, Pittsburgh, PA. Purified mARC1 and mARC2 were supplied by
Dr. Courtney Sparacino-Watkins University of Pittsburgh, Pittsburgh, PA, following a
procedure previously published.[26] Pig liver mitochondrial fractions were supplied by
Dr. Antje Havemeyer of the Institute of Pharmaceutical Chemistry, Christian-Albrechts
University of Kiel, Kiel.
HEK-293 cells were lysed by resuspending the cell pellet in 5 mL of Pierce Lysis
Buffer and sonicating them with 5 cycles of 3-second pulses on ice. The lysis buffer
contains a mild detergent capable of releasing proteins in the membrane fraction. The
soluble cell fraction was collected by centrifuging at 11,250xg for 15 minutes at 4°C. Rat
liver tissue was washed using the PierceTM Lysis Buffer (Appendix I). The liver was then
diced into smaller pieces using a stainless steel razor blade. The pieces were resuspended
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in 5 mL of lysis buffer (Appendix I) and sonicated for 5 cycles of 3-second pulses on ice.
The soluble cell fraction was collected by centrifuging at 11,250xg for 15 minutes at 4°C.
2.2 Experimental Methods to Identify Interacting Proteins with mARC Protein
Three different methods to identify protein-protein interactions were used to
identify potentially affiliated partners with mARC1 and mARC2. Each type of
experiment had experimental and control conditions to improve the results interpreted.
The experimental conditions used purified mARC proteins and HEK-293 cell lysate to
identify interacting partners. The control conditions were to ensure there were no false
Table 2.1: Experimental and control conditions for each method used to
identify protein-protein interactions.
Experimental
Co-immunoprecipitation

Crosslinking

Pull-down
Reverse CoImmunoprecipitation

† mARC1 + HEK-293 Lysate
‡ mARC2 + HEK-293 Lysate
† mARC1 + HEK-293 Lysate
‡ mARC2 + HEK-293 Lysate
† Reduced mARC1 + HEK-293 Lysate
‡ Reduced mARC2 + HEK-293 Lysate
† mARC1 + HEK-293 Lysate
‡ mARC2 + HEK-293 Lysate
†‡ HEK-293 Lysate
†‡ Pig Liver
†‡ Rat Liver

Control
†‡ HEK-293 Lysate
† Purified mARC1
‡ Purified mARC2
†‡ HEK-293 Lysate

†‡ HEK-293 Lysate
† Purified mARC1
‡ Purified mARC2
†‡ HEK-293 Lysate

† Conditions used for mARC1
‡ Conditions used for mARC2
†‡ Conditions used for mARC1 and mARC2

positives identified by the affinity purification methods and used either purified mARC
proteins or HEK-293 cell lysate. In Table 3.3 the experimental and control conditions are
listed. All experimental and control conditions (co-immunoprecipitation, crosslinking,
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pull-down assay and associated mass spectrometric analyses) were performed in
triplicate to improve the robustness of the data.
2.2.1 Co-immunoprecipitation of Interacting proteins with mARC Proteins
The mARC antibodies used for co-immunoprecipitation can be found in Table 2.1.
A stock of 1X coupling buffer (0.01 M sodium phosphate, 0.15 M sodium chloride, pH
Table 2.2: Antibodies that were used in the co-immunoprecipitation and reverse coimmunoprecipitation.
Antibody Gene Name
MAP3K5 (ASK1)
PIK3C2B
SLC25A4 (ANT 1/2)
MTM1
GAPDH
mARC1 (MOSC1)
mARC2 (MOSC2)
mARC2 (MOSC2)*

Type

Company

Monoclonal

Santa Cruz Biotechnology, Santa
Cruz, California
Santa Cruz Biotechnology, Santa
Cruz, California
Santa Cruz Biotechnology, Santa
Cruz, California
Santa Cruz Biotechnology, Santa
Cruz, California

Monoclonal
Polyclonal
Monoclonal
Monoclonal

Invitrogen, Waltham, Massachusetts

Polyclonal

Abcam, Cambridge, United
Kingdom
Abcam, Cambridge, United
Kingdom
Abcam, Cambridge, United
Kingdom

Polyclonal
Polyclonal

Catalog Number
sc-5194
sc-100407
sc-9299
sc-377309
39-8600
ab103191
ab111685
ab197195

*Used previously and was not able to purify mARC2 based on mass spectrometry data.

7.2) was prepared from the 20X coupling buffer (0.20 M sodium phosphate, 3 M sodium
chloride, pH 7.2)(Appendix I) by diluting 3 mL of buffer into 57 mL of ultra-pure water.
The AminoLink® Plus Coupling Resin, aldehyde-activated agarose beads, and coupling
buffer were equilibrated to room temperature. The AminoLink® Coupling Resin was
resuspended, and 50 µL was pipetted into labeled spin column tubes. Using a table top
centrifuge (1,000xg), the supernatant was removed. The resin was washed with 200 µL
aliquots of 1X coupling buffer, centrifuged to remove supernatant and repeated once
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more. Antibody (50 µg) was added to the resin, and the volume was adjusted to 200 µL
using 1X coupling buffer. The antibody was coupled to the AminoLink® Coupling Resin
by adding 3 µL of 5 M sodium cyanoborohydride solution in the fume hood. The reaction
was allowed to proceed for 120 minutes at room temperature on a rotator. The
supernatant was removed using centrifugation at 1,000xg. The reaction mixture was
rinsed with 200 µL 1X coupling buffer, centrifuged, and the process was repeated once
more. The reaction was quenched by adding 200 µL of quenching buffer (Appendix I),
the supernatant was removed through centrifuging. Quenching buffer was again added
(200 µL) with 3 µL of sodium cyanoborohydride and incubated for 15 minutes at room
temperature on a rotator. The supernatant was removed by centrifuging, and the resin
was washed twice with 200 µL of 1X coupling buffer. The resin was then washed a total
of 6 times with 150 µL of the wash buffer (Appendix I). The bait/prey interaction mixture
was prepared by adding 50 µg of purified mARC protein to 1 mg of protein in HEK-293
cell lysate. The resin was washed twice using 200 µL of IP lysis/wash buffer (Appendix
I), and centrifuged to remove supernatant. The reaction was added to the resin and
incubated overnight at 4°C on a rotator to ensure the mixture remains suspended. The
flow through was removed by centrifuging and the resin was washed three times with
200 µL of IP lysis/wash buffer. The bait/prey proteins were eluted from the resin by
adding 25 µL of the elution buffer (Appendix I) and incubating at room temperature for
5 minutes. Elution was repeated a total of 3 times resulting in ~75 µL if flow-through.
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2.2.2 Crosslinking of Interacting proteins with mARC Proteins
The Sulfo-SBED Label Transfer Reagent (Appendix I, Figure A.1A) was purchased
from Thermo Fisher Scientific, Waltham, MA. The No-WeighTM microtubes contained
1.12 mg of Sulfo-SBED Label Transfer Reagent and were reconstituted in 22 µL of DMSO.
The K-BLoC (Appendix I, Figure A.1B) compound was a customized to bind to the active
site in mARC and bind the non-specific crosslinking reagent transforming it into a site
specific complex. was reconstituted in phosphate buffer (0.01 M sodium phosphate, 0.15
M sodium chloride, pH 7.2). K-BLoC and Sulfo-SBED crosslinker were reacted by adding
5 mg of K-BLoC and 11 µL of the reconstituted Sulfo-SBED crosslinker and incubated for
30 minutes at room temperature; the resulting complex will be referred to as LTR-K-BLoC
complex (Appendix I, Figure A.1C). The precipitate was seperated from the soluble
fraction by centrifugation. To bind the LTR-K-BLoC complex to purified mARC proteins,
200 µg was added to 50 µg of protein. They were incubated together for 15 minutes at
room temperature. The LTR-K-BLoC complex binding to mARC1 was confirmed after
buffer exchange, using intact protein mass spectrometry. The buffer exchange was
carried out using ZebaTM Micro Spin Desalting Columns. The storage solution was
removed by centrifuging using a table top centrifuge. The resin was then rinsed 3 times
with 50 µL of 50 mM triethylammonium acetate. The sample was added to the final
volume of 12 µL and 3 µL of 50 mM triethylammonium acetate was added as a stacking
layer to aid in flow-through. The column was centrifuged at 1000xg for 2 minutes, and
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the sample was collected. Excess LTR-K-BLoC complex was removed using ZebaTM Micro
Spin Desalting Columns. The storage solution was removed by centrifuging using a table
top centrifuge. The sample was added to the final volume of 12 µL and 3 µL of ultrapure
water was added as a stacking layer to aid in flow-through. The column was centrifuged
at 1,000xg for 2 minutes, and the sample was collected. Once the mARC complex was
desalted, 1 mg of HEK-293 cell lysate was incubated for 5 minutes at room temperature.
The sample was then placed on ice under a long-wave UV lamp for 15 minutes to bond
interacting partners through the photoactive aryl azide covalently. Three biological
replicates from mARC1 and mARC2 interacting with HEK-293 cell lysate were reduced
by adding 10 µL of 50 mM dithiothreitol (DTT) and incubated for 15 minutes to reduce
the disulfide bond present in the Sulfo-SBED crosslinker. Immobilized Streptavidin was
resuspended, and 50 µL aliquots were placed into each spin column. The resin was rinsed
using 250 µL of TBS buffer and inverted several times. The supernatant was removed
using centrifugation at 1,000xg for 30 seconds. This process was repeated a total of three
times. The bait/prey crosslinked samples were then incubated with the streptavidin resin
for 1 hour at 4°C. The unbound proteins were rinsed from the resin using centrifugation
at 1,000xg for 30 seconds. The resin was washed by adding 250 µL of wash buffer and
inverted several times to resuspended the slurry. The eluent was removed using
centrifugation at 1,000xg for 30 seconds. This process was repeated a total of four times.
Proteins were eluted from the Streptavidin resin by first neutralizing the pH of the sample
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by adding 10 µL of the neutralization buffer. Then 250 µL of elution buffer was added to
the samples and inverted several times. Samples were incubated for 5 minutes at room
temperature and then collected using centrifugation at 1,000xg for 30 seconds.
2.2.3 Pull-down Assay of Interacting proteins with mARC Proteins
The bait proteins, i.e., mARC1 and mARC2, were overexpressed and purified
using a polyhistidine tag as previously discussed in Chapter 2.1.[26] The bait protein was
immobilized onto HisPurTM Cobalt Resin by pipetting 50 uL of the slurry resin into spin
columns. The resin was rinsed using 400 uL of wash solution (1:1 tris-buffered saline:lysis
buffer, 10 mM imidazole)(Appendix I) and inverting the spin columns. The caps were
then removed and placed into a tabletop centrifuge to remove buffer. There was a total
of 5 washing steps to prepare the cobalt resin. The purified mARC1 and mARC2 were
added to the PierceTM spin columns to the final concentration of 50 µg of protein. The
samples were then incubated at 4°C for 60 min using a rotator to maintain suspension of
the resin. Both caps were removed, and the supernatant was removed using a table top
centrifuge. The resin was rinsed using 400 µL of wash buffer and inverted several times.
Again, the supernatant was removed using a table top centrifuge. This wash process was
repeated a total of 5 times. The HEK-293 cell lysate was added to the spin columns to the
final amount of 1 mg of proteins. Samples were then incubated at 4°C overnight on a
rotating platform. The supernatant was then removed using a table top centrifuge. The
samples were then washed with 400 µL of the wash buffer a total of 5 times. Bait and prey
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protein were then eluted from the resin by adding 250 µL of 290 mM imidazole elution
buffer (Appendix I). Samples were incubated at room temperature for 5 min on a rotating
platform. The bait and prey protein was collected in sample tubes using a table top
centrifuge.
2.3 Mass Spectrometry Method for Protein Analysis
All mass spectrometric data collection and analyses was performed at Duquesne
University, Pittsburgh, PA at the Agilent Technologies Center of Excellence, supported
by NSF DBI 0821401
2.3.1 In-solution Trypsin Digestion
Tryptic peptides were produced by first adding equal volumes of 2,2,2trifluoroethanol (TFE) to samples with 5 µL of 200 mM dithiothreitol (DTT). Samples
were then incubated at 56°C for 1 hour to denature and reduce proteins. A 10 µL aliquot
of 200 mM iodoacetamide (IAM) was added to each sample and incubated at room
temperature and covered for 1 hour. Samples were dried using a Forma Speed Vac and
resuspended in 50 µL of 100 mM ammonium bicarbonate buffer. Digestion occurred by
adding 5 µg of trypsin and incubated at 36°C overnight. The pH of the solution was
adjusted by adding 2 µL of formic acid and vortexed to cease the digestion. The samples
were again dried and then reconstituted in 95% water, 5% acetonitrile, and 0.1% formic
acid for LC-MS/MS analysis.
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2.3.2 Liquid Chromatography Mass Spectrometry (LC-MS/MS) Peptide Analysis
The protein mass spectrometric analysis was performed using a quadrupole-timeof-flight (Q-TOF) LC-MS system (Agilent Technologies, Santa Clara, CA) equipped with
a 1200 Series binary liquid chromatography, Dual AJS ESI source, and a 6530 Q-TOF mass
spectrometer. The instrument was operated under the MassHunter Data Acquisitions
software (version B.05.01 build 5.01.5125.1, Agilent Technologies, Santa Clara, CA).
Tryptic digested peptides were separated on a Aeris™ 3.6 μm WIDEPORE XB-C18 200
Å, LC Column 150 x 2.1 mm (00F-4482-AN, Phenomenex, Torrance, CA) using a gradient
of 5% acetonitrile, 95% water, and 0.1% formic acid to 80% acetonitrile 10% water, 10%
2,2,2-trifluoroethanol, and 0.1% formic acid using the time table and flow rates in Table
2.2. The source parameters were set to the values in Table 2.3. Fragmentor voltage,
skimmer voltage, and OCT RF Vpp were set to 200 V, 65 V, and 750 V, respectively. The
MS settings used were the following: precursor ion selection, medium (4 m/z); mass
range, 120−1700 m/z; acquisition rate MS, 7 scans/sec; acquisition rate MS/MS, 4 scans/s
(m/z 59-3000). The collision energy was adjusted based on the charge of the precursor
(Table 2.4). Reference mass correction was enabled using reference mass of 121.05087300,
and 922.00979800 m/z.
2.3.2 Intact Protein Mass Spectrometry
The intact protein mass spectrometric analysis was performed using a
quadrupole-time-of-flight (Q-TOF) LC-MS system (Agilent Technologies, Santa Clara,
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Table 2.3: Binary pump gradient table used for LC-MS/MS analysis.
Time

A [%]

B [%]

Flow [mL/min]

Max Pressure [bar]

0.00

100.0

0.0

0.450

400.00

35.00

70.0

30.0

0.450

400.00

40.00

0.0

100.0

0.450

400.00

42.00

0.0

100.0

0.450

400.00

43.00

100.0

0.0

0.450

400.00

45.00

100.0

0.0

0.450

400.00

CA) equipped with a 1200 Series binary liquid chromatography, Dual AJS ESI source,
and a 6530 Q-TOF mass spectrometer. The instrument was operated under the
MassHunter Data Acquisitions software (version B.05.01 build 5.01.5125.1, Agilent
Table 2.4: Dual AJS ESI source parameters
for LC-MS/MS analysis.
Dual AJS ESI
Gas Temperature

Value
340°C

Drying Gas

10 L/min

Nebulizer

45 psig

Sheath Gas Temperature

400°C

Sheath Gas Flow

11 L/min

Voltage Capillary

3500 V

Nozzle Voltage

1000 V

Technologies, Santa Clara, CA). Intact proteins were injected using a 10 µL injection
volume with a 3-second needle wash and set with an isocratic gradient of 5% acetonitrile,
95% water, 0.1% formic acid with 5 minutes run time using a flow rate of 0.450 mL/min.
The source parameters were set to the values in Table 2.3. Fragmentor voltage, skimmer
voltage, and OCT RF Vpp were set to 400 V, 65 V and 750 V, respectively. The MS settings
used were the mass range, 100−3200 m/z; acquisition rate MS, 7.00 scans/sec.
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Table 2.5: Collision energy to
generate product ions.
Charge

Slope

Offset

2

3

2

3

3.6

-4.8

>3

3.6

-4.8

Unknown

3.6

-4.8

1

3.5

6

2.4 Bioinformatics Software for Peptide and Protein Identification
2.4.1 Spectrum Mills Proteomic Workbench (Rev B.04.01.141)
Our research group has previously published a proteomic research paper in a
peer-reviewed journal using the similar parameters as will be discussed.[137] Collisioninduced dissociation (CID) data were searched against a custom homo sapiens databases
that were created using the UniProt (uniprot.org) database, and all protein identifiers
used in this investigation were denoted by their UniProt numbers and gene name. Peak
lists were created with the Spectrum Mills Proteomic Workbench Data Extractor program
with the following attributions. Scans with the same precursor ±1.4 m/z were merged
within a time frame of ±30 seconds. Precursor ions needed to have a minimum signal to
noise value of 25. Charges up to a maximum of 7 were assigned to the precursor ion, and
the 12C peak was determined by the Data Extractor. The custom database was searched
for tryptic peptides with a mass tolerance of ±1.2 Da for the precursor ions and a tolerance
of ±0.7 Da for the product ions. Two missed cleavages were allowed. A Spectrum Mills
auto validation was performed first in the protein details followed by peptide mode using
a.) in protein details mode; protein score ≥20, peptide score (scored percent intensity
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[SPI]) charge +2 (>6.0, >60.0%), peptide charge +1 (>6.0, >70.0%), peptide charge +3 (>8.0,
>70.0%), peptide charge +4 (>8.0, >70%), peptide charge +5 (>12.0, >70.0%), peptide charge
+2 (>6.0, >90.0%), and rank 1 minus rank 2 score threshold >2.0 for all rules the last which
was set to >1.0; b.) in peptide mode: precursor charge +2 (>11.0, >60.0%), peptide charge
+1 (>13.0, >70%), peptide charge +3 (>13.0, >70.0%), peptide charge +4 (>13.0, >70.0%),
peptide charge +5 (>15.0, >70.0%), and rank 1 minus rank 2 score threshold >2. All protein
hits found in a distinct database search by Spectrum Mill are non-redundant.
2.4.2 Agilent MassHunter Qualitative Analysis with BioConfirm (Version B.06.00,
Build 6.0.633.0)
Once proteins were identified using Spectrum Mills Proteomic Workbench the
BioConfirm software package was used to investigate the identified proteins further
using high-resolution mass spectrometry data. Once the files were loaded into the
software “Find by Molecular Feature” was used to identify the compound in the samples
meeting the criteria found in Table 2.5. The protein sequences from each protein
identified were loaded into the software using trypsin as the digestion reagent allowing
Table 2.6: BioConfirm "Find by Molecular Feature" parameters
used to identify compounds from mass spectrometry data.
Find by molecular Feature

Parameter

Target Data type

Small molecules (chromatographic)

Restrict m/z to

350.00-2000.00 m/z

Use Peaks with height

≥100 counts

Ion Species

H+, Na+, K+

Peak Space tolerance

0.0025 m/z, plus 7.0 ppm

Isotope Model

Peptides

Maximum charge state

15
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for up to 2 missed cleavages, global modifications were set to alkylation (iodoacetamide),
and variable modifications were set to deamidation and oxidation. The compounds
identified from “Find by Molecular Feature” were then analyzed using “Define and
Match Sequences” with the MS tolerance of 10.00 ppm, and the MS/MS tolerance of 50.00
ppm.
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Chapter 3: Results and Discussion for Proteins Interacting with mARC1 and mARC2
3.1 K-BLoC, LTR-K-BLoC Complex, and mARC1 Native Intact Protein Mass
Spectrometry
Mass spectrometric analysis was used to identify LTR-K-BLoC complex binding
to mARC1. A bottom-up approach was used first to identify the starting materials KBLoC, and Sulfo-SBED reagent, then the LTR-K-BLoC complex, and finally intact mARC1
with LTR-K-BLoC bound.
The K-BLoC compound (179.22 MW) was identified by mass spectrometry as seen
in Figure 3.1. The highest abundant peak at 180.1105 m/z (M+H)+ suggests the protonated
form of K-BLC. The second most abundant peak at 163.0838 m/z indicates a loss of a –OH
group suggesting the reduced form of K-BLoC may also be present.
(M+H)+

Figure 3.1: Mass spectrum for K-BLC compound.

Analysis of Sulfo-SBED label transfer reagent was performed under the same
instrument parameters. Upon the addition of DMSO the NHS-ester side chain is
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(M-NHS ester)+

(M-NHS ester+Na)+

(M+H)+

(M+Na)+

Figure 3.2: Mass spectrum for Sulfo-SBED label transfer reagent.

removed, activating one of the reactive group. In Figure 3.2 of the mass spectrometry
analysis of Sulfo-SBED label transfer reagent, there are four compounds present from the
m/z range of 675 to 885. The most abundant peak at 681.2291 m/z is proposed to be
activated Sulfo-SBED reagent with the loss of the NHS-ester. The peak present at 703.2108
m/z denotes a mass shift of ~22 m/z from the activated Sulfo-SBED reagent suggesting a
sodium adduct. The peaks present at 858.2019 and 880.1828 m/z are proposed to be the
starting/unactivated form of Sulfo-SBED, without and with a sodium adduct.
Once the Sulfo-SBED label transfer reagent was activated by removal of the NHSester side chain, it was anticipated to bind to the lysine side chain of the K-BLoC
compound. Figure 3.3 is the mass spectrometry analysis of the LTR-K-BLoC complex.
The peaks present at 681.2266 and 703.2084 m/z are the activated Sulfo-SBED without and
with sodium adduct. The peaks of interest are present at 842.3227 and 864.3047 m/z which
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(M)+

(M+Na)+

Figure 3.3: Mass spectrum for LTR-K-BLC complex.

are suggested to be the bound Sulfo-SBED and K-BLoC compound (LTR-K-BLoC
complex).
To identify the interaction of the LTR-K-BLoC complex and mARC proteins, native
intact protein mass spectrometry was used. Figure 3.4 show the purified mARC1
analyzed intact (A) and the deconvoluted results (B). The calculated MW of the
cytoplasmic portion (41-337 AA) of mARC1 is 33,635.80 Da, and the molybdopterin
cofactor is 519.26 Da. Adding the protein and the cofactor the calculated mass is 34,155.06
Da. The calculated value and observed (34,146.42 Da) from the deconvoluted results
agree reasonably with a 0.025% difference. After incubating with the LTR-K-BLoC
complex and deconvoluting the results (Figure 3.5) there is a noticeable split of the intact
mARC1 peak. The unreacted mARC1 appears at 34,144.47 Da, but four other peaks
appear to have emerged. The calculated MW of mARC1, the cofactor, and the LTR-K-
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A

B

Figure 3.4: Mass spectrum for intact mARC1 unreacted with LTR-K-BLoC complex. A. Mass
spectrum gathered from the analysis of intact mARC1, B. the deconvoluted results of intact
mARC1.

BLoC complex is 34,997.38 Da. The peak of interest is 34,982.86 Da; the difference is
approximately 0.041% difference (or ~14.5 Da) which may be a loss of nitrogen or possibly
oxygen in the complexed protein.
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A

B

Figure 3.5: Mass spectrum for intact mARC1 reacted with LTR-K-BLoC complex. A. Mass
spectrum gathered from the analysis of intact mARC1 reacted with LTR-K-BLoC complex, B. the
deconvoluted results of intact mARC1 reacted with LTR-K-BLoC complex.

3.2 Data Mining mARC1 and mARC2 Protein-protein Interactions
Very few interaction studies have been performed using mARC1 and mARC2.
Using STRING database (string-db.org/), reported protein-protein interactions were
compiled for mARC1 and mARC2.[138] Interactions in the database classified under 8
categories (neighborhood, gene fusion, co-occurrence, experiments, databases, data
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mining, and homology). Each interaction is scored with a confidence score, which was
set to ≥0.5 for mARC1 and mARC2 interactions. The confidence score is calculated by
combining the probabilities of various evidence and correcting for the random
observations of interaction.[139] STRING database also categorizes the interacting
proteins into functional networks (e.g., GOTerm biological process, GOTerm molecular
function, and KEGG pathways). The categories are ranked by false discovery rate;
nothing was reported with a score of ≥0.03 for biological process, ≥0.01 molecular
function, and ≥0.01 KEGG pathway. The false discovery rate was calculated using a
statistical enrichment test referred to as LRpath.[140, 141] This form of statistical
comparison uses logistic regression so the data can remain on a continuous scale and
results can be interpreted similarly to the Fisher’s Exact test.[140, 141]
There were 20 proteins that were reported in the STRING database to be shown as
interacting with mARC1. There were 8 of the 20 were identified from data mining, and
12 identified from experiments (i.e. co-immunoprecipitation, and affinity capture-MS
assay) for mARC1. The 20 proteins can be found in Table 3.1 and labeled according to
their associated categories, functional networks, and scores.
There are 12 GOTerm biological processes involving the interacting proteins.
Interestingly, the three biological processes with the lowest false discovery rate are: small
molecules metabolic, single-organism metabolic, and oxidation-reduction processes.
Based on this information, 8 of the interacting proteins are involved in the oxidation41

reduction process, and mARC1 is known to reduce compound with amidoxime groups
suggesting its potential physiological involvement. There are also 3 biological processes,
respiratory electron transport chain, mitochondrial electron transport, and mitochondrial
ATP synthesis coupled electron transport. All of which are involved in electron transfer
processes, suggesting mARC may function as a redox protein.
There are 4 GOTerm molecular functions identified for the interacting proteins.
The top two molecular functions are oxidoreductase activity, and oxidoreductase activity
acting on NAD(P)H. Again strengthening the proposal that mARC1 may be involved in
reductive processes as its biological function.
Of the 20 interacting proteins identified with mARC1, 9 were affiliated with 7
different KEGG pathways identified for interacting proteins with mARC1. The pathway
with the lowest false discovery score is oxidative phosphorylation. Interestingly enough
the next 4 pathways identified are different disease pathways, non-alcoholic fatty liver
disease, Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. There were
8 potential interacting proteins with mARC2 predicted through data mining. The 8
proteins can be found in Table 3.2 and labeled according to their associated categories,
functional networks, and scores. There were 4 GOTerm biological processes that were
reported for interacting proteins with mARC2, molybdopterin cofactor biosynthetic
proteins, small molecule, water-soluble vitamin, and single-organism metabolic process.
The interactions of molybdopterin proteins (MOCS1, MOCS2, GPHN) may be involved
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in the maturation process of mARC2. Similar to mARC1, cytochrome b5 reductase has
also been proposed to interact with mARC proteins because it is involved in the reductive
system.
The information provided regarding the GOTerm molecule function and KEGG
pathways provides almost no information regarding the potential physiological function
of mARC2. Xanthine dehydrogenase contains a molybdopterin cofactor binding domain
similar to that in mARC2. The MOCS1 and MOCS2 proteins are both involved in the
sulfur relay system and the folate biosynthesis pathways. The sulfur relay system is a
signaling system involved in cell cycles processes like cell proliferation, apoptosis, and
DNA repair.
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Table 3.1: Proteins identified in the STRING database as interacting proteins with mARC1.
UniProt ID (Gene
Name), Protein
Name

Category
(Score)

GOTerm Biological Process (False Discovery Rate)

Experiments
(0.644)

small molecule metabolic process (0.00878); singleorganism metabolic process (0.00878); purine
nucleotide metabolic process (0.024); ATP metabolic
process (0.0252); organonitrogen compound
metabolic process (0.0341)

Q9UKI2
(CDC42EP3), Cdc42
effector protein
3[142-152]
Q6BCY4 (CYB5R2),
NADH-cytochrome
b5 reductase 2[105]

Data mining
(0.675)

Data mining
(0.567)

small molecule metabolic process (0.00878); singleorganism metabolic process (0.00878); oxidationreduction process (0.00878)

Q52LR7 (EPC2),
Enhancer of
polycomb homolog
2[49, 153]
Q96DN0 (ERP27),
Endoplasmic
reticulum resident
protein 27[105]
Q15031 (LARS2),
Probable leucine-tRNA ligase,
mitochondrial[154]
Q9P015 (MRPL15),
39S ribosomal
protein L15,
mitochondrial[20]

Data mining
(0.526)

single-organism metabolic process (0.00878)
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P15313 (ATP6V1B1),
V-type proton
ATPase subunit B,
kidney isoform[20]

Data mining
(0.517)

Data mining
(0.596)

Experiments
(0.644)

GOTerm
Molecular
Function (False
Discovery Rate)

small molecule metabolic process (0.00878); singleorganism metabolic process (0.00878);
organonitrogen compound metabolic process
(0.0341)
single-organism metabolic process (0.00878);
organonitrogen compound metabolic process
(0.0341)

KEGG Pathway (False Discovery
Rate)
Oxidative phosphorylation
(0.0000516); Metabolic pathways
(0.00512); Phagosome (0.0163)

oxidoreductase
activity (0.0055);
oxidoreductase
activity, acting on
NAD(P)H (0.0055)

Table 3.1: Continued
UniProt ID (Gene
Name), Protein
Name

Category
(Score)

GOTerm Biological Process (False Discovery Rate)

Experiments,
Data mining
(0.695)

single-organism metabolic process (0.00878);
organonitrogen compound metabolic process
(0.0341)

Experiments,
Data mining
(0.676)

O95168 (NDUFB4),
NADH
dehydrogenase
[ubiquinone] 1 beta
subcomplex subunit
4[5, 14, 20]

Experiments
(0.644)

small molecule metabolic process (0.00878); singleorganism metabolic process (0.00878); oxidationreduction process (0.00878); respiratory electron
transport chain (0.0202); mitochondrial electron
transport, NADH to ubiquinone (0.024); purine
nucleotide metabolic process (0.024); energy
derivation by oxidation of organic compounds
(0.024); mitochondrial ATP synthesis coupled
electron transport (0.0252); cellular respiration
(0.0252); ATP metabolic process (0.0252); oxidative
phosphorylation (0.0286); organonitrogen compound
metabolic process (0.0341)
small molecule metabolic process (0.00878); singleorganism metabolic process (0.00878); oxidationreduction process (0.00878); respiratory electron
transport chain (0.0202); mitochondrial electron
transport, NADH to ubiquinone (0.024); purine
nucleotide metabolic process (0.024); energy
derivation by oxidation of organic compounds
(0.024); mitochondrial ATP synthesis coupled
electron transport (0.0252); cellular respiration
(0.0252); ATP metabolic process (0.0252); oxidative
phosphorylation (0.0286); organonitrogen compound
metabolic process (0.0341)
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Q9NYK5 (MRPL39),
39S ribosomal
protein L39,
mitochondrial[20]
O96000 (NDUFB10),
NADH
dehydrogenase
[ubiquinone] 1 beta
subcomplex subunit
10[20, 155]

GOTerm
Molecular
Function (False
Discovery Rate)

KEGG Pathway (False Discovery
Rate)

oxidoreductase
activity (0.0055);
oxidoreductase
activity, acting on
NAD(P)H
(0.0055); NADH
dehydrogenase
(ubiquinone)
activity (0.0114)

Oxidative phosphorylation(0.0000516);
Non-alcoholic fatty liver disease
(0.00133); Parkinson s disease
(0.00133); Alzheimer s disease
(0.00154); Huntington s disease
(0.00181); Metabolic pathways
(0.00512)

oxidoreductase
activity (0.0055);
oxidoreductase
activity, acting on
NAD(P)H
(0.0055); NADH
dehydrogenase
(ubiquinone)
activity (0.0114)

Oxidative phosphorylation
(0.0000516); Non-alcoholic fatty liver
disease (0.00133); Parkinson s disease
(0.00133); Alzheimer s disease
(0.00154); Huntington s disease
(0.00181); Metabolic pathways
(0.00512)

Table 3.1: Continued
UniProt ID (Gene
Name), Protein
Name

Category
(Score)
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O43181 (NDUFS4),
NADH
dehydrogenase
[ubiquinone] ironsulfur protein 4,
mitochondrial[20]

Experiments
(0.644)

Q9H0N0 (RAB6C),
Ras-related protein
Rab-6C[14, 20]
P31040 (SDHA),
Succinate
dehydrogenase
[ubiquinone]
flavoprotein
subunit,
mitochondrial[20]
Q8IWL2 (SFTPA1),
Pulmonary
surfactantassociated protein
A1[156, 157]

Experiments
(0.644)
Experiments,
Data mining
(0.655)

Data mining
(0.53)

GOTerm Biological Process (False Discovery Rate)
small molecule metabolic process (0.00878); singleorganism metabolic process (0.00878); oxidationreduction process (0.00878); respiratory electron
transport chain (0.0202); mitochondrial electron
transport, NADH to ubiquinone (0.024); purine
nucleotide metabolic process (0.024); energy
derivation by oxidation of organic compounds
(0.024); mitochondrial ATP synthesis coupled
electron transport (0.0252); cellular respiration
(0.0252); ATP metabolic process (0.0252); oxidative
phosphorylation (0.0286); organonitrogen compound
metabolic process (0.0341)

small molecule metabolic process (0.00878); singleorganism metabolic process (0.00878); oxidationreduction process (0.00878); respiratory electron
transport chain (0.0202); energy derivation by
oxidation of organic compounds (0.024); cellular
respiration (0.0252)

GOTerm
Molceular
Function (False
Discovery Rate)
oxidoreductase
activity (0.0055);
oxidoreductase
activity, acting on
NAD(P)H
(0.0055); NADH
dehydrogenase
(ubiquinone)
activity (0.0114)

oxidoreductase
activity (0.0055)

KEGG Pathway (False Discovery
Rate)
Oxidative phosphorylation(0.0000516);
Non-alcoholic fatty liver disease
(0.00133); Parkinson s disease
(0.00133); Alzheimer s disease
(0.00154); Huntington s disease
(0.00181); Metabolic pathways
(0.00512)

Oxidative phosphorylation
(0.0000516); Non-alcoholic fatty liver
disease (0.00133); Parkinson s disease
(0.00133); Alzheimer s disease
(0.00154); Huntington s disease
(0.00181); Metabolic pathways
(0.00512)
Phagosome (0.0163)

Table 3.1: Continued
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UniProt ID (Gene Name),
Protein Name

Category
(Score)

O00330 (PDHX), Pyruvate
dehydrogenase protein X
component,
mitochondrial[11, 20]
Q8IWL1 (SFTPA2),
Pulmonary surfactantassociated protein A2[156,
157]
Q96AG3 (SLC25A46),
Solute carrier family 25
member 46[20]
P0CG48 (UBC),
Polyubiquitin-C[158]

Experiments,
Data mining
(0.662)

P47989 (XDH), Xanthine
dehydrogenase/oxidase[49,
105, 159-161]

Data mining
(0.52)

Q9UPT8 (ZC3H4), Zinc
finger CCCH domaincontaining protein 4[20]

Experiments
(0.644)

GOTerm Biological Process (False Discovery
Rate)

GOTerm
Molceular
Function (False
Discovery Rate)

small molecule metabolic process (0.00878);
single-organism metabolic process (0.00878)

KEGG Pathway (False Discovery
Rate)
Metabolic pathways (0.00512)

Data mining
(0.527)

Phagosome (0.0163)

Experiments
(0.644)
Experiments
(0.86)

small molecule metabolic process (0.00878);
single-organism metabolic process (0.00878);
oxidation-reduction process (0.00878); energy
derivation by oxidation of organic compounds
(0.024)
small molecule metabolic process (0.00878);
single-organism metabolic process (0.00878);
oxidation-reduction process (0.00878); purine
nucleotide metabolic process (0.024);
organonitrogen compound metabolic process
(0.0341)

oxidoreductase
activity (0.0055);
molybdopterin
cofactor binding
(0.0114)

Metabolic pathways (0.00512)

Table 3.2: Proteins identified in the STRING database as interacting proteins with mARC2.
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UniProt ID (Gene Name),
Protein Name

Category
(Score)

Q15031 (LARS2), Probable
leucine-tRNA ligase,
mitochondrial[154]
Q96DN0 (ERP27),
Endoplasmic reticulum
resident protein 27[105]
Q6BCY4 (CYB5R2),
NADH-cytochrome b5
reductase 2[105]
Q52LR7 (EPC2), Enhancer
of polycomb homolog
2[162]
O96007 (MOCS2),
Molybdopterin synthase
catalytic subunit[49, 160,
163]

Texting
mining (0.636)

Q9NP27 (MOCS1),
Molybdenum cofactor
synthesis-step 1 protein A
splice type I[49]

Texting
mining (0.882)

P47989 (XDH), Xanthine
dehydrogenase oxidase[49,
105, 160, 164, 165]
Q9NQX3 (GPHN),
Gephyrin[49]

Texting
mining (0.505)

GOTerm Biological Process (False Discovery
Rate)

GOTerm
Molecular
Function (False
Discovery Rate)

KEGG Pathway (False Discovery
Rate)

small molecule metabolic process (0.00489),
single-organism metabolic process (0.0147)

Texting
mining (0.500)
Texting
mining (0.560)

small molecule metabolic process (0.00489),
single-organism metabolic process (0.0147)

Texting
mining (0.566)

single-organism metabolic process (0.0147)

Texting
mining (0.842)

Mo-molybdopterin cofactor biosynthetic process
(0.00000325), small molecule metabolic process
(0.00489), water-soluble vitamin metabolic
process (0.0138), single-organism metabolic
process (0.0147)
Mo-molybdopterin cofactor biosynthetic process
(0.00000325), small molecule metabolic process
(0.00489), water-soluble vitamin metabolic
process (0.0138), single-organism metabolic
process (0.0147)
small molecule metabolic process (0.00489),
single-organism metabolic process (0.0147)

Neighborhood,
Data mining
(0.758)

Mo-molybdopterin cofactor biosynthetic process
(0.00000325), small molecule metabolic process
(0.00489), water-soluble vitamin metabolic
process (0.0138), single-organism metabolic
process (0.0147)

Sulfur relay system (0.00222), Folate
biosynthesis (0.00224)

Sulfur relay system (0.00222), Folate
biosynthesis (0.00224)

molybdopterin
cofactor binding
(0.00707)

3.3 Experimental and Control Conditions to Identify Interacting Partners with mARC
Proteins
3.3.1 Co-immunoprecipitation
Co-immunoprecipitation experiments utilize antigen-antibody reactions to
precipitate the targeted bait protein as well as interacting partners.[166] Monoclonal and
polyclonal antibodies have their advantages and challenges in co-immunoprecipitation
experiments. While monoclonal antibodies target specific epitopes within protein
sequences resulting in reduced background noise and cross-reactivity, polyclonal
antibodies allow for sequence flexibility in the target site tolerating sequence variability
leading to a more robust detection of the target proteins.[166] The advantages of coimmunoprecipitation include high specificity based on the characteristics of the antibody,
and compatibility with downstream analysis, in which mass spectrometric techniques
will be used.[167, 168] In contrast the disadvantages to co-immunoprecipitation include
the limitation of the specificity of the antibody used, and often a considerable amount of
protein extract (100-1000 µg) of protein is required for identification downstream.[166168] Co-immunoprecipitation experiments have been used in several instances to identify
interacting partners. Luethy et al. used co-immunoprecipitation to study protein-protein
interactions of pyruvate dehydrogenase complex (PDC) in pea seedlings.[169] PDC is a
large (5000-7000 kDa) multi-component complex comprised of three major enzymes
(pyruvate

dehydrogenase,

E1

dihydrolipoamide
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transacetylase,

E2;

and

dihydrolipoamide dehydrogenase, E3) with multiple subunits of each enzyme.[169] A
highly specific antibody to PDC-E1α subunit was found to precipitate subunits E1β, E2,
and E3 when separated on SDS-PAGE.[169] Using a novel approach in which coimmunoprecipitation was linked with crosslinking Huang et al. examined interacting
proteins with protein kinase B (Akt) in mouse neuroblastoma cells.[170] Akt is a
serine/threonine-specific protein kinase that is essential for multiple cellular
processes.[170] They were able to crosslink the Akt antibody to agarose bead, incubate
with cell lysate containing Akt protein, then chemically crosslinking interacting proteins
to Akt using dithiobis[succinimidylpropionate].[170] Using this method they were able
to identify ten interacting proteins with Akt, with only one of which that was able to be
detected without the added crosslinking step.[170] The previous examples are only a few
of the successful experiments utilizing co-immunoprecipitation to studying interacting
partners with target proteins.
3.3.2 Crosslinking
Chemical crosslinking involves the process of covalently binding interacting
proteins together using a reagent with two reactive groups separated by a spacer/linker
region.[171] The benefits of crosslinking allow for transient interactions between proteins
to be probed by “locking” the interactions.[166] Crosslink reagents have been customized
to meet the users’ needs by varying the chemical activity, length of that spacer, water
solubility, cell membrane permeability, and cleavability.[167] Crosslinking is coupled
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with including, but not limited to affinity purification, mass spectrometric identification,
and SDS-PAGE.[172, 173] A disadvantage to using crosslinking reagents is the
nonspecific interactions that may occur when other proteins are in the vicinity of the bait
protein.[166] These nonspecific interactions may not be in direct contact with the bait
protein. Downstream analysis of proteins or peptides can often be more difficult by the
addition of chemical crosslinking reagents.[167] One such example of chemical
crosslinking utilizes formaldehyde as the crosslinking reagent to investigate proteinprotein interactions within yeast cells.[174] In this study Hall et al. wished to develop a
way of investigating interactions within the cells using formaldehyde to crosslink
transcriptional activator proteins chemically.[174] They were able to demonstrate the
direct interaction of VP16 activation domain and TATA-binding protein, transcription
factor II B, and SAGA histone acetylase complex.[174] Li et al. performed a
comprehensive protein-protein interaction study of DmsD maturation protein in E. coli
strains by utilizing affinity chromatography, co-precipitation, and crosslinking.[175] The
study used the same crosslinking reagent as was used in this investigation, Sulfo-SBED
label transfer reagent. They were able to identify six chaperones and molybdenum
cofactor biosynthesis proteins through this method.[175] The use of crosslinking reagents
aids in the stabilization of protein interactions by covalently linking partners together,
allowing for the strong and weak interacting partners to be identified.
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3.3.3 Pull-down
The pull-down assay usually utilizes a fusion tagged (i.e. GST, MBP, CBP, polyHis, or biotin) bait protein which demonstrates a high affinity for an enzyme and
substrate, receptor and ligand, antibody and antigen.[166] The bait protein can often be
overexpressed and purified using the resin compatible with the fusion tag. The drawback
to pull-down assays is a significant amount of DNA manipulation is required to
overexpress tagged bait protein.[167] Matsunami et al. utilized pull-down assays to
identify interacting partners of FlgA-FlgI complex in E. coli OrigamiTM 2.[176] FlgI protein
was overexpressed with an N-terminal poly-histidine tag to investigate the isolation of
the complex using metal affinity chromatography.[176] Pull-down assays are not limited
to poly-histidine tags, Wei et al. utilized a GST-tag to affinity purify interacting proteins
in the ATP-binding cassette transport system in Bifidobacterium longum NCC2705.[177]
There are four subunits in the system, FruE, FruK, FruF, and FruG. Using the GST-tag
they were able to identify interactions between external-side membrane subunits FruF
and FruG with FruE which shows a high correlation with the proposed model for
bacterial ABC sugar transporters.[177] Pull-down assays can utilize a wide array of
affinity tags to affinity purify bait and target proteins to identify interacting partners with
high compatibility with downstream analysis methods.
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3.3.4 Protein-protein Interactions of mARC1 and mARC2 Results
Utilizing the antibodies listed in Table 2.1 a total of 176 proteins were identified
in mARC1 and 83 proteins were identified in mARC2 control and in the coimmunoprecipitation experiments. Figure 3.6A show the proteins that were identified in
control samples as well as in experimental conditions in mARC1 and mARC2 samples.
In mARC1 samples, 85 proteins were identified as unique when compared to the controls
conditions, and 23 proteins were identified as unique in mARC2 conditions.
Using the trifunctional crosslinking reagent (Appendix I, Figure A.1A) a total of
124 proteins were identified in mARC1 and 25 proteins identified in mARC2 control and
in experimental conditions in the crosslinking experiments. Figure 3.6B show the
proteins that were identified in control, and experimental conditions in mARC1 and
mARC2 samples. In mARC1 samples 106 proteins were identified as unique when
compared to the controls conditions and in mARC2 13 proteins were identified as unique.
A total of 181 proteins were identified in mARC1 and 112 proteins identified in
mARC2 control and experimental conditions in the crosslinking experiments. Figure 3.6C
show the proteins that were identified in control, and experimental conditions in mARC1
and mARC2 samples. In mARC1 samples 27 proteins were identified as unique when
compared to the control conditions, and in mARC2 samples 18 proteins were identified
as unique.
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Pull-down experiments including mARC1 and mARC2 proteins had the most
proteins identified from other protein-protein interaction methods. This may suggest an
increase number of false positives interacting with the Co-NTA resin. The crosslinking
experiments in both mARC1 and mARC2 yielded the lowest number of proteins
identified, suggesting a reduced number of false positive interactions and potentially a

mARC1
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mARC2

Control Conditions

6
B

Control Conditions

138 50
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Experimental Conditions

Control Conditions
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Experimental Conditions

Control Conditions
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1

Experimental Conditions

Control Conditions

19 18
Experimental Conditions

Control Conditions

26 154 12
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Experimental Conditions
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Figure 3.6: Venn diagrams depicting the number of proteins that were identified in control
conditions compared to experimental conditions. A. Co-immunoprecipitation experiments, B.
Crosslinking experiments, C. Pull-down experiments. The complete list of proteins identified for
all experiments can be found in Appendix II, Table A.1 for mARC1 samples and Appendix II,
Table A.2 for mARC2 samples.
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more reliable method for analyzing protein-protein interactions using the method used
for this investigation. The co-immunoprecipitation experiments yielded a number of
proteins between the pull-down crosslinking experiments, but there was difficulty
disguising interacting partners due to the lack of specificity of the mARC1 and mARC2
antibodies.
3.4 Bioinformatics Results and Discussion for Protein-protein Interactions
3.4.1 Reducing Falsely Identified Interacting Proteins with mARC Proteins
One of the issues with performing any protein-protein interaction studies is false
positives identified from the mass spectrometric analysis. To minimize the number of
false positives, the following criteria were set: BioConfirm score of ≥10, ≥2 MS/MS spectra
per peptide, ≥2 unique peptides per protein, and absent in the controls (Figure 3.7). The
number of total proteins meeting these criteria significantly reduced the number of

Figure 3.7: Workflow for reducing the potential false positive interactions in all three
experimental conditions.
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identified proteins. In mARC1 samples, 38 proteins were identified and 28 proteins
identified for mARC2. Figure 3.8 represents the number of proteins found in each of the
different experimental conditions. The proteins identified in the crosslinking experiment
seemed to demonstrate a higher similarity with proteins identified in both pull-down and
co-immunoprecipitation. Upon further analysis of the co-immunoprecipitation
experiments, it was determined that the mARC1 and mARC2 antibodies used were not
specific and subsequently also purified both mARC proteins. Therefore, we included a
single circle in the middle of the Venn diagram. In mARC1 samples, 12 proteins were
found in all three experimental types and mARC2 6 proteins were found in all three types
Crosslinking

mARC1*

Pulldown

0

1

0
2

11

20

5*+7†
15
0
6
mARC2†

0

0

Crosslinking

Co-IP

0
Pulldown

Figure 3.8: Venn diagram depicting the number of proteins
identified comparing the experimental conditions. Proteins
identified in co-immunoprecipitation for mARC1 (*) and mARC2
(†)
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(Table 3.4). The proteins in Table 3.5 were identified in two experimental conditions and
Table 3.6 were identified one experimental condition for mARC1 and mARC2
respectively.
Table 3.3: The proteins identified in all three experimental conditions for mARC1 and
mARC2 proteins.
UniProt ID

Interacting mARC
Protein

Protein Name

Q8N187

Calcium-responsive transcription factor

mARC1

Q8IYX3

Coiled-coil domain-containing protein 116

mARC1

Q7L0Q8

Rho-related GTP-binding protein RhoU

mARC1

P02768

Serum albumin

mARC1

Q15431

Succinate dehydrogenase [ubiquinone] flavoprotein subunit,
mitochondrial
Synaptonemal complex protein 1

Q9BZE0

Zinc finger protein GLIS2

mARC1

Q5VT66

Mitochondrial amidoxime-reducing component 1

mARC1

Protein BIVM-ERCC5 (Fragment)

mARC1

Q9P218

Collagen alpha(XX) chain

mARC1

P27816

Microtubule-associated protein 4

mARC1

Q04726

Transducin-like enhancer protein 3

mARC1

O75891

Cytosolic 10-formyltetrahydrofolate dehydrogenase

mARC2

O94927

HAUS augmin-like complex subunit 5

mARC2

O95696

Bromodomain-containing protein 1

mARC2

Q6UB35

Monofunctional C1-tetrahydrofolate synthase, mitochondrial

mARC2

Q86XP3

ATP-dependent RNA helicase DDX42

mARC2

Q969Z3

Mitochondrial amidoxime reducing component 2

mARC2

P31040

R4GMW8
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mARC1
mARC1

Table 3.4: Proteins identified in at least two experimental conditions interacting partners with
mARC1 and mARC2 in HEK-293 cell lysate.
UniProt ID

Protein Name

Interacting mARC
Protein; Technique

Q32M45

Anoctamin-4

mARC1; 1, 3

P06727

Apolipoprotein A-IV

mARC1; 1, 3

Q8IYE1

Coiled-coil domain-containing protein 13

mARC1; 1, 3

P51160

Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha

mARC1; 1, 3

P78334

Gamma-aminobutyric acid receptor subunit epsilon

mARC1; 1, 3

P04908

Histone H2A type 1-B/E

mARC1; 1, 3

Q6UXK5

Leucine-rich repeat neuronal protein 1

mARC1; 1, 3

E5KNQ5

Mitochondrial thymidine kinase 2

mARC1; 1, 3

Q969R2

Oxysterol-binding protein 2

mARC1; 1, 3

Q8IUH5

Palmitoyltransferase ZDHHC17

mARC1; 1, 3

Q8NFW9

Rab effector MyRIP

mARC1; 1, 3

Q3MIN7

Ral guanine nucleotide dissociation stimulator-like 3

mARC1; 1, 3

Q6MZT1

Regulator of G-protein signaling 7-binding protein

mARC1; 1, 3

P21549

Serine--pyruvate aminotransferase

mARC1; 1, 3

Q549N5

Signal recognition particle receptor beta subunit

mARC1; 1, 3

Q8NCR6

Spermatid-specific manchette-related protein 1

mARC1; 1, 3

Q9BT88

Synaptotagmin1

mARC1; 1, 3

O95049

Tight junction protein ZO-3

mARC1; 1, 3

Q8IYS4

Uncharacterized protein C16orf71

mARC1; 1, 3

Q3SY52

Zinc finger protein interacting with ribonucleoprotein K

mARC1; 1, 3

Q14684

Ribosomal RNA processing protein 1 homolog B

mARC1; 1, 2

P46977

Dolichyl-diphosphooligosaccharide-protein glycosyltransferase

mARC1; 1, 2

Q9NUT2

ATP-binding cassette sub-family B member 8, mitochondrial

mARC1; 1, 3

Q8TCU4

Alstrom syndrome protein 1

mARC1; 1, 3

Q6P2H3

Centrosomal protein of 85 kDa

mARC1; 1, 3

P62269

40S ribosomal protein S18

mARC2; 1, 3

P62701

40S ribosomal protein S4, X isoform

mARC2; 1, 3

P46782

40S ribosomal protein S5

mARC2; 1, 3

Q9C0H9

SRC kinase signaling inhibitor 1

mARC2; 1, 3

Q71U36

Tubulin alphaA chain

mARC2; 1, 3

Q9UKX5

Integrin alpha1

mARC2; 1, 3

Q6ZU35

Uncharacterized protein KIAA1211

mARC2; 1, 3

P54764

Ephrin type-A receptor 4

mARC2; 1, 3

P00748

Coagulation factor XII

mARC2; 1, 3

Protein FAM83B

mARC2; 1, 3

Q6PJ61

F-box only protein 46

mARC2; 1, 3

Q06787

Fragile X mental retardation protein 1

mARC2; 1, 3

Q5T0W9

Technique:
1. Co-immunoprecipitation
2. Crosslinking reagent
3. Pull-down assay
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Table 3.5: Proteins identified in one experimental conditions interacting partners with mARC1
and mARC2 in HEK-293 cell lysate.
UniProt ID

Protein Name

Interacting mARC
Protein; Technique

Q53EZ4

Centrosomal protein of 55 kDa

mARC1; 1

Q9BTM1

Histone H2A.J

mARC1; 1

A2A2F5

Protein TMEPAI

mARC1; 1

J3QRV1

Sodium/hydrogen exchanger 5

mARC1; 1

Q9H2M3

S-methylmethionine-homocysteine S-methyltransferase BHMT2

mARC1; 3

Q13496

Myotubularin

mARC2; 1

O76074

cGMP-specific 3',5'-cyclic phosphodiesterase

mARC2; 1

C9JH25

Proline-rich transmembrane protein 4

mARC2; 1

Q5W0Q7

SUMO-specific isopeptidase USPL1

mARC2; 1

Q8N7Q3

Zinc finger protein 676

mARC2; 1

O75128

Protein cordon-bleu

mARC2; 1

O75947

ATP synthase subunit d, mitochondrial

mARC2; 1

Technique:
1. Co-immunoprecipitation
2. Crosslinking reagent
3. Pull-down assay

Samples were cross-compared searching to see if the other mARC protein was
present. To this end, co-immunoprecipitation experiments seemed to have both mARC1
and mARC2 present in the analysis, this data was represented in the center circle of the
Venn diagram (Figure 3.8) as it could not be distinguished if the proteins identified were
potentially interacting with mARC1 or mARC2. The chemical crosslinking reagent
appeared to have the greatest overlap in protein identified when compared to the coimmunoprecipitation and pull-down assay. There were no proteins identified in mARC1
and mARC2 samples that were uniquely identified using the LTR-K-BLoC complex,
suggesting that this method may have a lower false discovery rate.
To be able to propose a physiological function of mARC proteins, relationships of
the interacting proteins based on their functions and involvement need to be determined.
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To aid in the analysis two bioinformatics software will be used to help form relationships
of proteins.
3.4.2 Bioinformatics Platforms used to Form Relationships for Interacting Protein
To aid in the analysis of the proteins identified two different bioinformatics
platforms were used to develop connections of identified proteins (DAVID, Database for
Annotation, Visualization, and Integrated Discovery), and to help reduce contaminating
background proteins identified (CRAPome, Contaminant Repository for Affinity
Purification). DAVID was used by uploading the UniProt Accession numbers and
proteins were clustered based on similar annotations. CRAPome utilized the proteins
identified and the spectral counts for each protein within a sample. This software
platform uses experimental conditions and control conditions and applies a SAINT
probability score for each protein identified.
3.4.3 DAVID Bioinformatics Results using the Reduced Protein List
DAVID bioinformatics software was used to help compare the identified proteins
by comparing annotations found in several databases. To compare the proteins, GOTerm
function was used from The European Bioinformatics Institute (http://www.ebi.ac.uk/).
The initial analysis using DAVID were grouped into functional annotation clustering
using the parameters similarity term overlap of 3 with a threshold of 0.50, classified with
at least 3 proteins per group and multiple linkage thresholds of 0.50. The analysis of
proteins interacting with mARC1 showed 12 clusters with 70 biological process and
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molecular function annotations present. The identified proteins observed in mARC2
samples had 9 clusters with 76 biological process and molecular function annotations.
The full GOTerm trees with the cluster number, number of proteins annotated, and
similar annotation for proteins identified in mARC1 and mARC2 conditions can be found
in Appendix III, Figure A.2 to A.13. There is evidence that mARC proteins are found
outside of the mitochondria of cells, but our interest is potential physiological roles of
mARC proteins. To aid in the narrowing the scope to viable candidates, annotations were
required to be part of metabolic, and/or cellular function not including cell cycle type
functions to reduce the complexity and highlight features of interest. A truncated table
with a few interesting candidate annotations can be found in Table 3.7; the complete table
can be found in Appendix III, Table A.3, and A.4. A complete table of the identified
clusters of interacting proteins with mARC1 and mARC2 with their associated GOTerm
annotations can be found in Appendix III, Table A.8, and A.7. The annotations of interest
that were found in both mARC1 and mARC2 interacting proteins were several regulatory
process proteins both cellular and metabolic, and metabolism of various nitrogencontaining compounds (amine-containing, amino acid, and nucleic acid). The current
research for both mARC proteins has demonstrated their abilities to reduce several
amidoxime compounds, mutated base-pairs, and nitrite; which would suggest why
proteins annotated in nitrogen-containing metabolic processes are being identified as
well as nucleobase-containing compound metabolic process.[24, 26, 104, 109] More
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interestingly, however, is the number of proteins with regulatory annotations. With a list
of proteins that were identified under stringent conditions, using more than one method
of probing protein-protein interactions, and a potential relationship of proteins based on
clusters of GOTerm annotations the list of proteins was expanded to include all proteins
that were identified in the experimental conditions and not in the controls.
Table 3.6: Select GOTerm annotations for proteins interacting with mARC1 and mARC2. The
number of interacting proteins identified for mARC1 and mARC2 are listed under the annotation
tag with a short description that was found from http://www.ebi.ac.uk/
Annotated GOTerm (# of
Proteins)
Cellular protein
modification process
(mARC1 : 0)
(mARC2 : 3)
Nitrogen compound
metabolic process
(mARC1 : 8)
(mARC2 : 5)
Nucleobase-containing
compound metabolic
process
(mARC1 : 4)
(mARC2 : 3)
Regulation of biological
process
(mARC1 : 12)
(mARC2 : 8)

Signal transduction
(mARC1 : 0)
(mARC2 : 3)

Description of Term
The covalent alteration of one or more amino acids occurring in proteins, peptides
and nascent polypeptides (co-translational, post-translational modifications)
occurring at the level of an individual cell. Includes the modification of charged
tRNAs that are destined to occur in a protein (pre-translation modification).
The chemical reactions and pathways involving organic or inorganic compounds
that contain nitrogen, including (but not limited to) nitrogen fixation, nitrification,
denitrification, assimilatory/dissimilatory nitrate reduction and the
interconversion of nitrogenous organic matter and ammonium.
Any cellular metabolic process involving nucleobases, nucleosides, nucleotides
and nucleic acids.
Any process that modulates the frequency, rate or extent of a biological process.
Biological processes are regulated by many means; examples include the control
of gene expression, protein modification or interaction with a protein or substrate
molecule.
The cellular process in which a signal is conveyed to trigger a change in the
activity or state of a cell. Signal transduction begins with reception of a signal (e.g.
a ligand binding to a receptor or receptor activation by a stimulus such as light),
or for signal transduction in the absence of ligand, signal-withdrawal or the
activity of a constitutively active receptor. Signal transduction ends with
regulation of a downstream cellular process, e.g. regulation of transcription or
regulation of a metabolic process. Signal transduction covers signaling from
receptors located on the surface of the cell and signaling via molecules located
within the cell. For signaling between cells, signal transduction is restricted to
events at and within the receiving cell.

62

3.4.4 CRAPome Bioinformatics and KEGG Pathway Results for Proteins
By expanding the list to include all proteins not identified in the controls, there is
an increased likelihood of identifying false positive results. To help strengthen the results
a unique bioinformatics software was used. CRAPome utilizes all proteins identified in a
study (both control and experimental) and compares the spectral count of those proteins
to generate a SAINT score which is the likelihood of that protein being a positive
interactor or a background contaminant.[178] The spectral counts for each protein were
consolidated from the spectral count of each identified peptide in the replicates. By
expanding the search from the reduced list to the full list, we anticipate expanding the
list of proteins involved in pathways of interest to aid in the proposition of mARC
physiological function. Figure 3.9 shows the number of proteins compared to their
SAINT scores for all the proteins in the study (orange) and the proteins identified in the
reduced protein list (blue) for mARC1 (Figure 3.9A) and mARC2 (Figure 3.9B). The
majority of the total proteins had a SAINT score between 0 and 20% meaning the
likelihood of those proteins interacting with mARC proteins is reduced, and they may be
background or contaminant. In the reduced protein list the majority of the proteins had
a SAINT score between 20 and 40% allowing for greater confidence in these interacting
partners with mARC proteins. As the SAINT score increases the confidence of the
interacting protein increases. To aid in the analysis of the total proteins, KEGG annotated
pathways were investigated to see if any relationships could be generated.
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Figure 3.9: CRAPome SAINT score comparison between the proteins identified in the
reduced list and the total proteins identified in the study. Blue bars represent the number
of proteins identified and SAINT scores with the reduced protein list and the orange bars
represent all the proteins identified in the study. A. SAINT score comparison of identified
proteins in mARC1 experiments, B. SAINT score comparison of identified proteins in
mARC2 experiments
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The interacting proteins were compared using KEGG pathway annotations to
elucidate relationships of proteins further. The full list of proteins used in the CRAPome
analysis was used to compare pathways to attempt to capture a more complete overview
of interacting partners. To summarize the KEGG annotated proteins, two plots were
generated with this information for each mARC protein (Figure 3.10, and Figure 3.11).
When examining the pathway categories for mARC1 (Figure 3.10A), proteins
annotated in human disease and metabolism have the most identified. The number of
proteins identified in the category metabolism appears to have many proteins identified,
but when it is divided into the pathways, the proteins are annotated with “Global and
overview maps” which is a general pathway annotation. The pathways for human
disease and organism system categories can be found in Appendix III, Figure A.14A. In
Figure 3.10B the categories are divided into their pathways and the number of proteins
identified affiliated with each pathway. A complete list of proteins with their annotated
KEGG pathways can be found in Appendix III, A.8, and A.9. Interestingly enough, the
most proteins were identified as part of signal transduction pathways. The signal
transduction pathways can be further divided into specific pathways of involvement.
Investigating these pathways may be important in understanding the physiological role
of mARC1 within the cell. The proteins that were present in the signal transduction
pathways can be found in Table 3.8 with their specific pathway(s) of involvement. There
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is not a significant number of proteins identified for one pathway, with MAPK signaling
pathway having the most, but several of the pathways can be connected to one another
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Figure 3.10: KEGG categories and pathways for proteins interacting with mARC1. A. KEGG
categories for interacting proteins with mARC1, B. KEGG pathways for interacting proteins with
mARC1. Human disease, and organismal systems pathways can be found in Appendix III,
A.14A. Pathways in plot B are color coordinated with the category they are related to.
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Nitric oxide is an important second messenger molecule in several regulatory
processes. In fact, it has been reported that some cytokines including tumor necrosis
factors and interleukins are regulated by nitric oxide.[179, 180] Cytokines are important
signaling proteins which aid in immune response. The protein identified as an interacting
partner with mARC1 is tumor necrosis factor superfamily member 11 (O14788) which
may be involved in the modulation of intracellular concentration of calcium. More
interesting is that tumor necrosis factor-alpha has been shown to greatly impact the nitric
oxide synthase mRNA levels inside the endothelium cell.[181] In fact, it was reported that
the half-life of nitric oxide synthase mRNA was reduced from 48 hours to 3 hours.[181]
With the declining stability of nitric oxide synthase mRNA, it is possible that mARC1
may aid in the control of cytokines and promote homeostasis within the cell through the
production of nitric oxide from nitrite.
One of the predicted interactions with mARC1 is ubiquitin C which labels proteins
for degradation, DNA repair, cell cycle regulation, kinase modification, endocytosis, and
regulation of other cell signaling pathways. Two different E3 ubiquitin protein ligases
were identified as interacting with mARC1, mitogen-activated protein kinase 1, E3
ubiquitin protein ligase (Q13233) and E3 ubiquitin-protein ligase parkin (O60260).
Although there is no exact reason for the ubiquitination, we suggest it may be involved
in regulating mARC1 involvement in cell signaling.
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Mammalian signaling pathways aid the cellular response to external changes in
the cell to elicit a response inside the cell. Some signal responses are activated by receptors
or secondary messenger molecules resulting in several changes within the cell. It is of
interest that mARC1 was identified as interacting with several proteins in signaling
pathways because one of the predicted functions of mARC proteins is the reduction of
nitrite to nitric oxide under hypoxic conditions. Nitric oxide is known as a very potent
signaling molecule within cells. In the calcium signaling pathway, an efflux of calcium
into the cell binds calmodulin protein and subsequently activating the enzyme. Once
calmodulin is activated it targets proteins downstream within the NOS proteins, MAPK
and phosphatidylinositol signaling pathways, as well as other pathways. Interestingly,
the protein that was identified as interacting with mARC1, guanine nucleotide binding
protein (P30679), is upstream of calmodulin. Through a series of activations promoted by
Table 3.7: Signal transduction proteins and pathways identified as interacting proteins
with mARC1.
Signal Transduction Pathway

Proteins Names (UniProt ID)

Calcium signaling

Guanine nucleotide binding protein (P30679)

Hippo signaling

Par-6 family cell polarity regulator (Q9BYG4)

MAPK signaling

Mitogen-activated protein kinase 5 (Q99683)
Mitogen-activated protein kinase 6 (O95382)
Mitogen-activated protein kinase 1, ubiquitin protein ligase (Q13233)

NF-kappa B signaling

Tumor necrosis factor 11 (O14788)

Phosphatidylinositol signaling

Phosphatidylinositol-4-phosphate 3-kinase (O00750)

PI3K-Akt signaling

Integrin 6 (P18564)

Rap1 signaling

Par-6 family cell polarity regulator (Q9BYG4)

Sphingolipid signaling

Mitogen-activated protein kinase 5 (Q99683)

TGF-beta signaling

Retinoblastoma-like 1 (P28749)

TNF signaling

Mitogen-activated protein kinase 5 (Q99683)

Wnt signaling

LDL receptor related protein 6 (O75581)
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guanine nucleotide binding protein, calcium is released from the endoplasmic reticulum.
The release of calcium then activates calmodulin, promoting downstream processes. The
MAPK signaling pathway is a highly conserved cascade that is capable of controlling
several cellular processes. Three different mitogen-activated kinases (Mitogen-activated
protein kinase 1 (Q13233), Mitogen-activated protein kinase 5 (Q99683), Mitogenactivated protein kinase 6 (O95382)) were identified as interacting with mARC1. It has
been reported that the phosphorylation of eNOS occurs through interactions with MAPK
proteins.[182] Bernier et al. were able to isolate a complex containing eNOS, ERK1/2, Raf1,
and Akt through co-immunoprecipitation; through a Brandykinin treatment, they were
able to determine that eNOS is phosphorylated by extracellular signal-regulated kinase
(ERK) proteins.[182] The MAPK signaling pathway can be divided into three cascades,
ERK1/2 module, JNK/p38 module, and ERK5 module, each affecting different
downstream processes. The proteins that were identified as interacting with mARC1 are
affiliated with the JNK/p38 module of the MAPK signaling cascade. Suggesting that
mARC1 may be phosphorylated for activation or deactivation within the cell. The MAPK
signaling pathway has involvement in the phosphorylation of proteins in the Wnt, PI3KAkt, and the sphingolipid signaling pathways. Nitric oxide has been determined to
promote the regulation of the Wnt signaling pathway by inhibiting Dickkopf-1 gene
expression.[183] The Dickkopf family of proteins negatively inhibits the Wnt pathways
by binding the same receptor that is used to stimulate the pathway.[184] The PI3K-Akt
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and the sphingolipid signaling pathways promote the production of nitric oxide through
the phosphorylation of NOS proteins. It is unclear why mARC1 would interact with
integrin 6 (P18564), which is a β-subunit in the receptor complex; but Murohara et al.
report that nitric oxide aids in maintaining the functional expression of integrin αvβ3 in
endothelial cells.[185] The potential physiological involvement of mARC1 appears to be
extremely complex, but we propose it is involved in the regulation of signal transduction
pathways through nitric oxide production.
Comparing the annotated functions of mARC1 and mARC2 it is clear that fewer
proteins are annotated in mARC2 as affiliated with different metabolic functions.
Examining this information more closely, it can be noted that there are no proteins
annotated as “Global and overview maps” identified as interacting with mARC2 (Figure
3.11B). The general categories for mARC2 proteins (Figure 3.6A) exhibit a similar
relationship to mARC1 about “Environmental Information Processing,” and it is under
this category that the signaling pathways can be identified. The pathways for human
disease and organism system categories can be found in Appendix III, Figure A.14B. A
new third pathway list in Figure 3.11B was identified in proteins interacting with mARC2
(“Membrane transport”) when compared to mARC1 pathways.
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Figure 3.11: KEGG categories and pathways for proteins interacting with mARC2. A. KEGG
categories for interacting proteins with mARC1, B. KEGG pathways for interacting proteins with
mARC2. Human disease, and organismal systems pathways can be found in Appendix III,
A.14B. Pathways in plot B are color coordinated with the category they are related to.
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The annotated “Membrane transport” proteins are of interest to investigating the
potential physiological role of mARC2 because they can be related to what is currently
know about the enzyme. A complete list of annotated “Membrane transport” proteins
can be found in Appendix III, Table A.3. Three different ATP synthase subunits (P36542,
P48047, and O75947) were identified as being mitochondrial, similar to the known
location of the mARC2 protein. ATP synthase is a protein complex that utilizes a proton
gradient to produce ATP from ADP and inorganic phosphate. One cell process, in
particular, requires ATP to drive the uptake of calcium into the cell and results in muscle
contractions. Previously reported an increase in nitric oxide levels caused an inhibition
of ATP synthase in rat muscle cells.[186] Similar to mARC1, mARC2 is capable of
producing nitric oxide from nitrite.[26] Suggesting that mARC2 may aid in the relaxation
of muscle cell by generating nitric oxide to inhibit ATP synthase and as a result decreasing
the calcium uptake allowed through the energy-dependent calcium transport proteins.
A sequence analysis of mARC2 protein demonstrates the presence of a
molybdenum cofactor sulfurase (MOSC) domain, which is a highly conserved region in
other molybdenum containing enzymes (AO, and xanthine dehydrogenase). The three
molybdenum cofactor maturation proteins, MOCS1, MOCS2, and GPHN, were also
identified as interacting partners with mARC2. This would suggest that a complex
between the four proteins may take place in the maturation of mARC2.
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Similar to the mARC1 proteins, interacting proteins with mARC2 were identified
as being affiliated with several signaling pathways. The pathways and proteins for
interacting proteins with mARC2 can be found in Table 3.9. Comparable to the pathways
identified in mARC1 interacting proteins, the calcium, MAPK, phosphatidylinositol,
Table 3.9: Signal transduction proteins and pathways identified as interacting proteins
with mARC2.
Signal Transduction Pathway
Calcium signaling
cAMP signaling
cGMP-PKG signaling
MAPK signaling

Proteins Names (UniProt ID)
Solute carrier family 25 (P05141)
Calcium channel, voltage-dependent (Q13698)
Glutamate receptor, AMPA 2 (P42262)
Calcium channel, voltage-dependent (Q13698)
Phosphodiesterase 5A (O76074)
Solute carrier family 25 (P05141)
Calcium channel, voltage-dependent (Q13698)
Platelet derived growth factor (P01127)
Calcium channel, voltage-dependent (Q13698)

Phosphatidylinositol signaling

Myotubularin 1 (Q13496)

Phospholipase D signaling

Platelet derived growth factor (P01127)

PI3K-Akt signaling

Integrin subunit alpha 11 (Q9UKX5)
Platelet derived growth factor (P01127)

Rap1 signaling

Platelet derived growth factor (P01127)

Ras signaling

Platelet derived growth factor (P01127)

Wnt signaling

LDL receptor related protein 6 (O75581)

PI3K-Akt, Rap1 and Wnt signaling pathways seem to be present. Interestingly the cGMPPKG pathway is also present, which has involvement in nitric oxide and natriuretic
peptides regulation. Nitric oxide binds to soluble guanylate cyclase catalyzing the
conversion of cGTP to cGMP.[75] The resulting cGMP molecule activates protein kinase
G, subsequently influencing several downstream pathways including the reduction of
calcium within the cell causing muscle relaxation. The increase of cGMP within the cell
prevents the hydrolysis of cAMP by cGMP-inhibited phosphodiesterases.[187-189] The
cAMP signaling pathway also regulates downstream processes like metabolism, calcium
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homeostasis, and muscle contraction through the direct activation of protein kinase A,
Rap guanine nucleotide exchange factor, and cyclic nucleotide-gated ion channels.
Protein kinase A regulates ion channels, transporters, intracellular Ca2+-handling
proteins, and the contractile machinery, to name a few, through phosphorylation.
Guanine nucleotide exchange factor, on the other hand, modulates phospholipases and
Rap

signaling

downstream.

Phospholipase

D

catalyzes

the

hydrolysis

of

phosphatidylcholine to phosphatidic acid, which is an invaluable second messenger in
the activation of MAPK signaling pathway. In fact, nitric oxide has been reported as
stimulating the activation of phospholipase D and subsequently activating the MAPK
signaling cascade.[190-194] Nitric oxide is a potent second messenger that has an
immense impact on several pathways throughout the cells and the data presented
suggests that mARC2 may be involved as a proximity pathway activator through the
production of nitric oxide.
3.5 Protein-protein Interactions Summary for mARC1 and mARC2
Three methods of investigating protein-protein interactions were used to
understand the potential physiological role of mARC1 and mARC2 in mammalian cells.
The co-immunoprecipitation experiments were carried out using commercially available
antibodies and were able to identify 194 potential interacting proteins with mARC1 and
117 with mARC2. The crosslinking reagent experiments utilized a unique method
involving a substrate (K-BLoC) specifically designed to bind mARC proteins and “lock”
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into the binding pocket bound to a commercially available non-specific crosslinking
reagent. There was a total of 104 potential interacting proteins with mARC1 and 38
proteins with mARC2. The final experiment, pull-down assay, utilized recombinant polyhis tagged mARC1 and mARC2. There was a total of 192 potential interacting proteins
with mARC1 and 123 proteins with mARC2. To fortify the data collected from the three
methods, thresholds were applied to reduce the protein list and increase the validity. The
reduced protein list resulted in 38 proteins identified as interacting with mARC1 and 28
proteins with mARC2. There were 11 proteins that were identified in all three
experiments for mARC1 and 6 proteins for mARC2. The crosslinking reagent
experiments appeared to have the least number of potential false positive identified
proteins, as there were no unique proteins identified in the experiment.
The bioinformatics software DAVID and CRAPome were used to analysis and
group proteins together based on their GOTerm and KEGG pathway annotations. The
proteins identified as interacting with mARC1 and mARC2 proteins were clustered into
GOTerm biological and molecular function processes. There were 12 clusters of proteins
with 70 biological and molecular function processes for interacting proteins with mARC1
and 9 clusters with 76 biological and molecular function processes with mARC2. There
were 3 processes identified in proteins interacting with mARC1 and mARC2 that are of
potential importance based on what is currently known about mARC proteins and 2
processes identified only in mARC2 interacting proteins of interest. Nitrogen compound
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metabolic, regulation of biological, and nucleobase-containing compound metabolic
process were three processes had multiple identified interacting proteins with mARC1
and mARC2. The mARC proteins have been reported previously to reduce nitrogen
containing compounds, namely nitrite and compounds containing amidoxime
components as well as reducing mutated nucleobases. Interestingly, the regulation of
biological process and the other 2 processes identified in mARC2 interacting proteins,
signal transduction, and cellular proteins modification processes, may be related to
mARC proteins capabilities to produce nitric oxide from nitrite.
The bioinformatics software CRAPome was used to statistically compare the
proteins identified in the control and experimental conditions and scored for the
likelihood of positive identification. The CRAPome data was then analyzed and
compared using KEGG pathway annotations. It was found that when the interacting
proteins were grouped into their subcategories that the majority of the proteins were
grouped into signal transduction pathways. Upon further investigation of the interacting
proteins, it was found that mARC1 interacted with a tumor necrosis factor type protein
(O14788) and 2 ubiquitin-protein ligase (Q13233, O60260). We were unable to confirm a
connection between the ubiquitination of and the potential role of signaling cascades, but
we propose that mARC1 may it is possible that mARC1 may aid in the control of
cytokines and promote homeostasis within the cell through the production of nitric oxide
from nitrite. The effects of nitric oxide in several of the signaling pathways including
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calcium, Wnt, PI3K-Akt, and the sphingolipid. There is a chance that mARC1 may be
phosphorylated through the JNK/p38 module of the MAPK signaling cascade, and
subsequently affecting its reactivity or activation. We propose that the potential
physiological involvement of mARC1 appears to be involved in the regulation of signal
transduction pathways through nitric oxide production and a potential safety net for cells
if nitric oxide synthase proteins become functionally impaired. A very similar trend was
able to be followed with mARC2 protein. The signal transduction subcategory had the
majority of the proteins annotated when compared to the other categories. In addition,
there was a great deal of membrane transport proteins that were identified as interacting
with mARC2. Three subunits, in particular, that are part of the ATP synthase protein
(P36542, P48047, and O75947) may demonstrate the role of mARC2 in inhibiting the
calcium reuptake by nitric oxide and subsequently allowing muscle relaxation. The three
molybdenum cofactor maturation proteins, MOCS1, MOCS2, and GPHN, were also
identified as interacting partners with mARC2. Suggesting that a complex between the
four proteins may take place in the maturation of mARC2. The signaling pathways
identified in mARC2 are comparable to the ones identified in mARC1, except for the
cAMP, and cGMP-PKG signaling pathways that were found in mARC2. Nitric oxide aids
in the catalysis of cGTP to cGMP in the cGMP-PKG signaling pathways. The generation
of cGMP has been found to inhibit the hydrolysis of cAMP, promoting that cAMP
pathway which affects muscle contraction through calcium transport regulation. Nitric
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oxide is a potent second messenger that has an immense impact on several pathways
throughout the cells and the data presented suggest that mARC2 may be involved as a
proximity pathway activator through the production of nitric oxide.
3.6 Reverse Co-immunoprecipitation of mARC Proteins in HEK-293 Cells
Using the data derived from DAVID, and CRAPome analysis two proteins for
mARC1 and mARC2 were selected for reverse co-immunoprecipitation to support
evidence of the interactions. Reverse co-immunoprecipitation uses the same principles as
co-immunoprecipitation, except the intended target. The prey protein from the original
co-immunoprecipitation becomes the target of the antibody with the goal of precipitating
the proteins of interest. The objective of this reverse co-immunoprecipitation is to select
interacting proteins with mARC1 and mARC2, and using their antibodies to
immunoprecipitate the interacting protein with mARC proteins. The proteins selected
were of interest to signaling pathways and were identified in multiple experiments. This
was used as a confirmatory method to see if the mARC proteins interacted with the
proteins selected.
Reverse co-immunoprecipitation has been used previously by researchers to help
support their data from co-immunoprecipitation experiments. Denuc et al. used this
method to support evidence of connexin 43, a gap junction related protein found in
cardiomyocyte mitochondria, interacting with two new proteins that were identified
through co-immunoprecipitation.[195] A total of 80 candidate proteins were identified in
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three co-immunoprecipitation experiments using connexin 43 antibody.[195] Of those
proteins identified two proteins were selected for reverse co-immunoprecipitation
experiments to support evidence of protein-protein interactions, apoptosis-inducing
factor, and electron-transfer flavoprotein subunit beta.[195] They were able to determine
that connexin 43 preferentially interacts with apoptosis-inducing factor and electrontransfer flavoprotein subunit beta.[195] Using a similar strategy, Vandermoere et al. used
co-immunoprecipitation of serine/threonine kinase Akt and identified ten interacting
partners.[196] They were able to identify a 14-fold increase in the interaction of activatedAkt with cytoskeleton protein actin when compared to the non-activated form.[196] They
confirmed the interaction of Akt and cytoskeleton protein actin using reverse coimmunoprecipitation and confocal microscopy, in which they used the cytoskeleton
protein actin antibody to isolate Akt.[196] Reverse co-immunoprecipitation helps to
support evidence of protein-protein interactions when coupled with previous methods
(i.e., co-immunoprecipitation, crosslinking reagents, and pull-down assays).
The reverse co-immunoprecipitation followed the same method as coimmunoprecipitation except different antibodies were used (Table 2.1), and no purified
mARC1 and mARC2 protein were added to the sample, meaning all analysis was carried
out under native protein concentrations. The control antibody for the reverse coimmunoprecipitation experiments was an antibody for Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). GAPDH was not identified in any of the mARC experiments
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and the commercially available antibodies are specific. During the LC-MS/MS analysis, a
preferential auto MS/MS method was established in which specific mARC1 and mARC2
peptides that were previously identified consistently were scanned for and fragmented
using the parameters present in Table 3.10 and Table 3.11. Utilizing the preferred
function in auto MS/MS allows for the selected precursor ions to search for, while also
performing MS/MS on other peptides.
Table 3.9: Selected ions for preferential MS/MS for
analysis of mARC1 protein.
Sequence
(Amino Acid Location)
DLLLPIK
(133-139)
GVPVSEAECTAMGLR
(78-85)
KEPLETLK
(288-295)
KEPLETLKSYR
(288-298)
RPHQIADLFRPK
(191-202)
VGDPVYLLGQ
(328-337)
VHGLEIEGR
(151-159)

Precursor
m/z

Z

Retention
Time (min)

811.52

1

17

788.87

2

15.3

479.46

2

5.7

682.38

2

9.6

493.28

3

11.1

530.78

2

18.3

505.46

2

7.2
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Table 3.10: Selected ions for preferential MS/MS for
analysis of mARC2 protein
Sequence
(Amino Acid Location)
DRFWLVIK
(90-97)
GVPVSEAECTAMGLRSGNLR
(70-89)
IFGLDIK
(150-156)
IFGLDIKGR
(150-158)
IGSLRVGDPVYR
(322-333)
KQPLDTLK
(287-294)
LCDPSERELYK
(298-308)
LSPLFGIYYSVEK
(309-321)
LVQFETNMK
(179-187)
LVQFETNMKGR
(179-189)
LWIYPVK
(60-66)
LWIYPVKSCK
(60-69)
SGNLRDRFWLVIK
(85-97)
VGDPVYR
(327-333)

Precursor
m/z

Z

Retention
Time (min)

538.81

2

18.5

788.87

2

15.3

805.48

1

18.2

509.8

2

15

444.58

3

11.6

471.96

2

5.1

705.33

2

8.3

758.4

2

23.4

555.28

2

11.1

661.84

2

9.5

459.95

2

16.3

647.35

2

13.6

802.87

2

19.6

403.21

2

4.7

Agilent MassHunter Qualitative Analysis with BioConfirm software was used to
identify peptides in the spectrum data for each condition. In the control condition using
GAPDH antibody, no mARC1 or mARC2 peptides were identified, establishing it as a
viable negative control. For mARC1, mitogen-activated protein kinase 5 (Q99683) and
phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta (O00750)
were the target bait proteins. Table 3.12 is the number of unique mARC1 peptides and
the number of spectral counts for peptides using reverse co-immunoprecipitation in
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HEK-293 cells. In both replicates, mARC1 peptides were identified supporting the
evidence that the interactions of mARC1 with mitogen-activated protein kinase 5 and
phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta may exist.
It should be noted that in the LC-MS/MS method seven peptides were scanned for but in
the second replicate using mitogen-activated protein kinase 5 there were 8 unique
peptides identified, this is the benefits of using preferential auto MS/MS.
Table 3.11: The number of unique peptides and spectral counts for mARC1 in HEK293 cells lysate using reverse co-immunoprecipitation of selected proteins.
UniProt ID
Q99683
O00750
P04406

Unique Peptides (Spectral Counts)
Replicate 1
Replicate 2

Protein Name
Mitogen-activated protein kinase 5
Phosphatidylinositol 4-phosphate 3-kinase
C2 domain-containing subunit beta
Glyceraldehyde-3-phosphate
dehydrogenase

5 (8)

8 (17)

3 (6)

4 (7)

0 (0)

0 (0)

For mARC2 ADP/ATP translocase 1 (P12235) and myotubularin (Q13496) were the
target bait proteins. Table 3.13 is the number of unique mARC2 peptides and the number
of spectral counts for peptides using reverse co-immunoprecipitation in HEK-293 cells.
In both replicates, mARC2 peptides were identified supporting the evidence that the
Table 3.12: The number of unique peptides and spectral counts for mARC2 in HEK293 cells lysate using reverse co-immunoprecipitation of selected proteins.
UniProt ID

Unique Peptides (Spectral Counts)
Replicate 1
Replicate 2

Protein Name

P12235

ADP/ATP translocase 1

3 (3)

7 (8)

Q13496

Myotubularin

5 (5)

4 (4)

P04406

Glyceraldehyde-3-phosphate
dehydrogenase

0 (0)

0 (0)

interactions of mARC2 with ADP/ATP translocase 1 and myotubularin may exist.
It needs to be reiterated that all proteins were at natural abundances within the
experiments. In proteomic studies, it is accepted that proteins identified with 2 or more
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unique peptides with multiple spectral counts for the identified proteins to suggest a high
probability that the identified protein was confirmed. In mARC1 and mARC2 reverse coimmunoprecipitation experiments, more than 2 unique peptides were identified in each
experimental condition, and no mARC protein was identified in the GAPDH control
condition. This information helps to support that mARC1 and mARC2 interact with the
selected proteins.
3.7 Reverse Co-immunoprecipitation Results in Tissue Samples
The study was expanded further to include pig liver mitochondrial fraction and
rat liver tissue. The pig liver mitochondrial fractions were supplied by Dr. Antje
Havemeyer of the Institute of Pharmaceutical Chemistry, Christian-Albrechts University
of Kiel, Kiel and rat liver tissue was supplied by Dr. Courtney Sparacino-Watkins
University of Pittsburgh, Pittsburgh, PA. Sample preparation and further information can
be found in Chapter 2.1. The reverse co-immunoprecipitation of tissue cell lysate
followed the same method and antibodies as previously described in Chapter 3.6. The
protein sequences for mARC1 and mARC2 are not well annotated in pig and rat, a protein
BLAST using human mARC1 and mARC2 sequences was used to identify proteins in
both organisms. In rat mARC1 (UniProt ID: G3V6I4) had a 77.4% sequence identity to
human mARC1 and mARC2 (UniProt ID: O88994) had a 74.2% sequence identity to
human mARC2. After performing the protein sequence BLAST on the pig proteome,
mARC1 could not be identified but mARC2 (UniProt ID: F1S9I9) with a 74.1% sequence
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identity to human mARC2. Even though mARC1 was not identified in pig, a sequence
alignment using human mARC1 and pig mARC2 showed a sequence similarity of 70.0%.
Mass spectrometric analysis was performed using the method described in Chapter 2.3.1
and not the preferential auto MS/MS as employed in the previous reverse coimmunoprecipitation method.
Agilent MassHunter Qualitative Analysis with BioConfirm was again used to
identify peptides in the spectrum data for each condition using the mARC1 and mARC2
protein sequences for each species. Since mARC1 was not identified in pig, but there was
a high sequence similarity to human mARC1 and pig mARC2, it was in both mARC1 and
mARC2 analysis. Again, GAPDH antibody was used as a control as no mARC1 or
mARC2 peptides were not identified.
In rat liver samples mARC1was identified in both reverse co-immunoprecipitation
experiments involving mitogen-activated protein kinase 5 and phosphatidylinositol 4phosphate 3-kinase C2 domain-containing subunit beta proteins. However, the number
of unique peptides and spectral counts for rat mARC2 was much lower. Only 1 unique
peptide for ADP/ATP translocase 1 and 2 unique peptides for myotubularin, potentially
questioning if rat mARC2 interacts with these two proteins. It also may be caused to a
low reactivity between the antibody and rat proteins. In Table 3.14 and Table 3.15, the
number of unique peptides can be seen for mARC1 and mARC2 analysis of rat liver cell
lysate.
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In pig liver, mitochondrial fractions samples were analyzed for the presence of pig
mARC2. Interestingly, the experiments involving mitogen-activated protein kinase 5 and
phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta proteins
that were intended to immunoprecipitate mARC1 had unique peptides and spectral
count in all experiments. Pig mARC2 was also identified in proteins predicted to interact
with mARC2, ADP/ATP translocase, and myotubularin. In Table 3.14 and Table 3.15, the
number of unique peptides can be seen for mARC1 and mARC2 analysis of pig liver
mitochondrial fractions.
Table 3.13: The number of unique peptides and spectral counts for mARC1 in pig
liver mitochondria fractions and rat liver cell lysate using reverse coimmunoprecipitation of selected proteins.
UniProt ID
Q99683
O00750
P04406

Unique Peptides (Spectral Counts)
Pig Liver
Rat Liver

Protein Name
Mitogen-activated protein kinase 5
Phosphatidylinositol 4-phosphate 3-kinase
C2 domain-containing subunit beta
Glyceraldehyde-3-phosphate
dehydrogenase

14 (20)

7 (16)

11 (15)

5 (10)

0 (0)

0 (0)

Table 3.14: The number of unique peptides and spectral counts for mARC2 in pig
liver mitochondria fractions and rat liver cell lysate using reverse coimmunoprecipitation of selected proteins.
UniProt ID

Unique Peptides (Spectral Counts)
Pig Liver
Rat Liver

Protein Name

P12235

ADP/ATP translocase 1

8 (8)

1 (2)

Q13496

Myotubularin

8 (11)

2 (3)

P04406

Glyceraldehyde-3-phosphate
dehydrogenase

0 (0)

0 (0)

In the rat liver cell lysate samples mARC1 samples demonstrated a high
relationship with the interactions seen in human mARC1 and HEK-293 cell lysate
experiments. However, the mARC2 information was less supportive. This could be due
to a low reactivity of antibody to selected proteins or a low abundance of rat mARC2
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protein. Although there was no pig mARC1 identified from BLAST searches, pig mARC2
was identified in all four reverse co-immunoprecipitation experiments and thus
supporting the evidence of mARC proteins interacting with the four selected proteins.
The data collected from reverse co-immunoprecipitation experiments is not conclusive
because only single replicates were prepared for all conditions.
3.8 Protein-protein interactions of mARC1 and mARC2 summary and potential
opportunities for future work
The human mARC1 and mARC2 enzymes are pterin-based molybdenum
enzymes part of the SO family of molybdenum enzymes. Although the physiological
function of mARC proteins inside the cell remains elusive, studies have shown their
potential in the activation of pro-drugs, metabolism of mutated base pairs, and producing
nitric oxide from nitrite under hypoxic conditions. The latter is of interest to many
researchers as it provides another pathway for production of nitric oxide under oxygen
limiting conditions. The goal of these experiments was to investigate the protein-protein
interactions of mARC1 and mARC2 proteins in HEK-293 cell lysate that can corroborate
with the information obtained previously from co-immunoprecipitation. For this purpose
reverse co-immunoprecipitation experiments using HEK-293 cell lysate, pig liver
mitochondrial fractions, and rat liver cells were performed. Three methods were used to
investigate protein-protein interactions; co-immunoprecipitation, crosslinking reagents,
and pull-down assays.
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The crosslinking reagent experiments involved a novel approach of using a
commercially available non-specific crosslinking reagent (Sulfo-SBED) and creating a
compound (K-BLoC) that could bind crosslinking reagent and lock into the active site of
mARC proteins. Mass spectrometric analysis demonstrated that the crosslinking reagent
and compound were able to bind forming the complex referred to as LTR-K-BLoC. Using
intact protein mass spectrometry we were able to confirm that mARC1 is about to bind
the LTR-K-BLoC complex. This demonstrates not only a new way to transform nonspecific crosslinking reagents into site-specific complexes but also potentials a novel
method for the purification of mARC proteins from lysate samples.
Three methods were used to investigate protein-protein interactions and were
performed in triplicate with appropriate controls; co-immunoprecipitation, crosslinking
reagents, and pull-down assays. Using Agilent MassHunter Qualitative Analysis with
BioConfirm software a total of 176 proteins were identified in mARC1 coimmunoprecipitation experiments, 124 proteins in mARC1 crosslinking reagent
experiments, 181 protein in mARC1 pull-down assays, 83 proteins were identified in
mARC2 co-immunoprecipitation experiments, 25 proteins in mARC2 crosslinking
reagent experiments, and 112 protein in mARC2 pull-down assays. To aid in the
reduction of false positive identification, the original list of peptides needed to meet
certain criteria to be considered positive potential interacting partners with mARC
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proteins. There were 38 proteins identified as interacting with mARC1 and 28 proteins
identified as interacting with mARC2.
To aid in the formation of relationships in the identified proteins bioinformatics
software was used. The proteins from the reduced list of interacting partners were
clustered using GOTerm biological process and molecular function. Five GOTerm
annotations were interesting to proteins identified as interacting with mARC proteins;
cellular protein modification process, nitrogen compound metabolic process nucleobasecontaining metabolic process, regulation of biological process, and signal transduction.
The identified proteins were then compared using KEGG annotated pathways to
investigate relationships. Interestingly, both mARC1 and mARC2 had several interacting
partners that were identified as part of signaling pathways. There were 11 signaling
pathways that were affiliated with proteins identified as interacting with mARC1 and 10
signaling pathways for mARC2. In both cases, relationships were able to be connected
based on effects of nitric oxide production, and nitric oxide synthase involvement. Based
on the analysis of the data we suggest that mARC1 and mARC2 proteins may potentially
be involved in the production of nitric oxide under oxygen limiting conditions to aid in
maintaining cell homeostasis through signaling pathways.
Reverse co-immunoprecipitation was used to support the evidence of interactions
between mARC1 and mARC2 and selected proteins. This included probing interactions
in HEK-293 cell lysate, pig liver mitochondrial fractions, and rat liver cell lysate.
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Interestingly mARC1 and mARC2 proteins were identified in all experimental
conditions. The information gathered from the reverse co-immunoprecipitation
experiments supported the evidence of mARC proteins interacting with mitogenactivated protein kinase 5, phosphatidylinositol 4-phosphate 3-kinase C2 domaincontaining subunit beta, ADP/ATP translocase, and myotubularin.
The experiments that were compiled together in this study were not driven by a
common hypothesis but were used to help propel the mARC system research by
generating new testable hypotheses. A few testable hypotheses we were able to generate
from this study include:
1. Post-translational modification of mARC1 occurs through JNK/p38 signaling
cascade, modulating downstream processes of mARC1.
2. The mARC1 and mARC2 proteins aid in the regulation of the calcium signaling
pathway in mammalian systems through the production of nitric oxide from
nitrite under hypoxic conditions.
3. The maturation of mARC2 involves the formation of a complex consisting of
MOCS1, MOCS2, and GPHN.
4. Through the production of nitric oxide from nitrite under hypoxic conditions,
mARC2 is involved in the activity of phosphodiesterase 5A, subsequently
affecting the conversion cGMP to 5’GMP.
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The hypotheses that preceded are only examples of future direction for research into
mARC1 and mARC2 systems. We anticipate the information provided by this
investigation stimulates further research into mARC proteins and their potential
physiological roles in mammalian cells.
Although there were relationships that could be formed from the interacting
proteins with mARC1 and mARC2 through this study, the exact physiological function
of mARC1 and mARC2 can only be inferred from the data collected. There is still a great
deal of work that needs to be accomplished to determine their roles in the mammalian
system. The identified interacting partners with mARC proteins must be confirmed
through other methods to establish their requirements in the signaling pathways. After
the interactions have been confirmed, under what conditions is mARC proteins most
active, potentially under oxygen limiting or nitric oxide synthase inhibited conditions.
The protein-protein interactions identified in this study have not only raised questions
but have also allowed for the study of mARC proteins to be expanded outside the realm
of normal metabolic functions.
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Appendix I: Reagents, Kits, Materials and Buffers
Table A1: Reagents, kits, materials, companies, and catalog numbers for chemicals
used.
Reagent/Kit

Company

Catalog Number

Pierce™ His Protein Interaction Pull-Down Kit

Thermo Fisher Scientific

21277

Sulfo-SBED Biotin Label Transfer Reagent

Thermo Fisher Scientific

33033

Pierce™ Biotinylated Protein Interaction PullDown Kit

Thermo Fisher Scientific

21115

Pierce™ Co-Immunoprecipitation Kit

Thermo Fisher Scientific

26149

Pierce™ Trypsin Protease, MS Grade, Frozen

Thermo Fisher Scientific

90305

Zeba™ Micro Spin Desalting Columns, 7K
MWCO, 75 µL

Thermo Fisher Scientific

89877

Sigma Aldrich

A6141

Ammonium Bicarbonate
Dithiothreitol

Acros

16568

Oakwood Chemical

001273

Thermo Fisher Scientific

85190

Fischer Scientific

A117

Amresco

M216

Fluka

90357

Fischer Scientific

A996-4

JT Baker

9834-03

2,2,2-trifluoroethanol
Pierce™ Dimethylsulfoxide (DMSO), LC-MS
Grade
Formic Acid, Optima™ LC/MS Grade, Fisher
Chemical
Iodoacetamide
Triethylammonium acetate buffer
Acetonitrile (Optima™), Fisher Chemical
Water-0.1% Formic Acid

Buffers
IP Lysis/Wash Buffer
 25 mM tris hydrochloride
 150 mM sodium chloride
 1 mM EDTA (Edetic Acid)
 1% NP-40 (4-Nonylphenyl poly(ethylene glycol))
 5% glycerol
 pH 7.4
Coupling Buffer (20X)
 0.01 M sodium phosphate
 0.15 M sodium chloride
 pH 7.2
Quenching Buffer
 1 M tris hydrochloride
 pH 7.4
Wash Solution
 1 M sodium chloride
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Figure A.1: Reagents and chemical structures of the compounds used in
chemical crosslinking. A. Sulfo-SBED Label Transfer Reagent (MW:
879.97, MW-Na: 856.98), B. K-BLoC compounds (MW: 215.68, MW-HCl:
179.22), C. LTR-K-BLoC complex (MW: 841.06)
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Appendix II: Protein Lists for Interacting Proteins with mARC1 and mARC2
Table A.2: Protein identified as interacting with mARC1 proteins in HEK-293 cell lysate. The
technique in which proteins were identified in are; 1–co-immunoprecipitation, 2–crosslinking
reagent, 3–pull-down assay. The condition in which the proteins were identified in are; C–control
condition, E–experimental condition, CE–control and experimental condition.
UniProt ID

Protein Name

Technique and
Condition

A0A075B6Z2

Protein TRAJ56

1C, 2CE, 3CE

A2A2F5

Protein TMEPAI

1E, 2E, 3C

A8K761

NADH dehydrogenase (Ubiquinone) 1 beta subcomplex, 10, 22kDa,
isoform CRA_b

3C

A8MPX8

Protein phosphatase 2C-like domain-containing protein 1

1E, 3CE

C9J069

Uncharacterized protein C9orf172

1CE, 2E, 3CE

E5KNQ5

Mitochondrial thymidine kinase 2

1E, 3CE

E7EMC7

Sequestosome-1

2E, 3CE

F5H2Z5

Complement C1r subcomponent-like protein

3C

F8W1A0

Serine/threonine-protein phosphatase PP1-gamma catalytic subunit

3C

F8W1K5

Protein canopy homolog 2

1E

F8W6H6

Unconventional myosin-Va

1CE, 2E, 3CE

H0Y8F3

Folliculin-interacting protein 2

3E

H0YE05

Retinoblastoma-like protein 1

1E, 3CE

H3BP21

Nuclear factor of-activated T-cells 5

1E, 2E

H3BP40

Mitochondrial Rho GTPase 2

1E, 3E

H7C2G6

Probable 28S rRNA (cytosine-C(5))-methyltransferase

1E, 3E

J3KNJ8

DnaJ homolog subfamily C member 4

1CE, 2E, 3C

J3QRV1

Sodium/hydrogen exchanger 5

1E

O00267

Transcription elongation factor SPT5

1E, 2E, 3CE

O00330

Pyruvate dehydrogenase protein X component, mitochondrial

1E, 3CE

O00425

Insulin-like growth factor 2 mRNA-binding protein 3

1CE, 2E, 3C

O00750

Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit
beta

1CE, 2E, 3CE

O14730

Serine/threonine-protein kinase RIO3

1E, 2E, 3CE

O14788

Tumor necrosis factor ligand superfamily member 11

2E, 3CE

O15079

Syntaphilin

1CE, 2CE, 3C

O15240

Neurosecretory protein VGF

1E, 2E, 3C

O43181

NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial

1E, 2E, 3C

O43312

Metastasis suppressor protein 1

1CE

O43314

Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate
kinase 2

1CE, 2E, 3CE

O60260

E3 ubiquitin-protein ligase parkin

1E, 3CE

O60518

Ran-binding protein 6

3CE
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Table A.2: Continued
UniProt ID

Protein Name

Technique and
Condition

O60683

Peroxisome biogenesis factor 10

1E, 2E

O75061

Putative tyrosine-protein phosphatase auxilin

1CE, 2E, 3CE

O75128

Protein cordon-bleu

1E, 2E, 3CE

O75530

Polycomb protein EED

1E, 3CE

O75581

Low-density lipoprotein receptor-related protein 6

1CE, 2E, 3CE

O75891

Cytosolic 10-formyltetrahydrofolate dehydrogenase

1E, 2E, 3CE

O94761

ATP-dependent DNA helicase Q4

1CE, 2E, 3CE

O94806

Serine/threonine-protein kinase D3

1CE, 2E, 3C

O94983

Calmodulin-binding transcription activator 2

1CE, 2E, 3CE

O95049

Tight junction protein ZO-3

1CE, 2C, 3E

O95199

RCC1 and BTB domain-containing protein 2

1E, 2E, 3CE

O95382

Mitogen-activated protein kinase kinase kinase 6

1CE, 2E, 3CE

O95447

Lebercilin-like protein

1CE, 2E, 3C

O95602

DNA-directed RNA polymerase I subunit RPA1

1CE, 2E, 3CE

O95954

Formimidoyltransferase-cyclodeaminase

3C

P00734

Prothrombin

1E, 2E, 3CE

P01036

Cystatin-S

1E, 3C

P02768

Serum albumin

1E, 2E, 3E

P04406

Glyceraldehyde-3-phosphate dehydrogenase

1E, 3E

P04818

Thymidylate synthase

1C, 2E

P04908

Histone H2A type 1-B/E

1E, 3E

P06727

Apolipoprotein A-IV

1CE, 3C

P0C870

JmjC domain-containing protein 7

1E, 2E, 3C

P11216

Glycogen phosphorylase, brain form

1CE, 2E, 3CE

P12273

Prolactin-inducible protein

3C

P15313

V-type proton ATPase subunit B, kidney isoform

1E, 3CE

P18564

Integrin beta-6

1CE, 2E, 3CE

P20810

Calpastatin

1E, 3CE

P21549

Serine-pyruvate aminotransferase

1E, 3CE

P22059

Oxysterol-binding protein 1

1CE, 2CE, 3CE

P23396

40S ribosomal protein S3

1CE, 2CE, 3CE

P23467

Receptor-type tyrosine-protein phosphatase beta

1CE, 3CE

P25705

ATP synthase subunit alpha, mitochondrial

2E, 3E

P27816

Microtubule-associated protein 4

1E, 2E, 3CE

P30050

60S ribosomal protein L12

1CE, 2E, 3CE

P30679

Guanine nucleotide-binding protein subunit alpha-15

3E

P31040

Succinate dehydrogenase [ubiquinone] flavoprotein subunit,
mitochondrial

1CE, 2E, 3CE

P31937

3-hydroxyisobutyrate dehydrogenase, mitochondrial

1CE, 2E, 3CE

P43355

Melanoma-associated antigen 1

1C, 3CE
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P46977

Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit
STT3A

1E, 2E, 3C

P49862

Kallikrein-7

1E, 2E, 3C

P50479

PDZ and LIM domain protein 4

1C, 3CE

P51160

Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha

1E, 2E, 3CE

P52788

Spermine synthase

1CE, 2CE, 3C

P55056

Apolipoprotein C-IV

2E, 3E

P62330

ADP-ribosylation factor 6

1E

P62701

40S ribosomal protein S4, X isoform

1CE, 2E, 3C

P78334

Gamma-aminobutyric acid receptor subunit epsilon

1E, 3CE

P85037

Forkhead box protein K1

1CE, 2E, 3CE

P98088

Mucin-5AC

1CE, 2CE, 3CE

Q01970

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3

1CE, 2E, 3CE

Q02383

Semenogelin-2

1CE, 2E, 3E

Q03113

Guanine nucleotide-binding protein subunit alpha-12

1C, 2E

Q04726

Transducin-like enhancer protein 3

1E, 2E, 3CE

Q07021

Complement component 1 Q subcomponent-binding protein,
mitochondrial

1E, 3C

Q12879

Glutamate receptor ionotropic, NMDA 2A

1CE, 2E, 3CE

Q13112

Chromatin assembly factor 1 subunit B

1CE, 2E, 3C

Q13233

Mitogen-activated protein kinase kinase kinase 1

1CE, 2E, 3CE

Q13884

Beta-1-syntrophin

1E

Q14103

Heterogeneous nuclear ribonucleoprotein D0

1CE, 2E, 3CE

Q14141

Septin-6

1E, 2E, 3CE

Q14684

Ribosomal RNA processing protein 1 homolog B

1E, 2E, 3C

Q14789

Golgin subfamily B member 1

1CE, 2E, 3CE

Q15431

Synaptonemal complex protein 1

1CE, 2E, 3CE

Q155Q3

Dixin

1E, 2E, 3CE

Q15637

Splicing factor 1

1E, 3E

Q16555

Dihydropyrimidinase-related protein 2

1E, 2E, 3C

Q17R98

Zinc finger protein 827

1E, 3CE

Q2TAC6

Kinesin-like protein KIF19

1CE, 2E, 3CE

Q32M45

Anoctamin-4

1E, 3E

Q3MIN7

Ral guanine nucleotide dissociation stimulator-like 3

1CE, 3E

Q3SY52

Zinc finger protein interacting with ribonucleoprotein K

1E, 3C

Q49A26

Putative oxidoreductase GLYR1

1E, 2E, 3CE

Q53EZ4

Centrosomal protein of 55 kDa

1CE

Q53RY4

Keratinocyte-associated protein 3

3E

Q549N5

Signal recognition particle receptor beta subunit

3E

Q5JQC9

A-kinase anchor protein 4

1CE, 2E, 3CE

Q5T749

Keratinocyte proline-rich protein

1E, 2E, 3CE
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Q5TEU4

NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor
5

1E, 3E

Q5VVJ2

Histone H2A deubiquitinase MYSM1

1CE, 2CE, 3CE

Q66K64

DDB1- and CUL4-associated factor 15

2E, 3C

Q66K74

Microtubule-associated protein 1S

1CE, 2CE, 3CE

Q6BAA4

Fc receptor-like B

1E, 2E, 3CE

Q6IQ32

ADNP homeobox protein 2

1CE, 2E, 3CE

Q6MZT1

Regulator of G-protein signaling 7-binding protein

1CE, 3CE

Q6P1R4

tRNA-dihydrouridine(16/17) synthase [NAD(P)(+)]-like

1E, 2E, 3CE

Q6P3S6

F-box only protein 42

1CE, 2E, 3C

Q6P996

Pyridoxal-dependent decarboxylase domain-containing protein 1

3CE

Q6PF15

Kelch-like protein 35

1E, 2E, 3CE

Q6Q0C0

E3 ubiquitin-protein ligase TRAF7

1E, 2E, 3CE

Q6SJ96

TATA box-binding protein-like protein 2

1E, 3C

Q6TGC4

Protein-arginine deiminase type-6

1E, 3C

Q6UXK5

Leucine-rich repeat neuronal protein 1

1E, 2E, 3E

Q6UXU4

Germ cell-specific gene 1-like protein

1E

Q6ZNA1

Zinc finger protein 836

1CE, 2E, 3CE

Q6ZS94

Putative uncharacterized protein C1orf229

1C, 2E

Q7L0Q8

Rho-related GTP-binding protein RhoU

1E, 2E

Q7L590

Protein MCM10 homolog

1CE, 2E, 3C

Q7L8A9

Vasohibin-1

1CE

Q7Z4P5

Growth/differentiation factor 7

2E

Q7Z5M5

Transmembrane channel-like protein 3

1CE, 2E, 3E

Q7Z7G8

Vacuolar protein sorting-associated protein 13B

1CE, 2E, 3CE

Q86WI1

Fibrocystin-L

1E, 2E, 3CE

Q86YV0

RAS protein activator like-3

2E, 3CE

Q8IUH5

Palmitoyltransferase ZDHHC17

1CE, 3CE

Q8IWV8

E3 ubiquitin-protein ligase UBR2

1CE, 2E, 3CE

Q8IXY8

Peptidyl-prolyl cis-trans isomerase-like 6

1E, 3CE

Q8IYE1

Coiled-coil domain-containing protein 13

1CE, 2E, 3CE

Q8IYS4

Uncharacterized protein C16orf71

3E

Q8IYX3

Coiled-coil domain-containing protein 116

1CE, 2CE, 3CE

Q8IZ73

RNA pseudouridylate synthase domain-containing protein 2

1CE, 3CE

Q8N0U4

Protein FAM185A

1E

Q8N187

Calcium-responsive transcription factor

1CE, 2E

Q8N4H5

Mitochondrial import receptor subunit TOM5 homolog

3C

Q8N7S6

Uncharacterized protein ARIH2OS

1E

Q8N7X4

Melanoma-associated antigen B6

2C, 3CE

Q8NCR6

Spermatid-specific manchette-related protein 1

1E, 3CE

Q8ND04

Protein SMG8

1E, 2E, 3CE

97

Table A.2: Continued
UniProt ID

Protein Name

Technique and
Condition

Q8NDV3

Structural maintenance of chromosomes protein 1B

1CE, 2E, 3CE

Q8NEE6

F-box/LRR-repeat protein 13

1CE, 2E, 3CE

Q8NFW9

Rab effector MyRIP

1CE, 3CE

Q92616

eIF-2-alpha kinase activator GCN1

1E, 2CE, 3CE

Q92945

Far upstream element-binding protein 2

1CE, 2CE, 3CE

Q969R2

Oxysterol-binding protein 2

1CE, 3CE

Q96AG3

Solute carrier family 25 member 46

1E

Q96B01

RAD51-associated protein 1

1CE, 3CE

Q96BH3

Epididymal sperm-binding protein 1

3E

Q96F45

Zinc finger protein 503

1CE, 3CE

Q96FV2

Secernin-2

1E, 3CE

Q96GN5

Cell division cycle-associated 7-like protein

1E, 2E

Q96N96

Spermatogenesis-associated protein 13

1CE, 2E, 3CE

Q96QB1

Rho GTPase-activating protein 7

1CE, 2E, 3CE

Q99489

D-aspartate oxidase

3E

Q99683

Mitogen-activated protein kinase kinase kinase 5

1CE, 2E, 3CE

Q9BPX6

Calcium uptake protein 1, mitochondrial

1E, 3E

Q9BT88

Synaptotagmin-11

1E, 3E

Q9BTM1

Histone H2A.J

1E

Q9BYG4

Partitioning defective 6 homolog gamma

3E

Q9BZE0

Zinc finger protein GLIS2

1E, 2E, 3CE

Q9C0F0

Putative Polycomb group protein ASXL3

1CE, 2E, 3CE

Q9H0N0

Ras-related protein Rab-6C

1E, 2E, 3C

Q9H2D6

TRIO and F-actin-binding protein

1CE, 2E, 3CE

Q9H2M3

S-methylmethionine-homocysteine S-methyltransferase BHMT2

3E

Q9H490

Phosphatidylinositol glycan anchor biosynthesis class U protein

3C

Q9H5N1

Rab GTPase-binding effector protein 2

1E, 2E, 3CE

Q9H9Z2

Protein lin-28 homolog A

1E, 3CE

Q9HD20

Manganese-transporting ATPase 13A1

1E, 2E, 3CE

Q9NQW6

Actin-binding protein anillin

1CE, 2E, 3E

Q9NU02

Ankyrin repeat and EF-hand domain-containing protein 1

1E, 2E, 3CE

Q9NUQ3

Gamma-taxilin

1E, 3CE

Q9NY59

Sphingomyelin phosphodiesterase 3

1CE, 3CE

Q9NYK5

39S ribosomal protein L39, mitochondrial

1CE, 2CE, 3C

Q9P015

39S ribosomal protein L15, mitochondrial

1CE, 2E, 3CE

Q9P218

Collagen alpha-1(XX) chain

1E, 2E, 3CE

Q9P266

Junctional protein associated with coronary artery disease

1E, 2E, 3CE

Q9P2J5

Leucine--tRNA ligase, cytoplasmic

1CE, 3CE

Q9P2N5

RNA-binding protein 27

1CE, 2E, 3CE

Q9UBW7

Zinc finger MYM-type protein 2

1CE, 2CE, 3CE
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Q9UHN6

Transmembrane protein 2

1E, 2E, 3CE

Q9UHV7

Mediator of RNA polymerase II transcription subunit 13

1CE, 3CE

Q9UKS7

Zinc finger protein Helios

1CE, 2CE, 3CE

Q9UPT8

Zinc finger CCCH domain-containing protein 4

1CE, 2E, 3CE

Q9UPU5

Ubiquitin carboxyl-terminal hydrolase 24

1E, 2E, 3CE

Q9UQ10

Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase

1CE, 3C

Q9UQ84

Exonuclease 1

1CE, 2E, 3CE

Q9Y2P5

Bile acyl-CoA synthetase

1E, 3CE

Q9Y2X0

Mediator of RNA polymerase II transcription subunit 16

1CE, 2CE, 3CE

Q9Y426

C2 domain-containing protein 2

1C, 2E, 3CE

Q9Y466

Nuclear receptor subfamily 2 group E member 1

1CE, 2CE, 3CE

Q9Y6X6

Unconventional myosin-XVI

1E, 2E, 3CE

R4GMW8

Protein BIVM-ERCC5

1E, 2E, 3CE
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Table A.3: Protein identified as interacting with mARC2 proteins in HEK-293 cell lysate. The
technique in which proteins were identified in are; 1–co-immunoprecipitation, 2–crosslinking
reagent, 3–pull-down assay. The condition in which the proteins were identified in are; C–control
condition, E–experimental condition, CE–control and experimental condition.
UniProt ID
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A0A075B6Z2

Protein TRAJ56

1CE, 2CE, 3CE

A5YKK6

CCR4-NOT transcription complex subunit 1

1E, 2E, 3CE

A6NE02

BTB/POZ domain-containing protein 17

1C, 3CE

B1AL46

NUT family member 2E

3CE

B1ANS9

WD repeat-containing protein 64

1C, 3CE

C9IYN7

Elongator complex protein 6

1C

C9JH25

Proline-rich transmembrane protein 4

1C, 3CE

E9PIH7

Solute carrier family 26 member 10

3E

E9PKF4

Four and a half LIM domains protein 2

3E

G8JLL9

MYH14 protein

1CE, 2CE, 3CE

O14730

Serine/threonine-protein kinase RIO3

1CE, 3CE

O15020

Spectrin beta chain, non-erythrocytic 2

1CE, 2CE, 3CE

O43312

Metastasis suppressor protein 1

1CE, 3CE

O43708

Maleylacetoacetate isomerase

3E

O75061

Putative tyrosine-protein phosphatase auxilin

1CE, 3CE

O75128

Protein cordon-bleu

3CE

O75581

Low-density lipoprotein receptor-related protein 6

1CE, 3CE

O75695

Protein XRP2

3CE

O75891

Cytosolic 10-formyltetrahydrofolate dehydrogenase

1E, 3CE

O75947

ATP synthase subunit d, mitochondrial

3CE

O76074

cGMP-specific 3',5'-cyclic phosphodiesterase

3CE

O94927

HAUS augmin-like complex subunit 5

1CE, 2E, 3CE

O95696

Bromodomain-containing protein 1

1CE, 2E, 3CE

O95870

Protein ABHD16A

3CE

O96007

Molybdopterin synthase catalytic subunit

3E

P00748

Coagulation factor XII

1E, 3CE

P01127

Platelet-derived growth factor subunit B

3E

P05141

ADP/ATP translocase 2

1E, 2CE, 3CE

P06727

Apolipoprotein A-IV

1CE

P0C870

JmjC domain-containing protein 7

3E

P14410

Sucrase-isomaltase, intestinal

1E, 3CE

P14678

Small nuclear ribonucleoprotein-associated proteins B and B'

1CE, 2E, 3CE

P23396

40S ribosomal protein S3

1E, 2CE, 3CE

P27694

Replication protein A 70 kDa DNA-binding subunit

1C, 3C

P36542

ATP synthase subunit gamma, mitochondrial

1CE, 3CE

P39019

40S ribosomal protein S19

1E

P40855

Peroxisomal biogenesis factor 19

1E, 3C
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P42262

Glutamate receptor 2

3CE

P42285

Superkiller viralicidic activity 2-like 2

1CE, 3CE

P46782

40S ribosomal protein S5

1C, 2C, 3CE

P48047

ATP synthase subunit O, mitochondrial

2E, 3C

P50454

Serpin H1

3CE

P54259

Atrophin-1

1C

P54764

Ephrin type-A receptor 4

3E

P62249

40S ribosomal protein S16

1E, 3CE

P62269

40S ribosomal protein S18

3CE

P62273

40S ribosomal protein S29

3CE

P62701

40S ribosomal protein S4, X isoform

1CE, 3CE

P62750

60S ribosomal protein L23a

1E, 3CE

P85037

Forkhead box protein K1

1CE, 2E, 3CE

Q02952

A-kinase anchor protein 12

1CE, 3CE

Q06787

Synaptic functional regulator FMR1

1CE, 3CE

Q07021

Complement component 1 Q subcomponent-binding protein,
mitochondrial

1C

Q13404

Ubiquitin-conjugating enzyme E2 variant 1

1E

Q13496

Myotubularin

3CE

Q13698

Voltage-dependent L-type calcium channel subunit alpha-1S

1E, 2CE, 3CE

Q15185

Prostaglandin E synthase 3

1C, 3E

Q15390

Mitochondrial fission regulator 1

1C, 2E, 3CE

Q2M2I8

AP2-associated protein kinase 1

1CE, 3CE

Q32P51

Heterogeneous nuclear ribonucleoprotein A1-like 2

1C, 2CE, 3CE

Q5BKY1

Leucine-rich repeat-containing protein 10

1CE

Q5S007

Leucine-rich repeat serine/threonine-protein kinase 2

1CE, 2E, 3CE

Q5T0W9

Protein FAM83B

3CE

Q5U651

Ras-interacting protein 1

1CE, 3E

Q5W0Q7

SUMO-specific isopeptidase USPL1

3CE

Q6EEV4

DNA-directed RNA polymerase II subunit GRINL1A, isoforms 4/5

1C

Q6NUQ1

RAD50-interacting protein 1

1C, 3E

Q6P2H3

Centrosomal protein of 85 kDa

3CE

Q6PD62

RNA polymerase-associated protein CTR9 homolog

1CE, 2CE, 3CE

Q6PI77

Protein BHLHb9

3CE

Q6PJ61

F-box only protein 46

3CE

Q6UB35

Monofunctional C1-tetrahydrofolate synthase, mitochondrial

1C, 2CE, 3CE

Q6ZU35

Uncharacterized protein KIAA1211

1CE, 3E

Q71U36

Tubulin alpha-1A chain

1E, 3CE

Q7Z2K8

G protein-regulated inducer of neurite outgrowth 1

1E, 3CE

Q7Z388

Probable C-mannosyltransferase DPY19L4

1C, 2E, 3CE
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Q7Z7M0

Multiple epidermal growth factor-like domains protein 8

1CE, 3CE

Q86WI3

Protein NLRC5

1CE, 3CE

Q86XP3

ATP-dependent RNA helicase DDX42

1E, 2C, 3E

Q8IUR0

Trafficking protein particle complex subunit 5

3C

Q8IY51

Tigger transposable element-derived protein 4

1CE, 3CE

Q8IYE1

Coiled-coil domain-containing protein 13

1C, 3C

Q8N0U4

Protein FAM185A

3CE

Q8N187

Calcium-responsive transcription factor

3C

Q8N4Q0

Zinc-binding alcohol dehydrogenase domain-containing protein 2

1C, 3C

Q8N7Q3

Zinc finger protein 676

3E

Q8NBS9

Thioredoxin domain-containing protein 5

1CE, 2E, 3CE

Q8NBU5

ATPase family AAA domain-containing protein 1

1C, 3E

Q8NEM8

Cytosolic carboxypeptidase 3

1CE, 2E, 3CE

Q8TBB5

Kelch domain-containing protein 4

1CE, 3E

Q8TCU4

Alstrom syndrome protein 1

1E, 3CE

Q8TD16

Protein bicaudal D homolog 2

1CE, 3CE

Q8TD57

Dynein heavy chain 3, axonemal

1CE, 3CE

Q8WUY1

Protein THEM6

3CE

Q8WWN9

Interactor protein for cytohesin exchange factors 1

1E, 3C

Q8WXS8

A disintegrin and metalloproteinase with thrombospondin motifs 14

1CE, 3CE

Q96AE7

Tetratricopeptide repeat protein 17

1CE, 3CE

Q96F45

Zinc finger protein 503

1CE, 3C

Q96JH8

Ras-associating and dilute domain-containing protein

1C, 3C

Q96RP9

Elongation factor G, mitochondrial

1E, 3CE

Q96RS0

Trimethylguanosine synthase

3E

Q9BRT2

Ubiquinol-cytochrome-c reductase complex assembly factor 2

1E, 3CE

Q9BT88

Synaptotagmin-11

1E, 2E, 3C

Q9C0D5

Protein TANC1

1C, 3CE

Q9C0H9

SRC kinase signaling inhibitor 1

3CE

Q9HCE9

Anoctamin-8

1CE, 3CE

Q9NQW6

Actin-binding protein anillin

1CE, 3E

Q9NQX3

Gephyrin [Includes: Molybdopterin adenylyltransferase

3CE

Q9NUE0

Palmitoyltransferase ZDHHC18

1E, 3C

Q9NUT2

ATP-binding cassette sub-family B member 8, mitochondrial

1E, 3CE

Q9NY43

BarH-like 2 homeobox protein

3CE

Q9NZB8

Molybdenum cofactor biosynthesis protein 1

3E

Q9P2P1

Protein NYNRIN

1CE, 3CE

Q9P2Y5

UV radiation resistance-associated gene protein

3C

Q9UHD8

Septin-9

1E, 3C

Q9UKX5

Integrin alpha-11

3CE
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Q9UPA5

Protein bassoon

1CE, 2E, 3CE

Q9Y285

Phenylalanine-tRNA ligase alpha subunit

1CE, 3CE

Q9Y2G9

Protein strawberry notch homolog 2

3CE

R4GMW8

Protein BIVM-ERCC5

1C, 2CE, 3C
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Appendix III: GOTerm and KEGG Pathway Annotations
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Figure A.2: Biological processes GOTerm annotations for proteins that were identified as interacting partners with mARC1 and
mARC2. Green boxes depict annotations found in proteins identified in both mARC1 and mARC2, blue boxes depict annotations
found in proteins identified in both mARC1, and orange boxes depict annotations found in proteins identified in both mARC2. The
DAVID cluster number is in the top right corner of each box (mARC1:mARC2). The number of proteins with that annotation are found
in the top left of each box (mARC1:mARC2). Figures A.3 through Figure A.8 are expanded portions of the individual sections.
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Figure A.3: Expanded Section I of the GOTerm annotations tree for proteins that were identified
as interacting partners with mARC1 and mARC2.
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Figure A.4: Expanded Section II of the GOTerm annotations tree for proteins that were identified as
interacting partners with mARC1 and mARC2.
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Figure A.5: Expanded Section III of the GOTerm annotations tree for proteins that were identified as interacting partners with
mARC1 and mARC2.
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Figure A.6: Expanded Section IV of the GOTerm annotations tree for proteins that were identified as interacting partners
with mARC1 and mARC2.
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Figure A.7: Expanded Section V of the GOTerm annotations tree for proteins that were identified as interacting partners
with mARC1 and mARC2.
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Figure A.8: Expanded Section VI of the GOTerm annotations tree for proteins that were identified as interacting partners
with mARC1 and mARC2.

Figure A.9: Molecular functions GOTerm annotations for proteins that
were identified as interacting partners with mARC1 and mARC2. Green
boxes depict annotations found in proteins identified in both mARC1 and
mARC2, blue boxes depict annotations found in proteins identified in
both mARC1, and orange boxes depict annotations found in proteins
identified in both mARC2. The DAVID cluster number is in the top right
corner of each box (mARC1:mARC2). The number of proteins with that
annotation are found in the top left of each box (mARC1:mARC2). Figures
A.10 through Figure A.13 are expanded portions of the individual
quadrants.
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Figure A.10: Expanded Quadrant I of the GOTerm annotations
tree for proteins that were identified as interacting partners
with mARC1 and mARC2.
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Figure A.11: Expanded Quadrant II of the GOTerm annotations
tree for proteins that were identified as interacting partners
with mARC1 and mARC2.
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Figure A.12: Expanded Quadrant III of the GOTerm annotations tree for proteins
that were identified as interacting partners with mARC1 and mARC2.
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Figure A.13: Expanded Quadrant IV of the GOTerm
annotations tree for proteins that were identified as interacting
partners with mARC1 and mARC2.
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Table A.4: GOTerm biological and molecular process annotations for proteins interacting with
mARC1 and mARC2. The number of interacting proteins identified for mARC1 and mARC2 are
listed under the annotation tag with a short description that was found from
http://www.ebi.ac.uk/
Annotated GOTerm (# of
Proteins)
Amine metabolic process
(mARC1 : 3)
(mARC2 : 0)
Biosynthetic process
(mARC1 : 7)
(mARC2 : 7)
Carboxylic acid metabolic
process
(mARC1 : 3)
(mARC2 : 0)
Cellular amino acid
metabolic process
(mARC1 : 3)
(mARC2 : 0)
Cellular biosynthetic
process
(mARC1 : 7)
(mARC2 : 6)
Cellular ketone metabolic
process
(mARC1 : 3)
(mARC2 : 0)
Cellular macromolecule
biosynthetic process
(mARC1 : 5)
(mARC2 : 4)
Cellular macromolecule
metabolic process
(mARC1 : 8)
(mARC2 : 9)
Cellular metabolic process
(mARC1 : 11)
(mARC2 : 8)
Cellular nitrogen
compound metabolic
process
(mARC1 : 8)
(mARC2 : 4)

Description of Term
The chemical reactions and pathways involving any organic compound that is
weakly basic in character and contains an amino or a substituted amino group, as
carried out by individual cells. Amines are called primary, secondary, or tertiary
according to whether one, two, or three carbon atoms are attached to the nitrogen
atom.
The chemical reactions and pathways resulting in the formation of substances;
typically the energy-requiring part of metabolism in which simpler substances are
transformed into more complex ones.
The chemical reactions and pathways involving carboxylic acids, any organic acid
containing one or more carboxyl (COOH) groups or anions (COO-).

The chemical reactions and pathways involving amino acids, carboxylic acids
containing one or more amino groups, as carried out by individual cells.

The chemical reactions and pathways resulting in the formation of substances,
carried out by individual cells.
The chemical reactions and pathways involving any of a class of organic
compounds that contain the carbonyl group, CO, and in which the carbonyl
group is bonded only to carbon atoms, as carried out by individual cells. The
general formula for a ketone is RCOR, where R and R are alkyl or aryl groups.
The chemical reactions and pathways resulting in the formation of a
macromolecule, any molecule of high relative molecular mass, the structure of
which essentially comprises the multiple repetition of units derived, actually or
conceptually, from molecules of low relative molecular mass, carried out by
individual cells.
The chemical reactions and pathways involving macromolecules, any molecule of
high relative molecular mass, the structure of which essentially comprises the
multiple repetition of units derived, actually or conceptually, from molecules of
low relative molecular mass, as carried out by individual cells.
The chemical reactions and pathways by which individual cells transform
chemical substances.

The chemical reactions and pathways involving various organic and inorganic
nitrogenous compounds, as carried out by individual cells.
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Table A.4: Continued
Annotated GOTerm (# of
Proteins)
Cellular process
(mARC1 : 0)
(mARC2 : 19)
Cellular protein metabolic
process
(mARC1 : 0)
(mARC2 : 8)
Cellular protein
modification process
(mARC1 : 0)
(mARC2 : 3)
Heterocycle metabolic
process
(mARC1 : 0)
(mARC2 : 4)
Macromolecule
biosynthetic process
(mARC1 : 5)
(mARC2 : 3)
Macromolecule metabolic
process
(mARC1 : 8)
(mARC2 : 10)
Macromolecule
modification
(mARC1 : 0)
(mARC2 : 3)
Metabolic process
(mARC1 : 12)
(mARC2 : 15)
Nitrogen compound
metabolic process
(mARC1 : 8)
(mARC2 : 5)
Nucleobase-containing
compound metabolic
process
(mARC1 : 4)
(mARC2 : 3)
Organic acid metabolic
process
(mARC1 : 3)
(mARC2 : 0)

Description of Term
Any process that is carried out at the cellular level, but not necessarily restricted
to a single cell. For example, cell communication occurs among more than one
cell, but occurs at the cellular level.
The chemical reactions and pathways involving a specific protein, rather than of
proteins in general, occurring at the level of an individual cell. Includes cellular
protein modification.
The covalent alteration of one or more amino acids occurring in proteins, peptides
and nascent polypeptides (co-translational, post-translational modifications)
occurring at the level of an individual cell. Includes the modification of charged
tRNAs that are destined to occur in a protein (pre-translation modification).
The chemical reactions and pathways involving heterocyclic compounds, those
with a cyclic molecular structure and at least two different atoms in the ring (or
rings).
The chemical reactions and pathways resulting in the formation of a
macromolecule, any molecule of high relative molecular mass, the structure of
which essentially comprises the multiple repetition of units derived, actually or
conceptually, from molecules of low relative molecular mass.
The chemical reactions and pathways involving macromolecules, any molecule of
high relative molecular mass, the structure of which essentially comprises the
multiple repetition of units derived, actually or conceptually, from molecules of
low relative molecular mass.
The covalent alteration of one or more monomeric units in a polypeptide,
polynucleotide, polysaccharide, or other biological macromolecule, resulting in a
change in its properties.
The chemical reactions and pathways, including anabolism and catabolism, by
which living organisms transform chemical substances. Metabolic processes
typically transform small molecules, but also include macromolecular processes
such as DNA repair and replication, and protein synthesis and degradation.
The chemical reactions and pathways involving organic or inorganic compounds
that contain nitrogen, including (but not limited to) nitrogen fixation, nitrification,
denitrification, assimilatory/dissimilatory nitrate reduction and the
interconversion of nitrogenous organic matter and ammonium.
Any cellular metabolic process involving nucleobases, nucleosides, nucleotides
and nucleic acids.

The chemical reactions and pathways involving organic acids, any acidic
compound containing carbon in covalent linkage.
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Table A.4: Continued
Annotated GOTerm (# of
Proteins)
Oxoacid metabolic process
(mARC1 : 3)
(mARC2 : 0)
Primary metabolic process
(mARC1 : 11)
(mARC2 : 13)
Post-translational protein
modification
(mARC1 : 0)
(mARC2 : 3)
Protein metabolic process
(mARC1 : 0)
(mARC2 : 9)

Signal transduction
(mARC1 : 0)
(mARC2 : 3)

Description of Term
The chemical reactions and pathways involving any oxoacid; an oxoacid is a
compound which contains oxygen, at least one other element, and at least one
hydrogen bound to oxygen, and which produces a conjugate base by loss of
positive hydrogen ion(s) (hydrons).
The chemical reactions and pathways involving those compounds which are
formed as a part of the normal anabolic and catabolic processes. These processes
take place in most, if not all, cells of the organism.
The process of covalently altering one or more amino acids in a protein after the
protein has been completely translated and released from the ribosome.
The chemical reactions and pathways involving a specific protein, rather than of
proteins in general. Includes protein modification.
The cellular process in which a signal is conveyed to trigger a change in the
activity or state of a cell. Signal transduction begins with reception of a signal (e.g.
a ligand binding to a receptor or receptor activation by a stimulus such as light),
or for signal transduction in the absence of ligand, signal-withdrawal or the
activity of a constitutively active receptor. Signal transduction ends with
regulation of a downstream cellular process, e.g. regulation of transcription or
regulation of a metabolic process. Signal transduction covers signaling from
receptors located on the surface of the cell and signaling via molecules located
within the cell. For signaling between cells, signal transduction is restricted to
events at and within the receiving cell.
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Table A.5: GOTerm regulation process annotations for proteins interacting with mARC1 and
mARC2. The number of interacting proteins identified for mARC1 and mARC2 are listed under
the annotation tag with a short description that was found from http://www.ebi.ac.uk/
Annotated GOTerm (# of
Proteins)
Regulation of cellular
metabolic process
(mARC1 : 5)
(mARC2 : 4)
Biological regulation
(mARC1 : 13)
(mARC2 : 9)
Positive regulation of
biological process
(mARC1 : 3)
(mARC2 : 0)
Positive regulation of
cellular process
(mARC1 : 3)
(mARC2 : 0)
Regulation of biological
process
(mARC1 : 12)
(mARC2 : 8)
Regulation of Biological
Quality
(mARC1 : 0)
(mARC2 : 5)
Regulation of biosynthetic
process
(mARC1 : 5)
(mARC2 : 3)
Regulation of cellular
biosynthetic process
(mARC1 : 5)
(mARC2 : 3)
Regulation of cellular
protein metabolic process
(mARC1 : 0)
(mARC2 : 3)
Regulation of cellular
process
(mARC1 : 12)
(mARC2 : 8)

Description of Term

Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways by which individual cells transform chemical substances.
Any process that modulates a measurable attribute of any biological process,
quality or function.
Any process that activates or increases the frequency, rate or extent of a biological
process. Biological processes are regulated by many means; examples include the
control of gene expression, protein modification or interaction with a protein or
substrate molecule.
Any process that activates or increases the frequency, rate or extent of a cellular
process, any of those that are carried out at the cellular level, but are not
necessarily restricted to a single cell. For example, cell communication occurs
among more than one cell, but occurs at the cellular level.
Any process that modulates the frequency, rate or extent of a biological process.
Biological processes are regulated by many means; examples include the control
of gene expression, protein modification or interaction with a protein or substrate
molecule.
Any process that modulates a qualitative or quantitative trait of a biological
quality. A biological quality is a measurable attribute of an organism or part of an
organism, such as size, mass, shape, color, etc.
Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways resulting in the formation of substances.
Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways resulting in the formation of substances, carried out by individual
cells.
Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways involving a protein, occurring at the level of an individual cell.
Any process that modulates the frequency, rate or extent of a cellular process, any
of those that are carried out at the cellular level, but are not necessarily restricted
to a single cell. For example, cell communication occurs among more than one
cell, but occurs at the cellular level.
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Table A.5: Continued
Annotated GOTerm (# of
Proteins)
Regulation of
macromolecule
biosynthetic process
(mARC1 : 4)
(mARC2 : 3)
Regulation of
macromolecule metabolic
process
(mARC1 : 5)
(mARC2 : 4)
Regulation of metabolic
process
(mARC1 : 5)
(mARC2 : 4)
Regulation of nitrogen
compound metabolic
Process
(mARC1 : 4)
(mARC2 : 0)
Regulation of nucleobasecontaining metabolic
process
(mARC1 : 4)
(mARC2 : 0)
Regulation of primary
metabolic process
(mARC1 : 5)
(mARC2 : 4)
Regulation of protein
metabolic process
(mARC1 : 0)
(mARC2 : 3)
Regulation of RNA
metabolic process
(mARC1 : 3)
(mARC2 : 0)

Description of Term
Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways involving macromolecules, any molecule of high relative molecular
mass, the structure of which essentially comprises the multiple repetition of units
derived, actually or conceptually, from molecules of low relative molecular mass.
Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways involving macromolecules, any molecule of high relative molecular
mass, the structure of which essentially comprises the multiple repetition of units
derived, actually or conceptually, from molecules of low relative molecular mass.
Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways within a cell or an organism.

Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways involving nitrogen or nitrogenous compounds.

Any cellular process that modulates the frequency, rate or extent of the chemical
reactions and pathways involving nucleobases, nucleosides, nucleotides and
nucleic acids.
Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways within a cell or an organism involving those compounds formed as
a part of the normal anabolic and catabolic processes. These processes take place
in most, if not all, cells of the organism.
Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways involving a protein.

Any process that modulates the frequency, rate or extent of the chemical reactions
and pathways involving RNA.
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Figure A.14: KEGG pathways for proteins interacting with mARC proteins for human diseases
and organismal system categories. A. KEGG human diseases and organismal system categories
for proteins interacting with mARC1, B. KEGG human diseases and organismal system
categories for proteins interacting with mARC2.
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Table A.6: Annotated membrane transport proteins for proteins identified
as interacting with mARC2.
UniProt ID
Q9NUT2

Proteins Names
ATP binding cassette subfamily B member 8

P36542

ATP synthase, H+ transporting, mitochondrial F1 complex, gamma
polypeptide 1

P48047

ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit

O75947

ATP synthase, H+ transporting, mitochondrial Fo complex subunit D

O43708

Glutathione S-transferase zeta 1

Q6UB35

Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1like

Q9NZB8

Molybdenum cofactor synthesis 1

O96007

Molybdenum cofactor synthesis 2

Q13496

Myotubularin 1

Q15185

Prostaglandin E synthase 3

P14410

Sucrase-isomaltase
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Table A.7: GOTerm annotations and clusters for proteins identified as interacting with mARC1.
Cluster

1

123
2

UniProt ID

Protein Name

GOTerm Annotations

P02768

albumin

establishment of localization, ion binding, localization, transport

P06727

apolipoprotein A-IV

P21549

alanine-glyoxylate aminotransferase

P31040

succinate dehydrogenase complex, subunit A,
flavoprotein (Fp)

establishment of localization, localization, transport

P78334

gamma-aminobutyric acid (GABA) A receptor, epsilon

establishment of localization, ion binding, localization, transport

Q32M45

anoctamin 4

establishment of localization, ion binding, localization, transport

Q3SY52

zinc finger protein interacting with K protein 1 homolog

ion binding

Q7L0Q8

ras homolog gene family, member U

ion binding

Q8IUH5

zinc finger, DHHC-type containing 17

Q8NFW9

myosin VIIA and Rab interacting protein

establishment of localization, ion binding, localization, macromolecule
localization, transport
establishment of localization, localization, macromolecule localization,
transport

establishment of localization, ion binding, localization, macromolecule
localization, transport
establishment of localization, ion binding, localization, macromolecule
localization, transport
establishment of localization, localization, macromolecule localization,
transport

Q969R2

oxysterol binding protein 2

Q9BT88

synaptotagmin XI

establishment of localization, ion binding, localization, transport

Q9BZE0

GLIS family zinc finger 2

ion binding

Q9H2M3

betaine-homocysteine methyltransferase 2

ion binding
cellular component assembly, cellular component biogenesis, cellular
component organization, cellular macromolecular complex assembly,
cellular macromolecular complex subunit organization, macromolecular
complex assembly, macromolecular complex subunit organization
cellular component assembly, cellular component biogenesis, cellular
component organization, macromolecular complex assembly,
macromolecular complex subunit organization

P04908

histone cluster 1, H2ae; histone cluster 1, H2ab

P06727

apolipoprotein A-IV

P21549

alanine-glyoxylate aminotransferase

cellular component organization

Q14684

ribosomal RNA processing 1 homolog B

cellular component biogenesis

Q15431

synaptonemal complex protein 1

cellular component assembly, cellular component biogenesis, cellular
component organization

Table A.7: Continued
Cluster

UniProt ID

Protein Name

Q53EZ4

centrosomal protein 55kDa

cellular component organization

Q7L0Q8

ras homolog gene family, member U

cellular component organization

Q8NCR6

chromosome 9 open reading frame 24

Q9BTM1

H2A histone family, member J

2
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3

cellular component assembly, cellular component biogenesis, cellular
component organization, cellular macromolecular complex assembly,
cellular macromolecular complex subunit organization, macromolecular
complex assembly, macromolecular complex subunit organization
cellular component assembly, cellular component biogenesis, cellular
component organization, cellular macromolecular complex assembly,
cellular macromolecular complex subunit organization, macromolecular
complex assembly, macromolecular complex subunit organization
cellular component assembly, cellular component biogenesis, cellular
component organization, cellular macromolecular complex assembly,
cellular macromolecular complex subunit organization, macromolecular
complex assembly, macromolecular complex subunit organization
cellular component assembly, cellular component biogenesis, cellular
component organization, macromolecular complex assembly,
macromolecular complex subunit organization

P04908

histone cluster 1, H2ae; histone cluster 1, H2ab

P06727

apolipoprotein A-IV

P21549

alanine-glyoxylate aminotransferase

cellular component organization

Q14684

ribosomal RNA processing 1 homolog B

cellular component biogenesis

Q15431

synaptonemal complex protein 1

P06727

apolipoprotein A-IV

P21549

alanine-glyoxylate aminotransferase

Q9H2M3

4

GOTerm Annotations

betaine-homocysteine methyltransferase 2

cellular component assembly, cellular component biogenesis, cellular
component organization
amine metabolic process, cellular amine metabolic process, cellular
amino acid and derivative metabolic process
amine metabolic process, cellular amine metabolic process, cellular
amino acid and derivative metabolic process
amine metabolic process, cellular amine metabolic process, cellular
amino acid and derivative metabolic process

P04908

histone cluster 1, H2ae; histone cluster 1, H2ab

organelle organization

P21549

alanine-glyoxylate aminotransferase

organelle organization

Q15431

synaptonemal complex protein 1

cell cycle, cell cycle phase, cell cycle process, organelle organization

Q53EZ4

centrosomal protein 55kDa

cell cycle, cell cycle phase, cell cycle process, organelle organization

Table A.7: Continued
Cluster
4

5

125
6

UniProt ID

Protein Name

GOTerm Annotations

Q7L0Q8

ras homolog gene family, member U

cell cycle, cell cycle phase, cell cycle process, organelle organization

Q9BTM1

H2A histone family, member J

organelle organization

P02768

albumin

DNA binding, nucleic acid binding

P04908

histone cluster 1, H2ae; histone cluster 1, H2ab

chromosome organization, DNA binding, nucleic acid binding

Q15431

synaptonemal complex protein 1

chromosome organization, DNA binding, nucleic acid binding

Q3SY52

zinc finger protein interacting with K protein 1

DNA binding, nucleic acid binding

Q8N187

amyotrophic lateral sclerosis 2 (juvenile) chromosome
region, candidate 8

DNA binding, nucleic acid binding

Q9BTM1

H2A histone family, member J

chromosome organization, DNA binding, nucleic acid binding

Q9BZE0

GLIS family zinc finger 2

DNA binding, nucleic acid binding

P06727

apolipoprotein A-IV

macromolecule localization

P21549

alanine-glyoxylate aminotransferase

Q8IUH5

zinc finger, DHHC-type containing 17

Q8NFW9

myosin VIIA and Rab interacting protein

establishment of protein localization, macromolecule localization,
protein localization, protein transport
establishment of protein localization, macromolecule localization,
protein localization, protein transport
establishment of protein localization, macromolecule localization,
protein localization, protein transport

Q969R2

oxysterol binding protein 2

P21549

alanine-glyoxylate aminotransferase

P31040

succinate dehydrogenase complex, subunit A,
flavoprotein (Fp)

P46977

STT3, subunit of the oligosaccharyltransferase complex,
homolog A

catalytic activity

P51160

phosphodiesterase 6C, cGMP-specific, cone, alpha prime

catalytic activity

Q7L0Q8

ras homolog gene family, member U

catalytic activity

Q8IUH5

zinc finger, DHHC-type containing 17

catalytic activity

7

macromolecule localization
carboxylic acid metabolic process, catalytic activity, cellular ketone
metabolic process, organic acid metabolic process, oxoacid metabolic
process
carboxylic acid metabolic process, catalytic activity, cellular ketone
metabolic process, organic acid metabolic process, oxoacid metabolic
process

Table A.7: Continued
Cluster

UniProt ID

7

Q9H2M3

8

126
9

Protein Name
betaine-homocysteine methyltransferase 2

GOTerm Annotations
carboxylic acid metabolic process, catalytic activity, cellular ketone
metabolic process, organic acid metabolic process, oxoacid metabolic
process
cation binding, ion binding, metal ion binding, transition metal ion
binding
cation binding, ion binding, metal ion binding, transition metal ion
binding

P02768

albumin

P06727

apolipoprotein A-IV

P78334

gamma-aminobutyric acid (GABA) A receptor, epsilon

ion binding

Q32M45

anoctamin 4

cation binding, ion binding, metal ion binding

Q3SY52

zinc finger protein interacting with K protein 1

cation binding, ion binding, metal ion binding, transition metal ion
binding, zinc ion binding

Q7L0Q8

ras homolog gene family, member U

cation binding, ion binding, metal ion binding

Q8IUH5

zinc finger, DHHC-type containing 17

Q8NFW9

myosin VIIA and Rab interacting protein

Q9BT88

synaptotagmin XI

Q9BZE0

GLIS family zinc finger 2

Q9H2M3

betaine-homocysteine methyltransferase 2

cation binding, ion binding, metal ion binding, transition metal ion
binding, zinc ion binding
cation binding, ion binding, metal ion binding, transition metal ion
binding, zinc ion binding
cation binding, ion binding, metal ion binding
cation binding, ion binding, metal ion binding, transition metal ion
binding, zinc ion binding
cation binding, ion binding, metal ion binding, transition metal ion
binding, zinc ion binding

P02768

albumin

transition metal ion binding

P06727

apolipoprotein A-IV

positive regulation of biological process, positive regulation of cellular
process, transition metal ion binding

Q3SY52

zinc finger protein interacting with K protein 1 homolog

transition metal ion binding

Q8IUH5

zinc finger, DHHC-type containing 17

positive regulation of biological process, positive regulation of cellular
process, transition metal ion binding

Q8NFW9

myosin VIIA and Rab interacting protein

transition metal ion binding

Q9BZE0

GLIS family zinc finger 2

positive regulation of biological process, positive regulation of cellular
process, transition metal ion binding

Q9H2M3

betaine-homocysteine methyltransferase 2

transition metal ion binding

Table A.7: Continued
Cluster

10

127
11

UniProt ID

Protein Name

P02768

albumin

P06727

apolipoprotein A-IV

P27816

microtubule-associated protein 4

P51160

phosphodiesterase 6C, cGMP-specific, cone, alpha prime

Q04726

transducin-like enhancer of split 3

Q15431

synaptonemal complex protein 1

Q3MIN7

ral guanine nucleotide dissociation stimulator-like 3

Q3SY52

zinc finger protein interacting with K protein 1 homolog

Q6MZT1

regulator of G-protein signaling 7 binding protein

Q7L0Q8

ras homolog gene family, member U

Q8IUH5

zinc finger, DHHC-type containing 17

Q8N187

amyotrophic lateral sclerosis 2 (juvenile) chromosome
region, candidate 8

Q9BZE0

GLIS family zinc finger 2

P06727

apolipoprotein A-IV

GOTerm Annotations
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process, regulation of
cellular process
biological regulation, regulation of biological process, regulation of
cellular process
cellular macromolecule metabolic process, cellular metabolic process,
cellular nitrogen compound metabolic process, macromolecule metabolic
process, metabolic process, nitrogen compound metabolic process,
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process,
primary metabolic process, regulation of biosynthetic process, regulation
of cellular biosynthetic process, regulation of cellular metabolic process,
regulation of macromolecule metabolic process, regulation of metabolic
process

Table A.7: Continued
Cluster

UniProt ID

Protein Name

P21549

alanine-glyoxylate aminotransferase

biosynthetic process, cellular biosynthetic process, cellular metabolic
process, cellular nitrogen compound metabolic process, metabolic
process, nitrogen compound metabolic process, primary metabolic
process, transferase activity

P31040

succinate dehydrogenase complex, subunit A,
flavoprotein (Fp)

cellular metabolic process, metabolic process

P46977

STT3, subunit of the oligosaccharyltransferase complex

Q04726

transducin-like enhancer of split 3

Q14684

ribosomal RNA processing 1 homolog B

Q15431

synaptonemal complex protein 1

128
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GOTerm Annotations

biosynthetic process, cellular biosynthetic process, cellular
macromolecule biosynthetic process, cellular metabolic process,
macromolecule biosynthetic process, macromolecule metabolic process,
metabolic process, primary metabolic process, regulation of
macromolecule metabolic process, transferase activity
biosynthetic process, cellular biosynthetic process, cellular
macromolecule biosynthetic process, cellular macromolecule metabolic
process, cellular metabolic process, cellular nitrogen compound
metabolic process, gene expression, macromolecule biosynthetic process,
macromolecule metabolic process, metabolic process, nitrogen
compound metabolic process, nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process, primary metabolic process, regulation of
biosynthetic process, regulation of cellular biosynthetic process,
regulation of cellular metabolic process, regulation of gene expression,
regulation of macromolecule biosynthetic process, regulation of
macromolecule metabolic process, regulation of metabolic process,
regulation of nitrogen compound metabolic process, regulation of
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process,
regulation of primary metabolic process, regulation of RNA metabolic
process, regulation of transcription, regulation of transcription, DNAdependent, transcription
cellular metabolic process, cellular nitrogen compound metabolic
process, gene expression, macromolecule metabolic process, metabolic
process, nitrogen compound metabolic process, primary metabolic
process, regulation of macromolecule metabolic process, regulation of
primary metabolic process
cellular metabolic process, cellular nitrogen compound metabolic
process, macromolecule metabolic process, metabolic process, nitrogen
compound metabolic process, primary metabolic process, regulation of
macromolecule metabolic process, regulation of primary metabolic
process

Table A.7: Continued
Cluster

UniProt ID

Protein Name
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Q3SY52

zinc finger protein interacting with K protein 1

Q8IUH5

zinc finger, DHHC-type containing 17

Q8N187

amyotrophic lateral sclerosis 2 (juvenile) chromosome
region, candidate 8

Q969R2

oxysterol binding protein 2

11

GOTerm Annotations
biosynthetic process, cellular biosynthetic process, cellular
macromolecule biosynthetic process, cellular macromolecule metabolic
process, cellular metabolic process, cellular nitrogen compound
metabolic process, gene expression, macromolecule biosynthetic process,
macromolecule metabolic process, metabolic process, nitrogen
compound metabolic process, nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process, primary metabolic process, regulation of
biosynthetic process, regulation of cellular biosynthetic process,
regulation of cellular metabolic process, regulation of gene expression,
regulation of macromolecule biosynthetic process, regulation of
macromolecule metabolic process, regulation of metabolic process,
regulation of nitrogen compound metabolic process, regulation of
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process,
regulation of primary metabolic process, regulation of RNA metabolic
process, regulation of transcription, regulation of transcription, DNAdependent, transcription
biosynthetic process, cellular biosynthetic process, cellular
macromolecule biosynthetic process, cellular metabolic process,
macromolecule biosynthetic process, macromolecule metabolic process,
metabolic process, primary metabolic process, regulation of
macromolecule metabolic process, transferase activity
cellular macromolecule metabolic process, nucleobase, nucleoside,
nucleotide and nucleic acid metabolic process, regulation of biosynthetic
process, regulation of cellular biosynthetic process, regulation of cellular
metabolic process, regulation of gene expression, regulation of
macromolecule biosynthetic process, regulation of metabolic process,
regulation of nitrogen compound metabolic process, regulation of
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process,
regulation of RNA metabolic process, regulation of transcription,
regulation of transcription, DNA-dependent
metabolic process, primary metabolic process

Table A.7: Continued
Cluster

UniProt ID

Protein Name

Q9BZE0

GLIS family zinc finger 2

Q9H2M3

betaine-homocysteine methyltransferase 2

11

130
12

GOTerm Annotations
biosynthetic process, cellular biosynthetic process, cellular
macromolecule biosynthetic process, cellular macromolecule metabolic
process, cellular metabolic process, cellular nitrogen compound
metabolic process, gene expression, macromolecule biosynthetic process,
macromolecule metabolic process, metabolic process, nitrogen
compound metabolic process, nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process, primary metabolic process, regulation of
biosynthetic process, regulation of cellular biosynthetic process,
regulation of cellular metabolic process, regulation of gene expression,
regulation of macromolecule biosynthetic process, regulation of
macromolecule metabolic process, regulation of metabolic process,
regulation of nitrogen compound metabolic process, regulation of
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process,
regulation of primary metabolic process, regulation of transcription,
transcription
biosynthetic process, cellular biosynthetic process, cellular metabolic
process, cellular nitrogen compound metabolic process, metabolic
process, nitrogen compound metabolic process, primary metabolic
process, transferase activity

P06727

apolipoprotein A-IV

multicellular organismal process

P31040

succinate dehydrogenase complex, subunit A,
flavoprotein (Fp)

anatomical structure development, developmental process, multicellular
organismal development, multicellular organismal process, system
development

P51160

phosphodiesterase 6C, cGMP-specific, cone, alpha prime

multicellular organismal process

Q04726

transducin-like enhancer of split 3

anatomical structure development, developmental process, multicellular
organismal development, multicellular organismal process, system
development

Q15431

synaptonemal complex protein 1

multicellular organismal process

Q9BZE0

GLIS family zinc finger 2

anatomical structure development, developmental process, multicellular
organismal development, multicellular organismal process, system
development

Table A.8: GOTerm annotations and clusters for proteins identified as interacting with mARC2.
Cluster
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1

UniProt ID

Protein Name

GOTerm Annotations

O75891

aldehyde dehydrogenase 1 family, member L1

catalytic activity

O75947

ATP synthase, H+ transporting, mitochondrial F0
complex, subunit d

O76074

phosphodiesterase 5A, cGMP-specific

P00748

coagulation factor XII

catalytic activity, hydrolase activity

P54764

EPH receptor A4

adenyl nucleotide binding, adenyl ribonucleotide binding, ATP binding,
catalytic activity, nucleoside binding, nucleotide binding, purine
nucleoside binding, purine nucleotide binding, purine ribonucleotide
binding, ribonucleotide binding

Q13496

myotubularin 1

catalytic activity, hydrolase activity

Q5W0Q7

ubiquitin specific peptidase like 1

catalytic activity, hydrolase activity

Q6UB35

methylenetetrahydrofolate dehydrogenase (NADP+
dependent) 1-like

Q71U36

tubulin, alpha 1a

Q86XP3

DEAD (Asp-Glu-Ala-Asp) box polypeptide 42

ATPase activity, catalytic activity, hydrolase activity, hydrolase activity,
acting on acid anhydrides, hydrolase activity, acting on acid anhydrides,
in phosphorus-containing anhydrides, nucleoside-triphosphatase
activity, pyrophosphatase activity
catalytic activity, hydrolase activity, nucleoside binding, nucleotide
binding, purine nucleoside binding, purine nucleotide binding, purine
ribonucleotide binding, ribonucleotide binding

adenyl nucleotide binding, adenyl ribonucleotide binding, ATP binding,
catalytic activity, nucleoside binding, nucleotide binding, purine
nucleoside binding, purine nucleotide binding, purine ribonucleotide
binding, ribonucleotide binding
catalytic activity, hydrolase activity, hydrolase activity, acting on acid
anhydrides, hydrolase activity, acting on acid anhydrides, in
phosphorus-containing anhydrides, nucleoside-triphosphatase activity,
nucleotide binding, purine nucleotide binding, purine ribonucleotide
binding, pyrophosphatase activity, ribonucleotide binding
adenyl nucleotide binding, adenyl ribonucleotide binding, ATP binding,
ATPase activity, catalytic activity, hydrolase activity, hydrolase activity,
acting on acid anhydrides, hydrolase activity, acting on acid anhydrides,
in phosphorus-containing anhydrides, nucleoside binding, nucleosidetriphosphatase activity, nucleotide binding, purine nucleoside binding,
purine nucleotide binding, purine ribonucleotide binding,
pyrophosphatase activity, ribonucleotide binding

Table A.8: Continued
Cluster

1

132
2

UniProt ID

Protein Name

GOTerm Annotations

ATP-binding cassette, sub-family B (MDR/TAP), member
8

adenyl nucleotide binding, adenyl ribonucleotide binding, ATP binding,
ATPase activity, catalytic activity, hydrolase activity, hydrolase activity,
acting on acid anhydrides, hydrolase activity, acting on acid anhydrides,
in phosphorus-containing anhydrides, nucleoside binding, nucleosidetriphosphatase activity, nucleotide binding, purine nucleoside binding,
purine nucleotide binding, purine ribonucleotide binding,
pyrophosphatase activity, ribonucleotide binding

O75891

aldehyde dehydrogenase 1 family, member L1

cellular metabolic process, cellular process, metabolic process

O75947

ATP synthase, H+ transporting, mitochondrial F0
complex, subunit d

O76074

phosphodiesterase 5A, cGMP-specific

cellular metabolic process, cellular process, metabolic process, primary
metabolic process
cellular metabolic process, cellular process, metabolic process, primary
metabolic process

O94927

HAUS augmin-like complex, subunit 5

Q9NUT2

O95696

bromodomain containing 1

P00748

coagulation factor XII

P46782

ribosomal protein S5

P54764

EPH receptor A4

P62269

ribosomal protein S18 pseudogene 12; ribosomal protein
S18 pseudogene 5; ribosomal protein S18

cellular process
cellular macromolecule metabolic process, cellular metabolic process,
cellular process, cellular protein metabolic process, macromolecule
metabolic process, metabolic process, primary metabolic process, protein
metabolic process
macromolecule metabolic process, metabolic process, primary metabolic
process, protein metabolic process
cellular macromolecule metabolic process, cellular metabolic process,
cellular process, cellular protein metabolic process, macromolecule
metabolic process, metabolic process, primary metabolic process, protein
metabolic process
cellular macromolecule metabolic process, cellular metabolic process,
cellular process, cellular protein metabolic process, macromolecule
metabolic process, metabolic process, primary metabolic process, protein
metabolic process
cellular macromolecule metabolic process, cellular metabolic process,
cellular process, cellular protein metabolic process, macromolecule
metabolic process, metabolic process, primary metabolic process, protein
metabolic process

Table A.8: Continued
Cluster

UniProt ID

Protein Name

P62701

ribosomal protein S4X pseudogene 6; ribosomal protein
S4X pseudogene 13; ribosomal protein S4, X-linked

Q13496

myotubularin 1

Q5W0Q7

ubiquitin specific peptidase like 1
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cellular macromolecule metabolic process, cellular metabolic process,
cellular process, cellular protein metabolic process, macromolecule
metabolic process, metabolic process, primary metabolic process, protein
metabolic process
cellular macromolecule metabolic process, cellular metabolic process,
cellular process, cellular protein metabolic process, macromolecule
metabolic process, metabolic process, primary metabolic process, protein
metabolic process
cellular macromolecule metabolic process, cellular metabolic process,
cellular process, cellular protein metabolic process, macromolecule
metabolic process, metabolic process, primary metabolic process, protein
metabolic process
cellular macromolecule metabolic process, cellular metabolic process,
cellular process, cellular protein metabolic process, macromolecule
metabolic process, metabolic process, primary metabolic process, protein
metabolic process

Q6PJ61

F-box protein 46

Q6UB35

methylenetetrahydrofolate dehydrogenase (NADP+
dependent) 1-like

cellular metabolic process, cellular process, metabolic process

Q71U36

tubulin, alpha 1a

cellular process

Q8N7Q3

zinc finger protein 676

Q8TCU4

Alstrom syndrome 1

2

Q9C0H9
Q9NUT2
Q9UKX5
3

GOTerm Annotations

hypothetical LOC100132856; hypothetical LOC100128100;
hypothetical LOC100133017; SNAP25-interacting protein
ATP-binding cassette, sub-family B (MDR/TAP), member
8

cellular macromolecule metabolic process, cellular metabolic process,
cellular process, macromolecule metabolic process, metabolic process,
primary metabolic process
cellular metabolic process, cellular process, metabolic process, primary
metabolic process
cellular process
cellular process

integrin, alpha 11

cellular process

O75891

aldehyde dehydrogenase 1 family, member L1

biosynthetic process

O75947

ATP synthase, H+ transporting, mitochondrial F0
complex, subunit d

biosynthetic process, cellular biosynthetic process

Table A.8: Continued
Cluster

3

UniProt ID

Protein Name

GOTerm Annotations

O76074

phosphodiesterase 5A, cGMP-specific

biological regulation, multicellular organismal process, regulation of
biological process, regulation of biological quality, regulation of cellular
process, response to stimulus

Q6UB35

methylenetetrahydrofolate dehydrogenase (NADP+
dependent) 1-like

heterocycle metabolic process, nitrogen compound metabolic process

zinc finger protein 676

cellular nitrogen compound metabolic process, nitrogen compound
metabolic process, nucleobase, nucleoside, nucleotide and nucleic acid
metabolic process

O75891

aldehyde dehydrogenase 1 family, member L1

biosynthetic process

O75947

ATP synthase, H+ transporting, mitochondrial F0
complex, subunit d

biosynthetic process, cellular biosynthetic process

O76074

phosphodiesterase 5A, cGMP-specific

P00748

coagulation factor XII

P46782

ribosomal protein S5

Q8N7Q3
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4

biological regulation, multicellular organismal process, regulation of
biological process, regulation of biological quality, regulation of cellular
process, response to stimulus
biological regulation, gene expression, multicellular organismal process,
regulation of biological process, regulation of biological quality,
regulation of cellular metabolic process, regulation of cellular process,
regulation of cellular protein metabolic process, regulation of gene
expression, regulation of macromolecule metabolic process, regulation of
metabolic process, regulation of primary metabolic process, regulation of
protein metabolic process, response to stimulus
biological regulation, biosynthetic process, cellular biosynthetic process,
cellular macromolecule biosynthetic process, gene expression,
macromolecule biosynthetic process, nucleic acid binding, regulation of
biological process, regulation of biological quality, regulation of
biosynthetic process, regulation of cellular biosynthetic process,
regulation of cellular metabolic process, regulation of cellular process,
regulation of cellular protein metabolic process, regulation of gene
expression, regulation of macromolecule biosynthetic process, regulation
of macromolecule metabolic process, regulation of metabolic process,
regulation of primary metabolic process, regulation of protein metabolic
process, RNA binding, structural constituent of ribosome, structural
molecule activity, translation, translational elongation

Table A.8: Continued
Cluster

4

UniProt ID

Protein Name

GOTerm Annotations
biological regulation, multicellular organismal process, regulation of
biological process, regulation of cellular process, response to stimulus
biosynthetic process, cellular biosynthetic process, cellular
macromolecule biosynthetic process, gene expression, macromolecule
biosynthetic process, nucleic acid binding, RNA binding, structural
constituent of ribosome, structural molecule activity, translation,
translational elongation
biological regulation, biosynthetic process, cellular biosynthetic process,
cellular macromolecule biosynthetic process, gene expression,
macromolecule biosynthetic process, nucleic acid binding, regulation of
biological process, regulation of biological quality, regulation of
biosynthetic process, regulation of cellular biosynthetic process,
regulation of cellular metabolic process, regulation of cellular process,
regulation of cellular protein metabolic process, regulation of gene
expression, regulation of macromolecule biosynthetic process, regulation
of macromolecule metabolic process, regulation of metabolic process,
regulation of primary metabolic process, regulation of protein metabolic
process, RNA binding, structural constituent of ribosome, structural
molecule activity, translation, translational elongation

EPH receptor A4

P62269

ribosomal protein S18 pseudogene 12; ribosomal protein
S18 pseudogene 5; ribosomal protein S18

P62701

ribosomal protein S4X pseudogene 6; ribosomal protein
S4X pseudogene 13; ribosomal protein S4, X-linked

Q06787

fragile X mental retardation 1

multicellular organismal process, nucleic acid binding, RNA binding

Q13496

myotubularin 1

biological regulation, multicellular organismal process, regulation of
biological quality

Q6UB35

methylenetetrahydrofolate dehydrogenase (NADP+
dependent) 1-like

biosynthetic process, cellular biosynthetic process

Q71U36

tubulin, alpha 1a

structural molecule activity

Q86XP3

DEAD (Asp-Glu-Ala-Asp) box polypeptide 42

nucleic acid binding, RNA binding
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P54764

Table A.8: Continued
Cluster

UniProt ID

Protein Name

GOTerm Annotations

Q8N7Q3

zinc finger protein 676

Q8TCU4

Alstrom syndrome 1

Q9C0H9

hypothetical LOC100132856; hypothetical LOC100128100;
hypothetical LOC100133017; SNAP25-interacting protein

biological regulation, biosynthetic process, cellular biosynthetic process,
cellular macromolecule biosynthetic process, gene expression,
macromolecule biosynthetic process, nucleic acid binding, regulation of
biological process, regulation of biosynthetic process, regulation of
cellular biosynthetic process, regulation of cellular metabolic process,
regulation of cellular process, regulation of gene expression, regulation
of macromolecule biosynthetic process, regulation of macromolecule
metabolic process, regulation of metabolic process, regulation of primary
metabolic process
biological regulation, multicellular organismal process, regulation of
biological process, regulation of biological quality, regulation of cellular
process, response to stimulus
biological regulation, regulation of biological process, regulation of
cellular process

Q9UKX5

integrin, alpha 11

multicellular organismal process

4
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O76074

phosphodiesterase 5A, cGMP-specific

P00748

coagulation factor XII

P46782

ribosomal protein S5

P54764

EPH receptor A4

P62701

ribosomal protein S4X pseudogene 6; ribosomal protein
S4X pseudogene 13; ribosomal protein S4, X-linked

Q06787

fragile X mental retardation 1

Q13496

myotubularin 1

5

anatomical structure development, biological regulation, developmental
process, multicellular organismal development, multicellular organismal
process, nervous system development, regulation of biological quality,
response to stimulus, signal transduction, system development
biological regulation, multicellular organismal process, regulation of
biological quality, response to stimulus
biological regulation, regulation of biological quality
anatomical structure development, biological regulation, developmental
process, multicellular organismal development, multicellular organismal
process, nervous system development, response to stimulus, signal
transduction, system development
biological regulation, developmental process, multicellular organismal
development, multicellular organismal process
anatomical structure development, developmental process, multicellular
organismal development, multicellular organismal process, nervous
system development, system development
anatomical structure development, biological regulation, developmental
process, multicellular organismal development, multicellular organismal
process, organ development, regulation of biological quality, system
development

Table A.8: Continued
Cluster

UniProt ID
Q8N7Q3

Protein Name
zinc finger protein 676

biological regulation

Q8TCU4

Alstrom syndrome 1

anatomical structure development, biological regulation, developmental
process, multicellular organismal development, multicellular organismal
process, nervous system development, organ development, regulation of
biological quality, response to stimulus, signal transduction, system
development

Q9C0H9

hypothetical LOC100132856; hypothetical LOC100128100;
hypothetical LOC100133017; SNAP25-interacting protein

biological regulation

Q9UKX5

integrin, alpha 11

5
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6

7

8

GOTerm Annotations

anatomical structure development, developmental process, multicellular
organismal development, multicellular organismal process, organ
development, system development
cellular component assembly, cellular component biogenesis, cellular
component organization

O94927

HAUS augmin-like complex, subunit 5

O95696

bromodomain containing 1

cellular component organization

P54764

EPH receptor A4

cellular component organization

Q71U36

tubulin, alpha 1a

Q8TCU4

Alstrom syndrome 1

cellular component assembly, cellular component biogenesis, cellular
component organization
cellular component assembly, cellular component biogenesis, cellular
component organization
biopolymer modification, post-translational protein modification,
protein modification process
biopolymer modification, post-translational protein modification,
protein modification process
biopolymer modification, post-translational protein modification,
protein modification process

O95696

bromodomain containing 1

P54764

EPH receptor A4

Q13496

myotubularin 1

O75947

ATP synthase, H+ transporting, mitochondrial F0
complex, subunit d

establishment of localization, localization, transport

Q06787

fragile X mental retardation 1

establishment of localization, localization, transport

Q9C0H9
Q9NUT2
Q9UKX5

hypothetical LOC100132856; hypothetical LOC100128100;
hypothetical LOC100133017; SNAP25-interacting protein
ATP-binding cassette, sub-family B (MDR/TAP), member
8
integrin, alpha 11

establishment of localization, localization, transport
establishment of localization, localization, transport
localization

Table A.8: Continued
Cluster

9

UniProt ID

Protein Name

O76074

phosphodiesterase 5A, cGMP-specific

O95696

bromodomain containing 1

Q8N7Q3

zinc finger protein 676

Q9UKX5

integrin, alpha 11

GOTerm Annotations
cation binding, ion binding, metal ion binding, transition metal ion
binding, zinc ion binding
cation binding, ion binding, metal ion binding, transition metal ion
binding, zinc ion binding
cation binding, ion binding, metal ion binding, transition metal ion
binding, zinc ion binding
cation binding, ion binding, metal ion binding
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Table A.9: KEGG pathways for proteins identified as interacting with mARC1 in HEK-293 cell
lysate.
UniProt ID

Protein Name

O00330

pyruvate dehydrogenase
complex component X

O00750

phosphatidylinositol-4phosphate 3-kinase catalytic
subunit type 2 beta

O14788

tumor necrosis factor
superfamily member 11

O43181

NADH:ubiquinone
oxidoreductase subunit S4

O60260

parkin RBR E3 ubiquitin
protein ligase

O60683

peroxisomal biogenesis factor
10

O75581

LDL receptor related protein
6

KEGG Category, Pathway Class, and Pathway
Metabolism
Global and overview maps
-Metabolic pathways
Environmental Information Processing
Signal transduction
-Phosphatidylinositol signaling system
Metabolism
Carbohydrate metabolism
-Inositol phosphate metabolism
Global and overview maps
-Metabolic pathways
Environmental Information Processing
Signal transduction
-NF-kappa B signaling pathway
Signaling molecules and interaction
-Cytokine-cytokine receptor interaction
Human Diseases
Immune diseases
-Rheumatoid arthritis
Organismal Systems
Development
-Osteoclast differentiation
Endocrine system
-Prolactin signaling pathway
Human Diseases
Endocrine and metabolic diseases
-Non-alcoholic fatty liver disease (NAFLD)
Neurodegenerative diseases
-Alzheimer's disease
-Huntington's disease
-Parkinson's disease
Metabolism
Energy metabolism
-Oxidative phosphorylation
Global and overview maps
-Metabolic pathways
Genetic Information Processing
Folding, sorting and degradation
-Protein processing in endoplasmic reticulum
-Ubiquitin mediated proteolysis
Human Diseases
Neurodegenerative diseases
-Parkinson's disease
Cellular Processes
Transport and catabolism
-Peroxisome
Environmental Information Processing
Signal transduction
-Wnt signaling pathway

139

SAINT Score
0.39

0.26

0.37

0.2

0.17

0.28

0.18

Table A.9: Continued
UniProt ID

Protein Name

O95049

tight junction protein 3

O95382

mitogen-activated protein
kinase 6

O95602

polymerase (RNA) I
polypeptide A

P00734

coagulation factor II,
thrombin

P11216

phosphorylase, glycogen

KEGG Category, Pathway Class, and Pathway
Cellular Processes
Cellular community
-Tight junction
Environmental Information Processing
Signal transduction
-MAPK signaling pathway
Genetic Information Processing
Transcription
-RNA polymerase
Metabolism
Global and overview maps
-Metabolic pathways
Nucleotide metabolism
-Purine metabolism
-Pyrimidine metabolism
Cellular Processes
Cell motility
-Regulation of actin cytoskeleton
Environmental Information Processing
Signaling molecules and interaction
-Neuroactive ligand-receptor interaction
Organismal Systems
Immune system
-Complement and coagulation cascades
Human Diseases
Endocrine and metabolic diseases
-Insulin resistance
Metabolism
Carbohydrate metabolism
-Starch and sucrose metabolism
Global and overview maps
-Metabolic pathways
Organismal Systems
Endocrine system
-Glucagon signaling pathway
-Insulin signaling pathway
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SAINT Score
0.33

0.22

0.51

0.51

0.32

Table A.9: Continued
UniProt ID

Protein Name

P15313

ATPase, H+ transporting,
lysosomal 56/58kDa, V1
subunit B1

P18564

integrin subunit beta 6

P21549

alanine-glyoxylate
aminotransferase

KEGG Category, Pathway Class, and Pathway
Cellular Processes
Transport and catabolism
-Phagosome
Human Diseases
Immune diseases
-Rheumatoid arthritis
Infectious diseases: Bacterial
-Epithelial cell signaling in Helicobacter pylori
infection
-Vibrio cholerae infection
Metabolism
Energy metabolism
-Oxidative phosphorylation
Global and overview maps
-Metabolic pathways
Organismal Systems
Excretory system
-Collecting duct acid secretion
Nervous system
-Synaptic vesicle cycle
Cellular Processes
Cell motility
-Regulation of actin cytoskeleton
Cellular community
-Focal adhesion
Environmental Information Processing
Signal transduction
-PI3K-Akt signaling pathway
Signaling molecules and interaction
-ECM-receptor interaction
Human Diseases
Cardiovascular diseases
-Arrhythmogenic right ventricular
cardiomyopathy (ARVC)
-Dilated cardiomyopathy
-Hypertrophic cardiomyopathy (HCM)
Cellular Processes
Transport and catabolism
-Peroxisome
Metabolism
Amino acid metabolism
-Alanine, aspartate and glutamate metabolism
-Glycine, serine and threonine metabolism
Carbohydrate metabolism
-Glyoxylate and dicarboxylate metabolism
Global and overview maps
-Carbon metabolism
-Metabolic pathways
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SAINT Score

0.16

0.37

0.35

Table A.9: Continued
UniProt ID

Protein Name

P28749

retinoblastoma-like 1

P30679

guanine nucleotide binding
protein (G protein), alpha 15

P31040

succinate dehydrogenase
complex subunit A,
flavoprotein (Fp)

P46977

STT3A, subunit of the
oligosaccharyltransferase
complex

P51160

phosphodiesterase 6C

KEGG Category, Pathway Class, and Pathway
Cellular Processes
Cell growth and death
-Cell cycle
Environmental Information Processing
Signal transduction
-TGF-beta signaling pathway
Human Diseases
Cancers: Overview
-Viral carcinogenesis
Environmental Information Processing
Signal transduction
-Calcium signaling pathway
Human Diseases
Infectious diseases: Parasitic
-Amoebiasis
-Chagas disease (American trypanosomiasis)
Human Diseases
Endocrine and metabolic diseases
-Non-alcoholic fatty liver disease (NAFLD)
Neurodegenerative diseases
-Alzheimer's disease
-Huntington's disease
-Parkinson's disease
Metabolism
Carbohydrate metabolism
-Citrate cycle (TCA cycle)
Energy metabolism
-Oxidative phosphorylation
Global and overview maps
-Carbon metabolism
-Metabolic pathways
Genetic Information Processing
Folding, sorting and degradation
-Protein processing in endoplasmic reticulum
Metabolism
Global and overview maps
-Metabolic pathways
Glycan biosynthesis and metabolism
-N-Glycan biosynthesis
Metabolism
Nucleotide metabolism
-Purine metabolism
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SAINT Score

0.11

0.17

0

0.18

0.3

Table A.9: Continued
UniProt ID

Protein Name

P52788

spermine synthase

P78334

gamma-aminobutyric acid
(GABA) A receptor, epsilon

Q13233

mitogen-activated protein
kinase 1, E3 ubiquitin protein
ligase

Q16555

dihydropyrimidinase like 2

Q549N5

SRP receptor beta subunit

KEGG Category, Pathway Class, and Pathway
Metabolism
Amino acid metabolism
-Arginine and proline metabolism
-Cysteine and methionine metabolism
Global and overview maps
-Metabolic pathways
Metabolism of other amino acids
-beta-Alanine metabolism
-Glutathione metabolism
Environmental Information Processing
Signaling molecules and interaction
-Neuroactive ligand-receptor interaction
Human Diseases
Substance dependence
-Morphine addiction
-Nicotine addiction
Organismal Systems
Nervous system
-GABAergic synapse
-Retrograde endocannabinoid signaling
Environmental Information Processing
Signal transduction
-MAPK signaling pathway
Genetic Information Processing
Folding, sorting and degradation
-Ubiquitin mediated proteolysis
Human Diseases
Infectious diseases: Viral
-Hepatitis B
-HTLV-I infection
Organismal Systems
Endocrine system
-GnRH signaling pathway
Immune system
-RIG-I-like receptor signaling pathway
Nervous system
-Neurotrophin signaling pathway
Organismal Systems
Development
-Axon guidance
Genetic Information Processing
Folding, sorting and degradation
-Protein export
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SAINT Score

0.29

0.3

0.16

0.17

0.51

Table A.9: Continued
UniProt ID

Q6SJ96

Q8WZ42

Protein Name

TATA-box binding protein
like 2

titin

Q99683

mitogen-activated protein
kinase 5

Q9BYG4

par-6 family cell polarity
regulator gamma

Q9H2M3

betaine--homocysteine Smethyltransferase 2

KEGG Category, Pathway Class, and Pathway
Genetic Information Processing
Transcription
-Basal transcription factors
Human Diseases
Cancers: Overview
-Viral carcinogenesis
Infectious diseases: Viral
-Epstein-Barr virus infection
-Herpes simplex infection
-HTLV-I infection
Human Diseases
Cardiovascular diseases
-Dilated cardiomyopathy
-Hypertrophic cardiomyopathy (HCM)
Cellular Processes
Cell growth and death
-Apoptosis
Environmental Information Processing
Signal transduction
-MAPK signaling pathway
-Sphingolipid signaling pathway
-TNF signaling pathway
Genetic Information Processing
Folding, sorting and degradation
-Protein processing in endoplasmic reticulum
Human Diseases
Endocrine and metabolic diseases
-Non-alcoholic fatty liver disease (NAFLD)
Neurodegenerative diseases
-Amyotrophic lateral sclerosis (ALS)
Organismal Systems
Nervous system
-Neurotrophin signaling pathway
Cellular Processes
Cellular community
-Tight junction
Transport and catabolism
-Endocytosis
Environmental Information Processing
Signal transduction
-Hippo signaling pathway
-Rap1 signaling pathway
Organismal Systems
Development
-Axon guidance
Metabolism
Amino acid metabolism
-Cysteine and methionine metabolism
Global and overview maps
-Metabolic pathways
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SAINT Score

0.14

0.47

0.47

0.34

0.33

Table A.9: Continued
UniProt ID
Q9P2J5

Protein Name
leucyl-tRNA synthetase

Q9UHV7

mediator complex subunit 13

Q9UQ84

exonuclease 1

Q9Y2P5

solute carrier family 27 (fatty
acid transporter), member 5

Q9Y2X0

mediator complex subunit 16

KEGG Category, Pathway Class, and Pathway
Genetic Information Processing
Translation
-Aminoacyl-tRNA biosynthesis
Organismal Systems
Endocrine system
-Thyroid hormone signaling pathway
Genetic Information Processing
Replication and repair
-Mismatch repair
Human Diseases
Endocrine and metabolic diseases
-Insulin resistance
Metabolism
Global and overview maps
-Metabolic pathways
Lipid metabolism
-Primary bile acid biosynthesis
Organismal Systems
Digestive system
-Bile secretion
Endocrine system
-PPAR signaling pathway
Organismal Systems
Endocrine system
-Thyroid hormone signaling pathway
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SAINT Score
0.15

0.19

0.13

0.15

0.13

Table A.10: KEGG pathways for proteins identified as interacting with mARC2 in HEK-293 cell
lysate.
UniProt ID

Protein Name

A5YKK6

CCR4-NOT transcription
complex subunit 1

O43708

hsa:2954 GSTZ1; glutathione
S-transferase zeta 1

O75061

DnaJ heat shock protein
family (Hsp40) member C6

O75581

LDL receptor related protein
6

O75891

aldehyde dehydrogenase 1
family member L1

O75947

ATP synthase, H+
transporting, mitochondrial
Fo complex subunit D

O76074

phosphodiesterase 5A

O95685

protein phosphatase 1
regulatory subunit 3D

O96007

molybdenum cofactor
synthesis 2

KEGG Category, Pathway Class, and Pathway
Genetic Information Processing
Folding, sorting and degradation
-RNA degradation
Environmental Information Processing
Membrane transport
-Metabolic pathways
Metabolism
Amino acid metabolism
-Tyrosine metabolism
Cellular Processes
Transport and catabolism
-Endocytosis
Environmental Information Processing
Signal transduction
-Wnt signaling pathway
Metabolism
Metabolism of cofactors and vitamins
-One carbon pool by folate
Environmental Information Processing
Membrane transport
-Metabolic pathways
Human Diseases
Neurodegenerative diseases
-Alzheimer's disease
-Huntington's disease
Metabolism
Energy metabolism
-Oxidative phosphorylation
Environmental Information Processing
Signal transduction
-cGMP-PKG signaling pathway
Metabolism
Nucleotide metabolism
-Purine metabolism
Human Diseases
Endocrine and metabolic diseases
-Insulin resistance
Organismal Systems
Endocrine system
-Insulin signaling pathway
Environmental Information Processing
Membrane transport
-Metabolic pathways
Genetic Information Processing
Folding, sorting and degradation
-Sulfur relay system
Metabolism
Metabolism of cofactors and vitamins
-Folate biosynthesis
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SAINT Score
0.35

0.08

0.05

0.4

0.23

0.28

0.11

0

0.25

Table A.10: Continued
UniProt ID

Protein Name

P00748

coagulation factor XII

P01127

platelet derived growth
factor subunit B

P05141

solute carrier family 25
(mitochondrial carrier;
adenine nucleotide
translocator), member 5

P14410

sucrase-isomaltase (alphaglucosidase)

KEGG Category, Pathway Class, and Pathway
Organismal Systems
Immune system
-Complement and coagulation cascades
Cellular Processes
Cellular community
-Focal adhesion
-Gap junction
Cell motility
-Regulation of actin cytoskeleton
Environmental Information Processing
Signal transduction
-MAPK signaling pathway
-Phospholipase D signaling pathway
-PI3K-Akt signaling pathway
-Rap1 signaling pathway
-Ras signaling pathway
Signaling molecules and interaction
-Cytokine-cytokine receptor interaction
Human Diseases
Cancers
-Choline metabolism in cancer
-Glioma
-Melanoma
-MicroRNAs in cancer
-Pathways in cancer
-Prostate cancer
-Renal cell carcinoma
Infectious diseases
-HTLV-I infection
Environmental Information Processing
Signal transduction
-Calcium signaling pathway
-cGMP-PKG signaling pathway
Human Diseases
Infectious diseases
-HTLV-I infection
Neurodegenerative diseases
-Huntington's disease
-Parkinson's disease
Environmental Information Processing
Membrane transport
-Metabolic pathways
Metabolism
Carbohydrate metabolism
-Galactose metabolism
-Starch and sucrose metabolism
Organismal Systems
Digestive system
-Carbohydrate digestion and absorption
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SAINT Score
0.18

0.17

0.03

0.08

Table A.10: Continued
UniProt ID

Protein Name

P14678

small nuclear
ribonucleoprotein
polypeptides B and B1

P23396

ribosomal protein S3

P27694

replication protein A1

P36542

ATP synthase, H+
transporting, mitochondrial
F1 complex, gamma
polypeptide 1

P39019

ribosomal protein S19

P40855

peroxisomal biogenesis factor
19

KEGG Category, Pathway Class, and Pathway
Genetic Information Processing
Transcription
-Spliceosome
Human Diseases
Immune diseases
-Systemic lupus erythematosus
Genetic Information Processing
Translation
-Ribosome
Genetic Information Processing
Replication and repair
-DNA replication
-Fanconi anemia pathway
-Homologous recombination
-Mismatch repair
-Nucleotide excision repair
Environmental Information Processing
Membrane transport
-Metabolic pathways
Human Diseases
Neurodegenerative diseases
-Alzheimer's disease
-Huntington's disease
-Parkinson's disease
Metabolism
Energy metabolism
-Oxidative phosphorylation
Genetic Information Processing
Translation
-Ribosome
Cellular Processes
Transport and catabolism
-Peroxisome
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SAINT Score

0.04

0

0

0.12

0

0.1

Table A.10: Continued
UniProt ID

Protein Name

P42262

glutamate receptor,
ionotropic, AMPA 2

P42285

Ski2 like RNA helicase 2

P46782

ribosomal protein S5

P48047

ATP synthase, H+
transporting, mitochondrial
F1 complex, O subunit

P54764

EPH receptor A4

P62249

ribosomal protein S16

P62269

ribosomal protein S18

P62273

ribosomal protein S29

KEGG Category, Pathway Class, and Pathway
Environmental Information Processing
Signal transduction
-cAMP signaling pathway
Signaling molecules and interaction
-Neuroactive ligand-receptor interaction
Human Diseases
Neurodegenerative diseases
-Amyotrophic lateral sclerosis (ALS)
Substance dependence
-Amphetamine addiction
-Cocaine addiction
Organismal Systems
Environmental adaptation
-Circadian entrainment
Nervous system
-Dopaminergic synapse
-Glutamatergic synapse
-Long-term depression
-Long-term potentiation
-Retrograde endocannabinoid signaling
Genetic Information Processing
Folding, sorting and degradation
-RNA degradation
Genetic Information Processing
Translation
-Ribosome
Environmental Information Processing
Membrane transport
-Metabolic pathways
Human Diseases
Neurodegenerative diseases
-Alzheimer's disease
-Huntington's disease
-Parkinson's disease
Metabolism
Energy metabolism
-Oxidative phosphorylation
Organismal Systems
Development
-Axon guidance
Genetic Information Processing
Translation
-Ribosome
Genetic Information Processing
Translation
-Ribosome
Genetic Information Processing
Translation
-Ribosome
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SAINT Score

0.01

0.08

0.07

0.01

0.26

0.01

0

0.04

Table A.10: Continued
UniProt ID

Protein Name

P62701

ribosomal protein S4, Xlinked

P62750

ribosomal protein L23a

P62979

ribosomal protein S27a

Q06787

fragile X mental retardation 1

Q07021

complement component 1, q
subcomponent binding
protein

Q13496

myotubularin 1

KEGG Category, Pathway Class, and Pathway
Genetic Information Processing
Translation
-Ribosome
Genetic Information Processing
Translation
-Ribosome
Genetic Information Processing
Translation
-Ribosome
Genetic Information Processing
Translation
- RNA transport
Human Diseases
Infectious diseases
-Herpes simplex infection
Environmental Information Processing
Membrane transport
-Metabolic pathways
Signal transduction
-Phosphatidylinositol signaling system
Metabolism
Carbohydrate metabolism
-Inositol phosphate metabolism
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SAINT Score
0

0.01

0

0.29

0

0.29

Table A.10: Continued
UniProt ID

Protein Name

Q13698

calcium channel, voltagedependent, L type, alpha 1S
subunit

Q15185

prostaglandin E synthase 3

Q32P51

heterogeneous nuclear
ribonucleoprotein A1-like 2

Q5S007

leucine-rich repeat kinase 2

Q6UB35

methylenetetrahydrofolate
dehydrogenase (NADP+
dependent) 1-like

KEGG Category, Pathway Class, and Pathway
Environmental Information Processing
Signal transduction
-Calcium signaling pathway
-cAMP signaling pathway
-cGMP-PKG signaling pathway
-MAPK signaling pathway
Human Diseases
Cardiovascular diseases
-Arrhythmogenic right ventricular
cardiomyopathy (ARVC)
-Dilated cardiomyopathy
-Hypertrophic cardiomyopathy (HCM)
Neurodegenerative diseases
-Alzheimer's disease
Organismal Systems
Circulatory system
-Adrenergic signaling in cardiomyocytes
-Cardiac muscle contraction
-Vascular smooth muscle contraction
Endocrine system
-Aldosterone synthesis and secretion
-GnRH signaling pathway
-Insulin secretion
-Oxytocin signaling pathway
-Renin secretion
Nervous system
-Cholinergic synapse
-GABAergic synapse
-Retrograde endocannabinoid signaling
-Serotonergic synapse
Environmental Information Processing
Membrane transport
-Metabolic pathways
Metabolism
Lipid metabolism
-Arachidonic acid metabolism
Genetic Information Processing
Transcription
-Spliceosome
Human Diseases
Neurodegenerative diseases
-Parkinson's disease
Environmental Information Processing
Membrane transport
-Metabolic pathways
Metabolism
Metabolism of cofactors and vitamins
-One carbon pool by folate
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SAINT Score

0.24

0.05

0

0.27

0.14

Table A.10: Continued
UniProt ID

Protein Name

Q71U36

tubulin alpha 1a

Q86XP3

DEAD-box helicase 42

Q8NBS9

thioredoxin domain
containing 5

Q8TD57

dynein, axonemal, heavy
chain 3

Q96RS0

trimethylguanosine synthase
1

Q9BTM1

H2A histone family member J

Q9NQX3

gephyrin

Q9NUT2

ATP binding cassette
subfamily B member 8

Q9NZB8

molybdenum cofactor
synthesis 1

Q9UHD8

septin 9

KEGG Category, Pathway Class, and Pathway
Cellular Processes
Cell growth and death
-Apoptosis
Cellular community
-Gap junction
Transport and catabolism
-Phagosome
Human Diseases
Infectious diseases
-Pathogenic Escherichia coli infection
Genetic Information Processing
Transcription
-Spliceosome
Genetic Information Processing
Folding, sorting and degradation
-Protein processing in endoplasmic reticulum
Human Diseases
Neurodegenerative diseases
-Huntington's disease
Genetic Information Processing
Translation
-RNA transport
Human Diseases
Immune diseases
-Systemic lupus erythematosus
Substance dependence
-Alcoholism
Organismal Systems
Nervous system
-GABAergic synapse
Environmental Information Processing
Membrane transport
-ABC transporters
Environmental Information Processing
Membrane transport
-Metabolic pathways
Genetic Information Processing
Folding, sorting and degradation
-Sulfur relay system
Metabolism
Metabolism of cofactors and vitamins
-Folate biosynthesis
Human Diseases
Infectious diseases
-Bacterial invasion of epithelial cells
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SAINT Score

0

0.54

0.08

0.19

0.41

0

0.3

0.43

0.1

0.02

Table A.10: Continued
UniProt ID

Protein Name

Q9UKX5

integrin subunit alpha 11

Q9Y285

phenylalanyl-tRNA
synthetase alpha subunit

KEGG Category, Pathway Class, and Pathway
Cellular Processes
Cell motility
-Regulation of actin cytoskeleton
Cellular community
-Focal adhesion
Environmental Information Processing
Signal transduction
-PI3K-Akt signaling pathway
Signaling molecules and interaction
-ECM-receptor interaction
Human Diseases
Cardiovascular diseases
-Arrhythmogenic right ventricular
cardiomyopathy (ARVC)
-Dilated cardiomyopathy
-Hypertrophic cardiomyopathy (HCM
Genetic Information Processing
Translation
-Aminoacyl-tRNA biosynthesis

153

SAINT Score

0.3

0

Appendix IV: Protein sequence comparison for mARC1 and mARC2 in human, rat,
and pig

A

B

Figure A.15: Protein sequence comparison for mARC1 and mARC2 in
human and rat. A. mARC1 (Q5VT66) in human compared to mARC1
(G3V6I4) in rat, B. mARC2 (Q969Z3) in human compared to mARC2
(O88994) in rat.
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A

B

Figure A.16: Protein sequence comparison for mARC1 and mARC2 in
human and pig. A. mARC1 (Q5VT66) in human compared to mARC2
(F1S9I9) in pig, B. mARC2 (Q969Z3) in human compared to mARC2
(F1S9I9) in pig.
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